MicroRNA Expression during Chondrogenic Differentiation and
Inflammation of Equine Cells
by
Midori Elizabeth Buechli
A Thesis
presented to
The University of Guelph
In partial fulfilment of requirements
for the degree of
Master of Science
in
Biomedical Sciences
Guelph, Ontario, Canada
© Midori E. Buechli, January, 2013
ABSTRACT
MICRORNA EXPRESSION DURING CHONDROGENIC DIFFERENTIATION AND
INFLAMMATION OF EQUINE CELLS
Midori Elizabeth Buechli Advisors:
University of Guelph, 2012 Professor T.G. Koch
Professor J. LaMarre
Understanding the molecular networks that maintain articular cartilage and regulate
chondrogenic differentiation of mesenchymal stromal cells (MSCs) are important prerequisites
for the improvement of cartilage repair strategies. The first study within this thesis demonstrates
that equine cord blood-derived MSCs induced towards a chondrogenic phenotype showed
significantly increased miR-140 expression from day 0 to day 14, which was accompanied by
decreased expression of previously identified miR-140 targets; ADAMTS-5 and CXCL12. The
second study shows that in vitro chondrogenesis on fibronectin coated-PTFE inserts results in
more homogeneous hyaline-like cartilage with an increased number of differentiated cells
compared with pellet cultures. Finally, the expression of miR-140, miR-9, miR-155 and miR-
146a was investigated in an in vitro model of osteoarthritis and suggests a possible role for miR-
146a. These results suggest that microRNAs may be useful for directing or enhancing eCB-
MSC chondrogenic differentiation and for developing novel biomarker panels of in vivo joint
health.
iii
TABLE OF CONTENTS
ACKNOWLEDGEMENTS……………………………………….……………………………..i
DECLARATION OF WORK PERFORMED…………………………………………….......iii
LIST OF TABLES………………………………………………………………………….…...iv
LIST OF FIGURES…………………………………………………………………………...…v
LIST OF ABBREVIATIONS……………………………………………………………….…vii
INTRODUCTION……………………………………………………………………………….1
Natural Cartilage Development…………………………………………....……1
Synovial joint formation…………………………………………………..1
Endochondral ossification…………………………...…………………….3
Current Treatments for Cartilage Injury………………...…………………….5
Bone Marrow Stimulation……………………………...………………….5
Osteochondral Grafts…………………………………...…………………6
Autologous Chondrocyte Implantation……………………………………6
MSCs as a Cell Source for Chondrogenesis……………………………………7
Induction of in vitro Chondrogenesis………………………….………………..9
Role of MicroRNAs in Cartilage Development and Homeostasis…..……….12
MicroRNA Biogenesis…………………………………………...………13
Expression of microRNAs during chondrogenesis………………………15
MicroRNAs in articular cartilage…………………………………...……17
MicroRNAs in Osteoarthritis……………………………………….……18
RATIONALE...............................................................................................................................23
iv
CHAPTER 1 - MICRORNA-140 EXPRESSION DURING CHONDROGENIC
DIFFERENTIATION OF EQUINE CORD BLOOD DERIVED MESENCHYMAL
STROMAL CELLS……………………………………………………………………….……26
Introduction…………………………………………………..…………………………27
Materials and Methods…………………………………………………………………30
Study design…………………………………………………………………..….30
eCB-MSC isolation and culture….………………………………………………31
Chondrogenic differentiation………………………………………………….…31
Chondrocyte isolation………………………………………………………...….32
Histology and immunohistochemistry………………………………………...…32
RNA extraction, reverse transcription, qRT-PCR……………………………….33
Statistical analysis…………………………………………………………..……33
Results………………………………………………………………………………..….34
Chondrogenic differentiation of eCB-MSCs…………………………………….34
MicroRNA-140 expression in undifferentiated eCB-MSCs and equine articular
chondrocytes………………………………………………………………….….35
Expression of miR-140, Sox9 and miR-140 target genes during
chondrogenesis…………………………………………………………………...35
Discussion…………………………………………………………………………….…36
Tables…………………………………………………………………………………....42
Figures…………………………………………………………………………………...43
v
CHAPTER 2 - CHONDROGENIC DIFFERENTIATION OF EQUINE CORD BLOOD-
DERIVED MESENCHYMAL STROMAL CELLS IN MEMBRANE-BASED
CULTURES…………………………………………………………………………………..…47
Introduction…………………………………………………………………………..…48
Materials and Methods…………………………………………………………………50
Study design…………………………………………………………………..….50
eCB-MSC isolation and culture….…………………………………………..…..51
Chondrogenic differentiation………………………………………………...…..51
Histology and immunohistochemistry………………………………………..….52
Results ………………………………………………………………………...…...........52
Chondrogenic differentiation of pellets and membranes……………………...…52
Discussion……………………………………………………………………………….54
Figures………………………………………………………………………………..….58
CHAPTER 3 - THE EFFECT OF INFLAMMATORY STIMULI ON MICRORNA
EXPRESSION IN EQUINE CHONDROCYTES…………………………………………....61
Introduction………………………………………………………………………….….62
Materials and Methods…………………………………………………………………65
Study design………………………………………………………………...……65
Chondrocyte isolation, culture and treatment……………………………...…….65
RNA extraction, reverse transcription, qRT-PCR……………………………….66
Protein isolation and quantification………………………………………...……67
Statistical Analysis…………………………………………………………...…..67
vi
Results………………………………………………………………………………...…68
Decreased expression of cartilage markers………………………………………68
Increased expression of inflammatory markers……………………………….…68
MicroRNA expression…………………………………………………………...68
Expression of downstream targets……………………………………………….69
Discussion……………………………………………………………………………….69
Tables……………………………………………………………………………………75
Figures………………………………………………………………………………...…76
GENERAL DISCUSSION AND CONCLUSIONS…………………………………………..80
REFERENCES………………………………………………………………………………….89
APPENDICES……………………………………………………………………………..…..102
Screening of eCB-MSCs………………………………………………………………..102
Cell culture of equine cord-blood derived mesenchymal stromal cells…….………..…103
Cell Counting using Trypan Blue………………………………………………………107
Chondrogenic induction of MSCs – membrane and pellet protocols.……...….……….108
Tissue preparation for Histology and Immunohistochemistry.……………...………….111
Histology – Toluidine Blue and Hematoxylin and Eosin staining…………………….114
Immunostaining of cartilage/cartilage-like tissues…………………………………..…116
RNA isolation using mirVana miRNA isolation kit……………………………………120
RNA isolation using TRI Reagent ……………………………………………………..123
Reverse transcription using standard oligodT protocol…………………...……………125
Reverse transcription for microRNAs using TaqMan microRNA assays….…………..127
QPCR for messenger RNAs using SYBR Green……………………………………….129
vii
QPCR for microRNAs using TaqMan microRNA assays…………………………...…132
Chondrocyte isolation from articular cartilage…………………………………………135
Protein extraction from cells……………………………………………………………138
viii
ACKNOWLEDGEMENTS
I would like to express my immense gratitude to the many people who have contributed to my
graduate experience and without whom the completion of this program would not have been
possible.
I would like to thank my supervisors Drs. Thomas G. Koch and Jonathan LaMarre for taking me
under their wings when I first joined the Department of Biomedical Sciences. Their enthusiasm
and intellectual guidance have instilled in me a deeper appreciation for the sciences and a desire
for greater knowledge. I am grateful for their mentorship and unwavering support throughout
my master’s program. I am particularly indebted to Dr. Koch who encouraged me and facilitated
my transfer from the course-based MBS (Master of Biomedical Sciences) program to the thesis-
based M.Sc. program. Because of this choice, my first manuscript has been accepted for
publication in a peer-reviewed journal, I have had the amazing opportunity to spend three
months doing research in Copenhagen and present my research at the Nordic Orthopaedic
Federation (NOF) 56th
Congress in Estonia. Thank you for propelling me forward.
Many thanks to Dr. Lise C. Berg for welcoming me into the Department of Clinical Veterinary
and Animal Sciences at the University of Copenhagen and making me feel comfortable in the lab
during my stay in Denmark. It was a pleasure learning laboratory techniques, such as qRT-PCR
using the Lightcycler480, protein extraction and chondrocyte isolation under her tutelage. Her
ideas helped shape the third chapter of this thesis and I am grateful for her expertise, feedback
and support which have been instrumental in the completion of this thesis.
ix
Special thanks to Esther Semple, Erinne Barnett, Helen Coates, Ed Reyes, Michelle Ross and Dr.
Monica Antenos for teaching me many of the essential laboratory techniques and protocols
and/or for being excellent resources. Each one of you has been extremely helpful and supportive
during the past two years.
I would like to thank my fellow graduate students Carmon Co and Laurence Tessier for their
friendship and encouragement during trying times. It has been a pleasure procrastinating and
commiserating with you. Thank you for making my time in the lab (and out of the lab) even
more enjoyable!
None of this would have been possible without the love and support of my partner. I would like
to thank Rob for seeing me through highs and lows and always being there for me. Your
patience and understanding are deeply appreciated.
x
DECLARATION OF WORK PERFORMED
I declare that all work submitted for assessment of this thesis is my own work with the exception
of the items indicated below.
Equine cord blood-derived mesenchymal stromal cell isolation, cell line establishment and initial
cryopreservation were performed by Rajdeep Gill, Jacqueline Fountain and Dr. Thomas Koch.
Screening of adhesion proteins for the coating of the PTFE membranes was performed by Dr.
Koch. Primer pairs for equine Col II, Col X, CD-RAP, MMP-1, SAA and GAPDH were
designed and optimized by Dr. Lise Berg. Primer pairs for HDAC4 and Cxcl12 were designed
by Laurence Tessier, but optimized by me.
xi
LIST OF TABLES
Introduction
Table 1. MiRNAs involved in cartilage development and homeostasis…………………………22
Chapter 1
Table 1. Primer pairs used for qRT-PCR………………………………………………………...42
Chapter 3
Table 1. Primer pairs used for qRT-PCR……………………………………………………...…75
xii
LIST OF FIGURES
Introduction
Figure 1: Synovial joint morphogenesis: Interzone specification, formation and cavitation……..3
Figure 2: Schematic representation of the changes in morphology that occur during
chondrogenesis………………………………………………...…………………………………..4
Figure 3: MicroRNA biogenesis and mechanisms of miRNA-mediated repression……………14
Chapter 1
Figure 1: Study Design…………………………………………………………………………..30
Figure 2: Chondrogenic differentiation of eCB-MSCs…………………………………………..43
Figure 3: Gene expression of cartilage markers by eCB-MSC pellets cultured up to 21 days in
chondrogenic media……………………………………………………………………………...44
Figure 4: Expression of microRNA-140 (miR-140) in undifferentiated equine CB-MSCs and
articular chondrocytes……………………………………………………………………………45
Figure 5: Expression of miR-140, Sox9 and previously identified targets IGFBP5, CXCL12, and
ADAMTS5……………………………………………………………………………………….46
Chapter 2
Figure 1: Study design for in vitro chondrogenesis……..………………………………………50
Figure 2: Histology and immunostaining of chondrogenic differentiation in the membrane
culture system without 24 hour expansion step………………………………………………….58
Figure 3: Histological comparison of pellet cultures and membrane cultures with 24 hour
expansion step……………………………………………………………………………………59
Chapter 3
Figure 1: Study design for the isolation and treatment of equine articular chondrocytes……….65
xiii
Figure 2: Gene expression of cartilage markers…………………………………………………76
Figure 3: Gene expression of inflammatory markers……………………………………………77
Figure 4: Expression levels of microRNAs……………………………………………………...78
Figure 5: Gene expression of miR-140 and miR-146a downstream targets…………………......79
General Discussion and Conclusions
Figure 1: Schematic representation of biochemical reactions for RGD-coating on PTFE……....85
xiv
LIST OF ABBREVIATIONS
3-D Three dimensional
ABAM Anti-bacterial anti-mycotic
ACI Autologous chondrocyte implantation
ADAMTS A disintegrin and metalloproteinase with thrombospondin motifs
Ago-2 Argonaute-2
AIA Antigen induced arthritis
ALP Alkaline phosphatase
ANOVA Analysis of Variance
BM-MSC Bone marrow-derived multipotent mesenchymal stromal cell
BMP Bone morphogenic protein
BSA Bovine serum albumin
CB-MSC Cord blood-derived multipotent mesenchymal stromal cell
CD-RAP Cartilage-derived retinoic acid-sensitive protein
ChIP Chromatin immunoprecipitation
COL2A1 Collagen type IIA1
COMP Cartilage oligomeric matrix protein
CP Chondrogenic Potential
CTRL Control
CXCL12 Chemokine (C-X-C motif) ligand 12
DMEM Dulbecco’s modified eagle medium
ECM Extracellular matrix
FBS Fetal bovine serum
FGF Fibroblast growth factor
xv
FN Fibronectin
GAG Glycosaminoglycan
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
HDAC4 Histone deacetylase 4
HIF Hypoxia inducible factor
HRP Horseradish peroxidase
IGF Insulin growth factor
IGFBP Insulin growth factor binding protein
IL-1β Interleukin-1 beta
iNOS Inducible nitric oxide synthase
ITS Insulin transferrin selenium
LEF-1 Lymphoid enhancer binding factor-1
LPS Lipopolysaccharide
LRA Luciferase reporter assay
MACI Matrix-assisted autologous chondrocyte implantation
miR, miRNA MicroRNA
MMP Matrix metalloproteinase
MSC Multipotent mesenchymal stromal cell
mRNA Messenger RNA
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NSAIDs Non-steroidal anti-inflammatory drugs
OA Osteoarthritis
PBS Phosphate buffered saline
Pri-miRNA Primary microRNA
PPARα Peroxisome proliferator-activated receptor α
xvi
PTFE Polytetrafluoroethylene
PTHrP Parathyroid hormone related protein
qPCR Quantitative real-time polymerase chain reaction
RISC RNA induced silencing complex
Runx2 Runt-related transcription factor 2
SAA Serum amyloid A
SBE Smad binding element
SCID Severe combined immunodeficiency
SEM Standard error of mean
Smad Mothers against decapentaplegic homolog
Sox Sex determining region Y box
Sp1 Specificity protein 1
TGFβ Transforming growth factor beta
TLR Toll-like receptor
TNFα Tumour necrosis factor alpha
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling
UTR Untranslated region
VEGF Vascular endothelial growth factor
WMISH Whole mount in situ hybridization
1
INTRODUCTION
Cartilage is a flexible connective tissue, consisting of extracellular matrix (ECM) interspersed
with chondrocytes. There are three types of cartilage; elastic, fibrous and hyaline, which differ
in their relative composition of collagen fibers, proteoglycans and elastin. Elastic cartilage is
found in the epiglottis and the outer ear and its many elastin networks allow for great flexibility.
Fibrocartilage has excellent tensile strength due to the thick, parallel bundles of collagens type I
and II and is normally found in the intervertebral discs, pubic symphysis and meniscus.
However, the focus of this thesis will be restricted to hyaline cartilage, more specifically, the
articular cartilage that is found on the surfaces of articulating bones and allows for near
frictionless movement. Resident articular chondrocytes produce and maintain an extensive ECM
consisting of collagens and proteoglycans. Collagen type II is the main component of articular
cartilage and provides support and tensile strength to the tissue (Basser et al., 1998).
Proteoglycans, such as aggrecan, are highly hydrated due to the high level of glycosylation of the
core protein. This hydration confers the cartilage with the capacity to withstand load bearing and
absorb shock (Hardingham & Fosang, 1992). Articular chondrocytes retain a stable phenotype
and resist hypertrophy, calcification, apoptosis and vascular invasion, however the mechanisms
by which they maintain their phenotype remain largely unknown.
Natural cartilage development
Synovial Joint Formation
Synovial joints, also known as diarthrosis, allow for movement at the point of contact of
articulating bones and the distribution of biomechanical loads through the structure. They are
2
characterized by the presence of articular cartilage on opposing bony surfaces and lubricating
synovial fluid. The synovial joints are formed concomitantly with the skeletal elements. During
embryonic development, the transient cartilage that provides a framework for endochondral bone
formation and the permanent cartilage that protects the surfaces of articulating bones, both arise
from the mesenchymal progenitor cells of the blastema. The process is initiated by the
aggregation and condensation of mesenchymal cells, which favours cell-cell and cell-matrix
interactions important for triggering signal transduction pathways leading to chondrogenic
differentiation (Fig. 1). The formation and growth of the condensations are regulated by many
factors including homeobox (Hox) transcription factors, bone morphogenic proteins (BMPs),
fibroblast growth factors (FGFs) and Sonic hedgehog (Shh; Chen et al., 2009). The first
indication of synovial joint development is the formation of the interzone, where mesenchymal
cells become flattened and form a region of high cell density within the condensation. Joint
formation is thought to be initiated by Wnt/β-catenin signalling, which leads to the induction of
growth/differentiation factor 5 (GDF5), BMP family member (Guo et al., 2004). The interzone
evolves into a three-layered interzone. The cells of the central zone eventually disappear,
forming the joint cavity and although the mechanisms responsible are not fully elucidated,
programmed cell death and physical changes in the ECM are thought to be involved (DeBari et
al., 2010). The remaining zones are thought to form the articular cartilage covering the adjacent
bones (Araldi & Schipani, 2010) as well as periarticular and intraarticular joint structures (Fig.1)
(Rountree et al., 2004; Koyama et al., 2008).
3
Figure 1: Synovial joint morphogenesis: Interzone specification, formation and cavitation.
Within the mesenchymal condensation, an interzone of flattened cells appears. This evolves into
a three-layered interzone; the central layer undergoes cavitation, resulting in the formation of the
joint cavity, while the outer layers develop to form the articular cartilage, peri- and intra-articular
structures (Khan et al., 2007).
Endochondral Ossification
Concomitantly with synovial joint formation, the adjacent mesenchymal cells undergo
morphological changes, losing their processes to take on a rounded morphology (Fig. 2). They
begin to express SRY-related high-mobility-group box 9 (Sox9), a key transcriptional regulator
in early chondrogenesis. Along with Sox5 and Sox6, Sox9 regulates cartilage development by
activating the expression of collagen type 2, aggrecan and cartilage oligomeric matrix protein
(COMP; Huang et al., 2001; Ng et al., 1997). The expression of these cartilage-specific genes
leads to chondrocyte maturation and extracellular matrix (ECM) production (Lefebvre & Smits,
2005). The proliferating and pre-hypertrophic chondrocytes elongate the cartilage template
before undergoing cell cycle arrest and becoming hypertrophic. Hypertrophic chondrocytes are
4
defined by an increase in size and the expression of collagen type X, alkaline phosphatase
(ALP), matrix metalloproteinase 13 (MMP-13) and runt-related transcription factor 2 (Runx2).
These changes are associated with matrix mineralization (Kim et al., 2010). The expression of
vascular endothelial growth factor (VEGF) then stimulates vascular invasion, which facilitates
the replacement of the mineralized cartilage by bone through the migration of osteoclasts and
osteoblasts (Carlevaro et al., 2000). The terminally differentiated chondrocytes either
transdifferentiate towards osteoblasts or undergo apoptosis (Adams & Shapiro, 2002).
Figure 2. Schematic representation of the changes in morphology that occur during
chondrogenesis. The red box indicates the crucial step wherein the chondrocytes either maintain
their phenotype (articular chondrocytes) or progress towards hypertrophy and terminal
differentiation (Modified from Gadjanski et al., 2012).
These ossification events begin at a site known as the primary ossification centre, located in the
centre of the diaphysis (shaft), and then spread along the diaphysis. Secondary ossification
centres later appear at either end (epiphysis) of the developing long bone. The cartilage between
the primary and secondary ossification centre is known as the epiphyseal plate or ‘growth’ plate,
since this site is responsible for post-natal interstitial bone growth. Eventually, the cartilage of
the epiphyseal plate is also replaced by bone, forming a line where the primary and secondary
5
ossification centres meet. The articular cartilage however, can normally resist ossification and
maintain a stable phenotype.
Current treatments for articular cartilage defects
Cartilage defects can arise as a result of trauma or inflammation and, left untreated, can continue
to deteriorate and lead to osteoarthritis (Wang et al., 2006). Articular cartilage has a limited
healing response due to the avascular nature of the tissue and the extensive ECM which prevents
cell migration to the injury site. There are several surgical techniques aimed at restoring the
articular surface, reducing pain and increasing mobility. Focal cartilage injuries in humans are
currently treated by debridement, bone marrow stimulation, autologous chondrocyte
implantation or osteochondral grafts depending on the size and severity of the defect (Williams
et al., 2010).
Bone Marrow Stimulation
During bone marrow stimulation, the damaged articular cartilage is debrided to expose the
subchondral bone which can then be penetrated by one of the following techniques; arthroscopic
abrasion, drilling or microfracture (Ahmed & Hincke, 2010). The penetration of the bone
releases blood and marrow into the defect to form a fibrin clot. The theory is that the marrow
contains chondroprogenitors that will differentiate and repair the lesion. Although these
techniques may offer some pain reduction (Nehrer & Minas, 2000), the long term results are
largely dependent on patient age and size of the defect. One of the major limitations of bone
marrow stimulation is that the repair tissue consists of fibrocartilage, a biomechanically inferior
tissue compared with articular cartilage, that can deteriorate over time. Additional drawbacks
6
include incomplete filling and bone formation in the defect site (Steinwachs et al., 2008). The
cause of this inadequate repair is not fully understood but speculations are that the number of
MSCs released may be insufficient to stimulate full repair or that the MSCs may require
additional growth factors to differentiate fully. Moreover, the inferior long-term results in older
patients could be attributed to the decreased proliferative capacity and differentiation potential of
adult stem cells (Stenderup et al., 2003).
Osteochondral Grafts
Cartilage transfer procedures involve the transplantation of healthy sections of bone and cartilage
to the damaged area. Cylindrical osteochondral plugs are harvested from low weight bearing
areas and inserted into recipient holes in the affected part of the joint. As the subchondral bone
is penetrated during this procedure, the spaces between the grafts are filled with fibrocartilage,
while the donor sites are filled by cancellous bone covered in fibrocartilage (Hangody et al.,
2008). Although this method can restore the articular surface, the limited availability of
autologous osteochondral plugs can limit the repair of large defects. Additional concerns include
donor site morbidity, risk of infection and lack of integration between the plugs and the
surrounding cartilage (Ahmed & Hincke, 2010).
Autologous Chondrocyte Implantation
The clinical procedure known as autologous chondrocyte implantation (ACI) or matrix-assisted
ACI (MACI) involves the introduction of in vitro expanded chondrocytes into the defect site and
has been used to treat cartilage defects with relative success (Brittberg et al., 1994; Knutsen et
al., 2004; Ebert et al., 2011). However, this repair strategy requires a preliminary surgery to
7
harvest chondrocytes from a low weight bearing area of the articular cartilage, which causes
donor site morbidity and may result in further degenerative changes (Lee et al., 2000). Due to
the limited amount of tissue available and the low proliferative capacity of chondrocytes,
prolonged expansion is required to obtain sufficient numbers of cells. Furthermore,
chondrocytes tend to lose their chondrocytic features during expansion in a process known as
dedifferentiation (von der Mark et al., 1977), which may be responsible for the formation of
fibrous rather than hyaline tissue in the joint following ACI/MACI (Saris et al., 2008).
Improvement of the MACI approach through the application of different biomaterials and
alternative cell sources may help overcome the limitations of current cartilage repair modalities.
Mesenchymal stromal cells as a cell source for chondrogenesis
Mesenchymal stromal cells are a promising cell source for the treatment of articular cartilage
defects because they eliminate the need to harvest healthy cartilage and they can be rapidly
expanded to generate large numbers of cells. They are multipotent and given the appropriate
culture conditions, can be differentiated into bone, cartilage, muscle or adipose tissue (Baksh et
al., 2004). MSCs can be isolated from many sources such as adipose tissue, bone marrow,
synovial membrane and umbilical cord blood (Zuk et al., 2002; Castro-Malaspina et al., 1980;
De Bari et al., 2001; Lee et al., 2004). Although many comparative studies have been
undertaken, no consensus has been reached on the optimal MSC source for cartilage tissue
engineering.
The therapeutic use of human MSCs is not widely practiced, however MSCs derived from
equine bone marrow (BM-MSC) are currently used to treat horses with musculoskeletal injuries.
8
These equine cell-based therapies are primarily used to treat tendon and ligament injuries at this
time (Guest et al., 2008; Pacini et al., 2007; Smith et al., 2003) but the use of MSC in equine
cartilage repair is gaining significant interest. Most studies are restricted to in vitro work,
however Wilke et al. (2007) provides an example of an in vivo study of the effect of MSC
implantation on cartilage healing in an equine model. They induced cartilage lesions in the
femoropatellar joints of six horses and treated them with an autologous fibrin vehicle containing
culture-expanded BM-MSCs or with autologous fibrin alone as a control. An arthroscopic
examination 30 days after treatment revealed that the BM-MSC treated defects were significantly
improved; the repair tissue was thicker and more homogeneous compared to the controls. These
results were not sustained 8 months after treatment, at which point no difference was observed
between groups. Whether the initial improvement in healing response was MSC-mediated is
uncertain, however, MSCs do not harbour unlimited proliferative capacities in vitro therefore
death or metabolic inactivation of the MSCs may account for the lack of sustained improvement
(Kern et al., 2006).
Although BM-MSCs are the best-characterized, cord blood-derived MSCs (CB-MSCs) may
offer several advantages. The collection of bone marrow is an invasive procedure and the
proliferative capacities and differentiation potential decline with increasing age (Stenderup et al.,
2003). In contrast, umbilical cord blood can be obtained by a non-invasive method (Rubinstein et
al., 1993; Koch et al., 2007) and studies on both human and equine CB-MSCs have revealed
higher replicative potential and broader potency compared to BM-MSCs (Kern et al., 2006;
Kogler et al., 2006; Koch et al., 2007). In particular, human and equine CB-MSCs are reported
to be more chondrogenic than bone marrow and adipose tissue derived-MSCs (Berg et al., 2009;
9
Zhang et al., 2011). Despite the apparent superiority of CB-MSCs, little data regarding their
performance in vivo is available. However, a phase III clinical trial using the recently approved
allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product known as
CartiStem® was recently completed (ClinicalTrials.gov Identifier NCT01041001). This study
compared the safety and efficacy of CB-MSC administration to microfracture treatment in
patients with articular cartilage lesions of the knee. Although a peer-reviewed paper has not yet
been published, Nature Medicine reported that improvement in knee mobility was 26% percent
higher in the cell treated group (CartiStem®) compared to the control group treated by
microfracture alone (Wohn, 2012).
Induction of in vitro chondrogenesis
Chondrogenic differentiation of MSCs has traditionally been induced by applying three-
dimensional (3-D) culture conditions and including transforming growth factor-β (TGF-β) and
dexamethasone in the media, as described by Johnstone and colleagues in 1998. In the
micromass pellet culture system, MSCs are centrifuged into pellets in polypropylene tubes,
resulting in the formation of cell aggregates. The use of polypropylene is crucial because the
cells form aggregates in favor of cell-cell interactions rather than adhering to the substrate.
However, the micromass pellet culture system is primarily used to study in vitro chondrogenesis
rather than use the differentiated cells for biological repair. In fact, only 250 000 - 500 000 cells
are seeded to form the cell aggregates and increasing pellet size can result in cell necrosis in the
center of the aggregate (Ebisawa et al.., 2004). Although immunohistochemistry of the pellets in
several reports indicate successful differentiation through collagen type II and sulfated
glycosaminoglycan (GAG) staining, it is often heterogeneous and accompanied by expression of
10
collagen type I, which is characteristic of fibrous tissue, and collagen type X, which is typical of
terminal differentiation of hypertrophic chondrocytes (Steck et al., 2005; Nelea et al., 2005).
Lee and colleagues have recently developed a protocol in which ovine BM-MSCs are
differentiated towards a chondrogenic fate on collagen IV-coated polytetrafluoroethane
membrane inserts. They reported that GAG and collagen content was similar in pellet and
membrane-based cultures. Hypertrophic markers Runx2 and collagen X were expressed in both
culture types however, the expression level of collagen type I mRNA was significantly lower in
membrane cultured cells compared to pellet cultures (Lee et al., 2011).
A plethora of other differentiation protocols have been developed in an attempt to optimize in
vitro cartilage engineering. Different cocktails of exogenous anabolic factors have been applied
with variable results. For instance, TGF-β3 in combination with BMP-2, -4 or -6 improved
chondrogenesis of human BM-MSCs compared to TGF-β3 alone. BMP-2 induced the most
significant improvement, as evidenced by increased size and weight of pellets and positive
staining for collagen II and proteoglycans (Sekiya et al., 2005). In a similar study, the addition
of parathyroid hormone related protein (PTHrP) to TGF-β2 increased GAG content and
expression of collagen II mRNA and protein, while decreasing the expression of collagens I and
X and Runx2 (Kim et al., 2008). Monolayer expansion of MSCs in media containing fibroblast
growth factor 2 (FGF-2) is thought to extend the proliferative lifespan of MSCs and enhance
chondrogenesis once differentiation is induced (Solchaga et al., 2010).
Another important factor influencing chondrogenic differentiation is oxygen tension. In general
in vitro engineered cartilage tissues are cultured in a 20% oxygen environment even though the
11
physiological environment in which articular cartilage resides is hypoxic; approximately 1-7%
O2 (Silver et al., 1975; Kellner et al., 2002). Several studies have reported that hypoxic
conditions enhance chondrogenesis of bone marrow derived-MSCs (Khan et al., 2010; Markway
et al., 2010), an effect that is thought to be mediated by hypoxia inducible factor-1α (HIF-1α:
Kanichai et al., 2008). A study using chromatin immunoprecipitation (ChIP) demonstrated that
HIF-1α may promote chondrogenesis by binding to a hypoxia response element in the promoter
region of Sox9 (Amarilio et al., 2007).
Additional protocols include MSC co-culture with articular chondrocytes (Ahmed et al., 2007;
Chen et al., 2009), the use of biomaterials such as alginate and agarose (Vinatier et al., 2009),
chondrogenic growth factor delivery via gene transfer (Palmer et al., 2005; Steinert et al., 2008)
and mechanical stimulation using bioreactor systems (Grad et al., 2011). Chondrogenic
differentiation techniques aim to increase the expression and production of ECM components
and prevent the upregulation of hypertrophy-associated markers such as MMP-13, collagen X,
Runx2 and activity of ALP. A study by Pelttari et al. (2006) demonstrated that premature
induction of hypertrophy in vitro leads to matrix calcification and vascular invasion of BM-MSC
pellet cultures following ectopic transplantation into severe combined immunodeficiency (SCID)
mice. However, when articular chondrocytes were subjected to the same conditions, they formed
stable cartilage. This suggests that there are inherent differences between articular and MSC-
derived chondrocytes that need to be characterized in order to develop protocols that can
generate a stable differentiated phenotype in vitro and in vivo.
12
The role of microRNAs in cartilage development and homeostasis
MicroRNAs (miRNAs) are a class of endogenous non-coding RNAs, approximately 20-25
nucleotides in length, which are potent regulators of gene expression. These molecules are
thought to be involved in regulating at least one third of all mammalian genes (Lewis et al.,
2005). MiRNAs function at the post-transcriptional level by binding to complementary
sequences in the 3’-untranslated region (3’-UTR) of target mRNAs and inhibiting their
expression, either by blocking translation or by inducing mRNA degradation. Thus, microRNAs
are directly involved in regulating cellular phenotype (Bartel, 2004).
The first microRNA was discovered in 1993, when two independent studies using
Caenorhabditis elegans found that the Lin-14 protein, which is essential for cell lineage
patterning during larval development, was negatively regulated by a short untranslated RNA
fragment within the lin-4 gene (Lee et al., 1993; Wightman et al., 1993). Upon closer
examination, researchers found that this RNA fragment was complementary to a sequence in the
3’UTR of lin-14 and suggested that an antisense RNA-RNA interaction inhibited the translation
of lin-14. This phenomenon was originally thought to be nematode specific and it was not until
2001 that the importance of these discoveries was revealed when a number of small RNAs with
similar regulatory potential was identified in both vertebrates and invertebrates, thus the term
‘microRNA’ was coined (Lagos-Quintana et al., 2001). Numerous studies have since shown that
they are important regulators of various biological processes such as differentiation, development
and tumorigenesis (Chen et al., 2003; Krichevsky et al., 2006; Nicoloso et al., 2009).
13
MicroRNA biogenesis
In order to generate mature single-stranded miRNAs, multiple processing steps are required (Fig.
3). Long primary transcripts known as pri-miRNAs, are generally transcribed by RNA
polymerase II and can originate from genes, polycistronic clusters or intronic regions (Winter et
al., 2009). The classical miRNA originates from a small gene within an intergenic region and
can be regulated through its promoter. However, a number of miRNAs can be found in
polycistronic units or ‘miRNA clusters’, where a single transcript contains multiple miRNA
precursors (Lagos-Quintana et al., 2001). MiRNA genes or clusters form stem-loop
conformations for each miRNA due to the sequence complementarity within the arm of the stem.
The RNAse III known as Drosha acts in concert with DGCR8 (DiGeorge Critical Region 8) to
cleave the pri-miRNAs and produce small hairpin structures termed pre-miRNAs. Additionally,
many miRNAs are derived from intronic regions of messenger RNAs, in which case they are
regulated and transcribed together with their host gene. The mechanism of intronic miRNA
processing is not clear but pre-miRNA cleavage is thought to involve a functional association
between Drosha and the spliceosome (Kataoka et al., 2009).
14
Figure 3. MicroRNA biogenesis and mechanisms of miRNA-mediated repression. (1) Primary
transcripts are transcribed by polymerase II from genes (2a), polycistronic clusters (2b), or
introns (2c). The pre-miRNA is cleaved from the pri-miRNA by Drosha (2a,b) or through a
spliceosome-Drosha interaction (2c). Pre-miRNA are transported to the cytoplasm by exportin-5
(3). The stem-region is cleaved by Dicer (4) forming a miRNA duplex (5). The guide strand
associates with the RISC (6) and anneals to the 3’UTR of target genes (7) to either repress
translation (8a) or induce mRNA degradation. (Araldi & Schipani, 2010).
Once released, the pre-miRNAs are recognized by Exportin5 and exported from the nucleus into
the cytoplasm through the nuclear pore complex. The cytoplasmic RNAse III, Dicer, cleaves the
15
loop region of the hairpin to generate a short RNA duplex which contains the miRNA guide
strand as well as the passenger strand, denoted by an asterisk (miRNA*). Although either strand
can act as a functional miRNA, it is normally the strand with the less thermodynamically stable
5’ end that becomes incorporated into the RNA-induced silencing complex (RISC; Du &
Zamore, 2005), while the other is degraded. Once the miRNA:RISC binds to a target mRNA,
gene silencing can occur either by blocking translation or by inducing transcript degradation.
The outcome is thought to depend on the degree of mismatch between the microRNA and the
target mRNA, with degradation being the result of best-matched targets.
Expression of microRNAs during chondrogenesis
The first indication that microRNAs may be involved in chondrogenesis was provided by
Wienholds et al. (2005). Using whole mount in situ hybridization reactions (WMISH), they
showed that most conserved vertebrate microRNAs are expressed in a tissue-specific manner in
zebrafish embryos and they revealed that miR-140 is only expressed in cartilaginous tissue. This
expression pattern of miR-140 was also shown in mouse embryos and histone deacetylase 4
(HDAC4) was identified as a target (Tuddenham et al., 2006). As HDAC4 is a known co-
repressor of Runx2, its suppression by miR-140 may promote chondrocyte hypertrophy and
osteoblast differentiation during skeletal development. Further evidence of the crucial role of
microRNAs during chondrogenesis was provided by a study in which Dicer, an
endoribonuclease required for microRNA processing, was knocked out in the cartilage of mice
(cKO). As a result, the proliferating pool of chondrocytes was reduced and hypertrophic
differentiation was accelerated, causing severe growth defects and premature death of the mice
(Kobayashi et al., 2008). Abundant expression of miR-140 was detected in the chondrocytes of
16
the control mice compared to the cKO mice, however the effect of its reduction on the phenotype
of the cKO mice is unclear since a global miRNA deficiency was induced.
In order to further characterize the role of miR-140 during chondrogenesis and skeletal
development, Kobayashi and colleagues generated miR-140 null mice. These mice reached
adulthood but exhibited growth retardation and skeletal defects, which were attributed to
accelerated hypertrophic differentiation, since no alteration in proliferation of chondrocytes was
detected. Using argonaute-2 immunoprecipitation (Ago2-IP), Ago-2 being the catalytic
component of the RISC that binds miRNAs and consequently their target genes, Dnpep (aspartyl
aminopeptidase) was identified as a miR-140 target because its mRNA levels were enriched in
wild type chondrocytes compared to miR-140 null chondrocytes. They found that Dnpep
overexpression had an antagonist effect on BMP signalling and proposed that the skeletal defects
of miR-140 null mice were due in part to reduced BMP signalling caused by Dnpep upregulation
(Nakamura et al., 2011).
Several reports have demonstrated that miR-140 expression increases during in vitro
chondrogenesis (Miyaki et al., 2009; Yang et al., 2011), therefore in vitro studies have been used
to elucidate microRNA targets during chondrogenic differentiation. A key transcription factor in
the TGF-β signalling pathway, Smad3, was identified as a direct target of miR-140.
Overexpression and knockdown of miR-140 in a murine MSC line showed that Smad3 mRNA
was unaffected by miR-140 manipulation but Smad3 protein levels were decreased in cells
treated with a miR-140 mimicking siRNA, while they were increased in response to antimiR-
140, revealing that Smad3 is regulated at the protein level. Direct binding of miR-140 to the
17
3’UTR of Smad3 was confirmed by luciferase reporter assay (LRA; Pais et al., 2010).
Specificity protein 1 (Sp1), which is a transcription factor that inhibits the cell cycle, was also
shown to be directly regulated by miR-140 through translational repression. Thus, miR-140 may
be implicated in the maintenance of chondrocyte proliferation by repressing Sp1 (Yang et al.,
2011). In the same study, miR-140 was found to be co-expressed with its host gene, Wwp2-C,
and directly induced by Sox9, the master transcriptional regulator of chondrogenesis (Yang et al.,
2011).
Another microRNA that has been associated with chondrogenesis is miR-145. While other
studies have identified a role for this microRNA in embryonic stem cell differentiation (Xu et al.,
2009) and vascular smooth muscle cell maintenance (Xin et al., 2009; Elia et al., 2009), recent
reports have demonstrated that miR-145 expression decreases during chondrogenic
differentiation of human and murine MSCs. Interestingly, both studies identified Sox9 as a
target of miR-145, albeit through different binding sites in the 3’UTR (Yang et al., 2011;
Martinez-Sanchez et al., 2012). Knocking down miR-145 was reported to increase the
expression of cartilage ECM genes COL2A1 and aggrecan and decrease the levels of
hypertrophic markers RUNX2 and MMP13 (Martinez-Sanchez et al., 2012), making miR-145 an
attractive target in cartilage tissue engineering. Many additional microRNAs have been
identified as having a role in chondrogenesis and can be found in Table I.
MicroRNAs in articular cartilage
The identification of abundantly expressed microRNAs in articular cartilage suggests an
important role for microRNAs in cartilage homeostasis. MicroRNA microarray revealed that the
18
largest difference in expression between human BM-MSCs and articular chondrocytes was
exhibited by miR-140 (Miyaki et al., 2009). In another study, genome-wide profiling comparing
healthy primary human chondrocytes and dedifferentiated chondrocytes showed that H19, a
primary miRNA transcript for miR-675 (Cai & Cullen, 2007), was highly abundant. Collagen
type II gene expression was found to be upregulated by miR-675, possibly through a de-
repression mechanism (Dudek et al., 2010). Mechanical stimulation is essential for chondrocyte
differentiation and cartilage homeostasis. In order to identify miRNAs that may be involved in
mechanical stress response, microRNA expression profiles were determined in the articular
cartilage of regions with differing mechanical loading conditions. MiR-221 and miR-222 were
up-regulated in the weight-bearing anterior medial condyle compared with the non-weight-
bearing posterior medial condyle, suggesting that these miRNA species may be regulators of an
articular cartilage mechanotransduction pathway (Dunn et al., 2009). Guan et al. (2011)
identified miR-365 as a mechanosensitive miRNA by screening primary chicken chondrocytes
before and after cyclic loading. Chondrocyte proliferation and differentiation towards a
hypertrophic phenotype was stimulated by miR-365, an effect that was proposed to be mediated
by direct repression of its target, HDAC4.
MicroRNAs in osteoarthritis
Osteoarthritis (OA) is a highly prevalent degenerative joint disease that affects both horses and
humans (Lacourt et al., 2012). Although the pathogenesis underlying the disease is poorly
understood, it is generally accepted that cartilage degradation stems from an imbalance between
anabolic and catabolic factors. The development and progression of OA are believed to be
mediated by secreted proinflammatory cytokines, particularly interleukin (IL)-1β and tumour
19
necrosis factor (TNF). They are elevated in OA synovial fluid, synovial membrane, subchondral
bone and cartilage and suppress the expression of cartilage ECM components, while stimulating
the release of matrix metalloproteinases (Kapoor et al., 2011). In a study by Asahara and
colleagues, the expression of miR-140 was significantly reduced in OA articular cartilage
compared to normal cartilage and in vitro treatment of normal chondrocytes with IL-1β
suppressed miR-140 expression. They reported that expression of the aggrecanase, Adamts5 (a
disintegrin and metalloproteinase with thrombospondin motifs 5), is regulated by miR-140 since
its IL-1β-induced upregulation was abrogated by the introduction of a double stranded miR-140
mimic (ds-miR-140; Miyaki et al., 2009). More recently, the same group generated miR-140
null mice. The miR-140-/-
mice exhibited a short stature and craniofacial deformities that were
attributed to a reduction in proliferating chondrocytes. Articular cartilage of these mice appeared
normal at 1 month, however they developed age-related OA changes such as proteoglycan loss
and fibrillation of articular cartilage by 12 months. Cartilage-specific transgenic mice
overexpressing miR-140 were also generated and were found to be resistant against the antigen
induced arthritis (AIA) model. Both Adamts5 mRNA and protein were upregulated in the
articular cartilage of miR-140-/-
mice compared to wild-type mice and Adamts5 gene expression
was repressed in miR-140 null chondrocytes treated with ds-miR-140, suggesting negative
regulation by miR-140. Luciferase reporter assay indicated that miR-140 directly targets
Adamts5 through a miR-140 binding site in its 3’UTR. Thus the protective role of miR-140 in
OA pathology was speculated to be mediated by Adamts5 repression (Miyaki et al., 2010).
Insulin growth factor binding protein 5 (IGFBP5) is another putative target of miR-140.
Transfection of human OA chondrocytes with pre-miR-140 caused decreased IGFBP5
20
expression, while anti-miR-140 cause increased expression. Since these results were observed
24 hours post-treatment, direct regulation of IGFBP5 by miR-140 was suggested although
3’UTR LRA was not performed (Tardif et al., 2009). The role of IGFBP5 in cartilage
homeostasis is unclear but is thought to regulate the availability of insulin growth factor 1 (IGF-
1). Treatment of human chondrocytes with IL-1β increased the expression of MMP-13 and miR-
140, an effect that was abrogated by inhibition of NF-κB. MMP-13 was identified as a direct
miR-140 target by LRA and anti-miR-140 transfection caused elevated MMP-13 expression in
the IL-1β stimulated cells (Liang et al., 2012). The increased expression of miR-140 in response
to IL-1β stimulation conflicts with a previous report where miR-140 was downregulated by IL-
1β (Miyaki et al., 2009). This inconsistency could be due to differences in passage number,
cytokine concentration and treatment duration. Whether decreased miR-140 expression in OA
chondrocytes (Miyaki et al., 2009; Tardif et al., 2009; Iliopoulos et al., 2008) is due to elevated
proinflammatory cytokines is yet to be determined.
Another miRNA that has recently emerged in OA pathology is miR-146a. A study by Yamasaki
and colleagues demonstrated that miR-146a is highly expressed in cartilage from patients with
mild OA and that expression decreases with severity. They also established that IL-1β induces
miR-146a in normal human articular chondrocytes (Yamasaki et al., 2009). In a subsequent
study miR-146a was overexpressed in IL-1β stimulated rat chondrocytes and in a surgical model
of OA. Its overexpression was accompanied by upregulation of VEGF and repression of Smad4,
an important mediator of the TGFβ signalling pathway. Smad4 was determined to be a direct
target of miR-146a that is regulated both by mRNA degradation and translational repression.
Transfection of miR-146a into chondrocytes induced apoptosis as indicated by an increase in
21
percentage of TUNEL positive cells. Thus, miR-146a may contribute to several hallmarks of
OA; impaired TGFβ signalling, pathological vascularization and reduced cellularity of articular
cartilage due to chondrocyte apoptosis (Li et al., 2012). Additional miRNAs have been
associated with OA and can be found in Table I.
Cartilage regeneration remains a clinical challenge because of its limited healing response. More
and more miRNAs with roles in cartilage development and homeostasis are being identified and
a better understanding of the molecular mechanisms at play will have profound implications for
cartilage repair and OA treatments. Despite the increasing interest in miRNA function in
cartilage biology, there appear to be no reports on microRNA expression in equine MSCs or
chondrocytes.
22
Table I. MiRNAs involved in cartilage development and homeostasis
miRNAs Targets Function of target Reference
miR-140 HDAC4 Inhibition of chondrocyte hypertrophy Tuddenham et al., 2006
CXCL12 Role in BMP-2 signalling Nicolas et al., 2008
IGFBP5 Regulates availability of IGF-1 Tardif et al., 2009
ADAMTS5 Aggrecan degradation Miyaki et al., 2010
SMAD3 TGFβ signalling Pais et al., 2010
DNPEP Inhibition of BMP signalling Nakamura et al., 2011
SP-1 Chondrocyte proliferation Yang et al., 2011
MMP-13 Collagen degradation Liang et al., 2012
miR-145 SOX9 Chondrogenic differentiation Yang et al., 2011
SOX9 Chondrogenic differentiation Martinez-Sanchez et al.,
2012
miR-199a* SMAD1 TGFβ signalling Lin et al., 2009
miR-221 MDM2 Chondrocyte proliferation Kim et al., 2010
miR-337 TGFBR2 TGFβ signalling Zhong et al., 2012
miR-449a LEF-1 Repression of chondrogenesis (↓ Sox9) Paik et al., 2012
miR-455-3p ACVR2B
SMAD2
Potential modulator TGFβ signalling
TGFβ signalling
Swingler et al., 2011
miR-18a CCN2 Role in stimulation of ECM production Ohgawara et al., 2009
miR-675 COL2A1 ECM component Dudek et al., 2010
miR-222 N.I. TBD (role in mechanosensitivity) Dunn et al., 2009
miR-365 HDAC4 Inhibition of chondrocyte hypertrophy Guan et al., 2011
miR-146a SMAD4 TGFβ signalling Li et al., 2012
miR-22 BMP7
PPARα
Regulation of IL-1β and MMP13
Regulation of IL-1β and MMP13
Iliopoulos et al., 2008
miR-27b MMP-13 Collagen degradation Akhtar et al., 2010
miR-34a COL2A1
iNOS
ECM component
Chondrocyte apoptosis
Abouheif et al., 2010
N.I. not identified
23
RATIONALE
Orthopaedic injuries involving the joint cartilage are some of the most common causes of
lameness in racehorses (Bailey et al., 1999). Articular cartilage repair remains a clinical
challenge due to the poor regenerative capacities of the tissue. Current procedures are primarily
palliative, none of which are capable of reversing injuries to this tissue. A number of different
stem cell-based therapies have considerable potential in the treatment of joint injuries. In
particular, mesenchymal stromal cells (MSCs) have been regarded as a promising cell source to
improve the quality of cartilage repair because of their ability to self-renew and differentiate into
various lineages. In fact, the use of bone marrow-derived MSCs (BM-MSCs) for the treatment
of equine orthopaedic injuries is increasing, but is primarily directed toward the repair of
ligaments and tendons at this time (Fortier & Smith, 2008). One key challenge of using stem
cells to repair damaged cartilage is the induction of a stable chondrocyte phenotype without
terminal differentiation. Current in vitro differentiation protocols have successfully induced cells
with chondrocyte-like morphology, production of extracellular matrix and expression of
cartilage-specific markers including collagen II, aggrecan and SOX9. However, these features
are often accompanied by markers of fibrous tissue such as collagen I, and/or markers of
hypertrophy such as collagen X (Johnstone et al., 1998).
One approach that may reduce the expression of fibrous and hypertrophic markers, and increase
the expression of cartilage-specific markers, is the use of a membrane culture system rather than
the traditional pellet culture system. On coated cell culture inserts 2 million cells can be seeded
for differentiation instead of 250 000 – 500 000. Additionally, this system may provide a more
24
homogeneous environment for the cultures by reducing the surface tension and nutrient gradients
compared to pellets.
Another parameter that could improve the outcome of in vitro chondrogenesis is the MSC
source. Although BM-MSCs are most commonly used, MSCs can be isolated from a number of
other sources including adipose tissue, synovial membrane and umbilical cord blood (Zuk et al.,
2001; De Bari et al., 2001; Lee et al., 2004). Cord blood is an attractive alternative MSC source
to bone marrow because of its superior multipotency, proliferative capacity and ease of
acquisition (Kern et al., 2006; Kogler et al., 2006; Koch et al., 2007). Additionally, human and
equine studies suggest that CB-MSCs are more chondrogenic than bone marrow and adipose
tissue derived-MSCs (Berg et al., 2009; Zhang et al., 2011). Therefore, equine CB-MSCs (eCB-
MSCs) were selected as the MSC source in this study.
In order to address the challenges posed by articular cartilage injury and degeneration, it is
important to elucidate the molecular mechanisms at play during chondrogenic differentiation and
pathological processes. Novel post-transcriptional regulators known as microRNAs have
recently emerged as important regulators and fine-tuners of gene expression. They are involved
in many biological processes including chondrogenic differentiation and pathogenesis of
arthropathies such as osteoarthritis (OA; Hong et al., 2012). Therefore, the involvement of
microRNAs in cartilage specific processes warrants further investigation.
Based on this rationale, hypotheses and objectives were proposed for each chapter:
25
Chapter 1
Hypothesis: Cartilage-specific microRNA miR-140 will be expressed in equine articular
chondrocytes and will be upregulated during chondrogenic induction of eCB-MSCs.
Objective: Characterise the expression of miR-140 and selected miR-140 targets in
chondrogenically differentiated eCB-MSCs and equine articular chondrocytes.
Chapter 2
Hypothesis: Chondrogenic differentiation of eCB-MSCs using membrane culture will allow
differentiation of high numbers of cells and yield more homogeneous, hyaline-like cartilage
compared to pellet culture.
Objective: Histologically evaluate pellet and membrane cultures following chondrogenic
differentiation.
Chapter 3
Hypothesis: Select microRNAs will be differentially expressed in response to inflammatory
stimuli in equine articular chondrocytes.
Objective: Characterise the expression of microRNAs previously associated with arthritis in
other species, in equine articular chondrocytes subjected to inflammatory stimuli.
26
CHAPTER 1
MicroRNA-140 Expression During Chondrogenic Differentiation of Equine Cord Blood-
Derived Mesenchymal Stromal Cells
(This chapter is a modified version of the manuscript SCD-2012-0411.R1 accepted for
publication by Stem Cells and Development on November 15th
, 2012)
27
Introduction
Orthopaedic injuries involving joint cartilage are some of the most common causes of lameness
in racehorses (Bailey et al., 1999). Mesenchymal stromal cells (MSCs) represent a promising
source of chondroprogenitors for cell-based cartilage repair therapies. Although bone marrow
derived MSCs (BM-MSCs) are the best-characterized, cord blood-derived MSCs (CB-MSCs)
may offer several advantages. In contrast to the invasive procedures necessary to collect bone
marrow and the rapid decline in the proliferative capacity of BM-MSCs (Stenderup et al., 2003),
umbilical cord blood can be obtained using a minimally invasive method (Rubenstein et al.,
1993; Koch et al., 2007) and studies on both human and equine CB-MSCs have revealed higher
replicative potential and broader potency compared to BM-MSCs (Kogler et al., 2006; Kern et
al., 2006). In particular, these CB-MSCs are reported to possess higher chondrogenic potential
compared to bone marrow and adipose tissue derived-MSCs (Berg et al., 2009; Zhang et al.,
2011).
MicroRNAs (miRNAs) are a class of endogenous non-coding RNAs, approximately 20-25
nucleotides in length. These potent regulators of gene expression are thought to be involved in
the regulation of one third of all mammalian genes (Lewis et al., 2005). They function at the
post-transcriptional level by binding to complementary sequences in the 3’-untranslated region
(3’-UTR) of target mRNAs and inhibiting their translation and/or facilitating their decay.
MicroRNAs have profound effects on cellular phenotype and biological function in many
different tissues and numerous studies have shown that they are important regulators of diverse
biological processes such as differentiation, development and tumorigenesis (Chen et al., 2004;
Krichevsky et al., 2006; Nicoloso et al., 2009).
28
During microRNA biogenesis, long primary transcripts (pri-miRNAs) are synthesized by RNA
polymerase II and then processed into small hairpin structures known as pre-miRNAs by the
enzymes Drosha and DGCR8. They are then exported to the cytoplasm where the RNAse III,
Dicer, cleaves the loop region of the hairpin to generate a short RNA duplex. One strand is
degraded leaving a mature single-stranded miRNA molecule that becomes incorporated into the
RNA-induced silencing complex (RISC) (Du & Zamore, 2005) and binds target mRNAs to
either block translation or induce transcript degradation.
Evidence for the crucial role of microRNAs in cartilage development was provided by a study in
which Dicer, an endoribonuclease required for the production of mature microRNA, was
knocked out in the cartilage of mice. This resulted in a smaller proliferating pool of
chondrocytes and accelerated hypertrophic differentiation, causing severe skeletal defects
(Kobayashi et al., 2008). Findings by Wienholds et al. demonstrating that most conserved
vertebrate microRNAs are expressed in a tissue-specific manner in zebrafish embryos and that
microRNA-140 (miR-140) is only expressed in cartilaginous tissue, suggested an important role
for this miRNA species in cartilage development (Wienholds et al., 2005). Subsequent studies
confirmed the cartilage specific nature of miR-140 in mice (Tuddenham et al., 2006) and humans
(Miyaki et al., 2009).
Several miR-140 targets have been identified; HDAC4 (Tuddenham et al., 2006), CXCL12
(Nicolas et al., 2008), IGFBP5 (Tardif et al., 2009), ADAMTS-5 (Miyaki et al., 2010), Smad3
(Pais et al., 2010), Dnpep (Nakamura et al., 2011) and Sp1 (Yang J et al., 2011). Additionally,
29
miR-140 was found to be directly induced by Sox9, the master transcriptional regulator of
chondrogenesis. Furthermore, it is co-expressed with the “host” gene from which it is
intronically transcribed, Wwp2-C an E3 ubiquitin protein ligase (Yang J et al., 2011).
Although miR-140 is the most frequently studied microRNA in cartilage biology and pathology,
studies have not been described in equine cells. In this study, we demonstrate that miR-140 is
highly expressed in normal equine cartilage and that expression increases after 14 days of
chondrogenic differentiation of equine CB-MSCs. Expression was directly correlated with the
transcriptional regulator Sox9 and previously identified targets ADAMTS-5 and CXCL12
showed expression patterns that suggest possible regulation by miR-140. These findings provide
further insight into the molecular mechanisms of chondrogenic differentiation in eCB-MSCs.
30
Materials and Methods
Figure 1: Study Design. All eCB-MSC cell lines were screened for chondrogenic potential prior
to the study by differentiating pellets for two weeks then staining with Toluidine Blue (Appendix
1.). Strongly stained pellets with hyaline-like morphology were grouped as high chondrogenic
potential (CP) eCB-MSCs, while weakly stained pellets were grouped as low CP eCB-MSCs.
High CP eCB MSCs were subjected to chondrogenic differentiation for 7, 14 or 21 days before
assessment of outcome parameters.
31
eCB-MSC Isolation and Culture
The isolation of equine MSCs from umbilical cord blood was performed as previously described
(Koch et al., 2009). Briefly, the nucleated cell fraction was isolated from 11 different cord blood
samples using PrepaCyte®-WBC medium (BioE Inc., St Paul, MN) according to the
manufacturer’s instructions. The cells were suspended in isolation medium [low-glucose
Dulbecco’s modified Eagle medium (DMEM; Lonza, Wakersville, MD), 30% FBS (Invitrogen,
Burlington, ON, Canada), dexamethasone (10-7
M; Sigma, Oakville, ON, Canada), penicillin
(100 IU/mL; Invitrogen), streptomycin (0.1 mg/mL; Invitrogen) and L-glutamine (2 mM;
Sigma)], seeded in polystyrene culture flasks and incubated at 38.5°C with 5% CO2 in a
humidified incubator. When cells reached 70-80% confluence, they were detached using 0.04%
trypsin/0.03% EDTA solution and re-seeded at 5000cells/cm2. For cryopreservation, trypsinized
cells were washed, resuspended in 10% dimethyl sulfoxide (Sigma), stored overnight at -80°C
and transferred to liquid nitrogen for long-term storage. Following preliminary screening, 5
eCB-MSC lines were selected, thawed and expanded; experiments were performed in passages
5-6.
Chondrogenic Differentiation
High density micromass pellet cultures were prepared by centrifuging 2.5x105 cells/pellet at 150
x g in 96-well V-bottom polypropylene plates (Phenix, Candler, NC). 20 pellets were prepared
for each cell line for each time point and cultured at 38.5°C in a hypoxic environment of 5% O2
for 7, 14 or 21 days in chondrogenic differentiation media containing DMEM-HG, 200mM
Glutamax-I, 100 mM Sodium pyruvate, 1x ABAM (Invitrogen), 0.1 mM dexamethasone, 100
μg/ml ascorbic acid-2 phosphate, 40 μg/ml proline (Sigma-Aldrich), 1x ITS (BD Biosciences,
32
Bedford, MA) and 10 ng/ml TGF-β3 (R&D Systems, Minneapolis, MN). Medium was changed
every 2-3 days.
Chondrocyte Isolation
Articular cartilage was collected from the fetlock joints of 3 horses without evidence of joint or
systemic disease immediately after euthanasia. Tissue was minced with a scalpel blade and
digested with 1.5 mg/ml collagenase type II (Sigma-Aldrich) overnight at 37˚C. Digested
samples were strained and isolated chondrocytes were snap frozen in mirVana lysis/binding
buffer (Ambion, Austin, TX) and stored at -80 °C until RNA isolation.
Histology and Immunohistochemistry
One representative pellet from each cell line was selected (N=5), fixed in 10% formalin and
embedded in paraffin. Five micrometer sections were prepared and stained with Hematoxylin
and Eosin or Toluidine Blue. For collagen type I and type II immunostaining, paraffin-
embedded sections were rehydrated and digested with 20 µg/ml proteinase K and 1600 U/ml
hyaluronidase, blocked with 3% bovine serum and incubated with an antibody reactive to
collagen type I (Calbiochem, Gibbstown, NJ) or collagen type II (Developmental Studies
Hybridoma Bank, Iowa City, IA) overnight at 4°C. Subsequently, samples were incubated with
HRP-conjugated anti-mouse secondary antibody (DAKO, Mississauga, ON, Canada) and
immunoreactivity was detected using diaminobenzidine chromagen (DAKO) with hematoxylin
counterstain. QCapture software was used for imaging.
33
RNA Extraction, Reverse Transcription, qRT-PCR
Total RNA, including small RNAs, was isolated from equine articular chondrocytes (N=3),
undifferentiated eCB-MSCs (N=5) and pellet cultures (N=5 with 5 pellets per cell line) using
mirVana microRNA isolation kit according to the manufacturer’s protocol (Ambion). RNA
concentration and purity were determined using the Nanodrop ND-1000 spectrophotometer. To
determine microRNA expression, 100 ng of RNA was reverse transcribed using the TaqMan
microRNA reverse transcription kit with the appropriate microRNA specific stem-loop primer;
mmu-miR-140. This primer, while designed for mouse, is identical to the homologous Equus
caballus sequence as confirmed by BLASTN sequence alignment of the probe on the equine
genome. qRT-PCR was then performed using the TaqMan PCR Master Mix and TaqMan
microRNA assay (Applied Biosystems, Foster City, CA). To assess mRNA expression,
complementary DNA was synthesized from total RNA using SuperScript II and oligo(dT)18
primers (Invitrogen) and qRT-PCR was performed using Roche LightCycler 480, Fast Start
DNA Master SYBR Green I (Roche Diagnostics) and the equine-specific primers found in Table
1. All reactions were run in triplicate. Crossing point (Cp) values for miR-140 were normalized
to U6 snRNA, while Cp values for mRNAs were normalized to GAPDH. Relative gene/miRNA
expression was determined using the delta-delta Ct method.
Statistical Analysis
GraphPad Prism 5 Software (San Diego, CA) was used to perform statistical analyses. One way
analysis of variance (ANOVA) with Bonferroni post-test was applied to determine the
differences between the gene expression levels and wet mass. Student’s unpaired t-test was used
to compare the expression of miR-140 between MSCs and chondrocytes. Gene expression data
34
are expressed as fold differences ± SEM compared with undifferentiated eCB-MSCs.
Significance was determined using raw data and assigned at p<0.05.
Results
Chondrogenic differentiation of eCB-MSCs
eCB-MSCs formed white, glistening pellets, an appearance consistent with hyaline cartilage
(Fig. 2A). They increased in size and weight over 21 days of differentiation (Fig. 2B), with the
average wet mass increasing from 0.56 mg on day 7 to 0.93 mg on day 21. Additionally, pellet
sections were stained with hematoxylin and eosin to assess their morphology and with toluidine
blue to determine the presence of proteoglycans (Fig. 2C). Histological examination clearly
showed cartilage tissue development; cells with round morphology inside lacunae were visible at
day 14 and became more defined at day 21. Toluidine blue staining was visible as early as day 7
and showed a progressive increase in proteoglycan content in the accumulated matrix at days 14
and 21. Immunostaining was also performed to assess the protein expression of collagens type I
and II (Fig. 2C). As expected, the staining intensity for collagen type II increased from day 7 to
day 21, while decreasing for collagen type I.
Chondrogenesis was also evaluated over the three week period through the assessment of gene
expression for collagens I, II and X and aggrecan using qRT-PCR (Fig. 3). Expression levels of
collagens I and II, and aggrecan increased significantly from day 0 to day 7, then began to
decrease. The expression of aggrecan at 7 days of chondrogenesis was similar to articular
chondrocytes, while expression levels of collagens I and II were similar to equine articular
chondrocytes at 21 days. Collagen X expression peaked at day 14 then decreased at day 21, at
35
which point the expression level was not significantly different from that of articular
chondrocytes.
MicroRNA-140 expression in undifferentiated eCB-MSCs and equine articular chondrocytes
qPCR analysis using TaqMan microRNA assays revealed that the expression of miR-140 is
almost 300-fold higher in equine chondrocytes compared to undifferentiated eCB-MSCs (Fig. 4).
Expression of miR-140, Sox9 and miR-140 target genes during chondrogenesis
During chondrogenic differentiation, miR-140 increased significantly from day 0-14, then
decreased slightly, though not significantly, at day 21 (Fig. 5A). The expression of Sox9, the
master transcriptional regulator of chondrogenesis, also followed this pattern (Fig. 5B).The
expression patterns for previously identified miR-140 targets IGFBP5, CXCL12, ADAMTS-5
and HDAC4 [19, 18, 20, 16] were also examined. IGFBP5 expression levels increased from day
0-14, then decreased at day 21 (Fig. 5C). In contrast, CXCL12 expression was highest at day 0,
decreasing significantly by day 7 and remaining repressed throughout the differentiation period.
CXCL12 expression appeared higher in the chondrocytes compared with the differentiating
MSCs, though statistical significance was not achieved as there was considerable variability (Fig.
5D). A similar pattern was observed for ADAMTS-5, its expression decreased significantly
from day 0-7 and remained low until day 21, however this repression was not significant at day
14 and day 21 compared to day 0, likely due to inter-donor variation Surprisingly, ADAMTS-5
mRNA expression appeared relatively high in normal articular chondrocytes, although
significant variability was present (Fig. 5E). Expression of histone deacetylase 4 (HDAC4), a
co-repressor of Runx2, was also examined but mRNA levels in most samples were below the
36
detection limit (data not shown). These results suggest that miR-140 may play an important role
in the chondrogenic differentiation of eCB-MSCs through selective targeting of specific mRNAs,
such as CXCL12 and ADAMTS-5.
Discussion
During vertebrate development, chondroprogenitor cells undergo morphological changes and
begin to express cartilage-specific genes, leading to chondrocyte maturation and ECM
production (Lefebvre & Smits, 2005). Chondrogenesis is initiated by the recruitment and
condensation of mesenchyme, a process which is regulated by cell-cell interactions. Similarly, in
vitro chondrogenesis involves the aggregation of mesenchymal cells into high density pellets
(Johnstone et al., 1998). Transforming growth factor-β (TGF-β) is one of the earliest genes
expressed in in vivo mesenchymal condensations, whereas TGF-β is applied exogenously in
vitro. Sox9 is a key transcriptional regulator in early chondrogenesis, with a crucial role in
regulating cartilage formation by activating the expression of cartilage-specific genes including
collagen type 2, aggrecan and cartilage oligomeric matrix protein (COMP) (Huang et al., 2001;
Ng et al., 1997). Sox9 is also expressed during chondrogenic differentiation of micromass
pellets. As previously reported, eCB-MSCs can be successfully differentiated towards a
chondrogenic fate, as indicated by a gradual increase in size and weight and by histological
evaluation of morphology, proteoglycan content and expression of chondrogenic markers (Koch
et al., 2007; Berg et al., 2009; Koch et al., 2009). Gene expression patterns for collagen II and
aggrecan in this study showed an initial increase after one week, then began to decrease. This
suggests that upon chondrogenic stimulation, the eCB-MSCs rapidly accumulate transcripts to
produce ECM. Collagen II mRNA levels did not correlate with the protein abundance seen in the
37
immunostaining. One possible explanation for this is that, as differentiation progresses and the
ECM is established, collagen II mRNA levels decrease to baseline expression as the
chondrocytes take on a maintenance role. However, the significantly lower expression of
aggrecan compared to chondrocytes and the increased expression of collagen X indicates that the
differentiation method does not perfectly recapitulate in vivo cartilage development.
Studies demonstrating the loss of the miRNA processing enzyme Dicer in the cartilage of mice
revealed an overall role for miRNAs in chondrogenesis and skeletogenesis. The absence of
mature miRNAs caused severe growth defects due to a decrease in proliferating chondrocytes
and accelerated hypertrophy (Kobayashi et al., 2008). Many miRNAs with roles in cartilage
specific processes have since been identified. For instance, miR-199a* was identified as an
inhibitor of early chondrogenic differentiation. While overexpression of miR-199a* in murine
MSCs decreased the expression of early chondrogenic markers during BMP2-induced
chondrogenesis, anti-miR-199a* increased their expression. This was mediated through Smad1
signalling, which was identified as a direct target of this microRNA through 3’UTR luciferase
reporter assay (Lin et al., 2009). In a similar study, miR-145 was reported to directly repress
Sox9 during TGF-β3 induced chondrogenic differentiation of murine MSCs (Yang B et al.,
2011). MiR-140 has been the focus of many cartilage studies due to its specificity in this tissue.
It is transcribed from an intron within the Wwp2-C gene and thought to be induced by Sox9
(Yang J et al., 2011). Identified targets include HDAC4, IGFBP5, ADAMTS-5, Cxcl12, Smad3,
Dnpep, Sp1 and MMP-13 (Tuddenham et al., 2006; Nicolas et al., 2008; Tardif et al., 2009;
Miyaki et al., 2010; Pais et al., 2010; Nakamura et al., 2011; Yang J et al., 2011; Liang et al.,
38
2012). The role of microRNAs in cartilage development and homeostasis has been reviewed
elsewhere (Hong & Reddi, 2012).
We demonstrate here that miR-140 is expressed in equine cells, specifically in chondrogenically
differentiating eCB-MSCs and articular chondrocytes. This observation is in agreement with
previous reports that miR-140 is cartilage specific (Wienholds et al., 2005) and highly expressed
in human articular chondrocytes (Miyaki et al., 2009). Significantly higher expression was
observed in eCB-MSCs following 2 weeks of in vitro differentiation stimuli, compared to
undifferentiated cells. The presence of miR-140 in undifferentiated eCB-MSCs suggests that
this miRNA could be involved in the maintenance of chondrogenic potential. This is consistent
with the detection of miR-140 in undifferentiated C3H10T1/2 cells that were subsequently
differentiated into chondrocytes (Nicolas et al., 2008). The expression pattern of miR-140
correlated with the expression of chondrogenic transcription factor Sox9. Yang and colleagues
reported that suppression of Sox9 reduced miR-140 expression in ATDC5 cells and they utilized
luciferase reporter assays to confirm the direct binding of Sox9 to the upstream region of miR-
140 (Yang J et al., 2011). Our data are consistent with the potential for Sox9 to regulate miR-
140 expression during eCB-MSC chondrogenic differentiation, however additional studies are
required to confirm this hypothesis.
MicroRNAs influence target gene expression by facilitating the decay of specific mRNA targets
or by inhibiting translation of target genes. In this study, we also evaluated the expression of
three previously identified miR-140 mRNA targets; IGFBP5, CXCL12 and ADAMTS-5. Insulin
growth factor binding protein 5 (IGFBP5) is a protein that regulates the availability of IGF-1, an
39
anabolic factor involved in matrix synthesis and chondrocyte survival (Jones et al., 1993).
IGFBP5 was reported to be directly targeted for mRNA degradation by miR-140 in human OA
chondrocytes. Pre-miR-140 treatment caused a significant decrease in IGFBP5 mRNA
expression while knockdown caused a significant increase. These changes occurred early (24
hours) and since a miR-140 seed sequence was predicted in the 3’UTR of IGFBP5, a direct
interaction between IGFBP5 and miR-140 was suggested, however, 3’UTR luciferase reporter
assays were not performed (Tardif et al., 2009). Chemokine (CXC motif) ligand 12 (CXCL12),
also known as stromal derived factor-1 (SDF-1), functions by activating the G-protein coupled
receptor CXC chemokine receptor 4 (CXCR4). CXCL12 is a potent chemoattractant for
CXCR4-expressing cells and may have a role in MSC migration (Kortesidis et al., 2005),
survival and initiation of differentiation (Son et al., 2006). Using an overexpression/knockdown
approach, CXCL12 was identified as one of 49 genes that were repressed by miR-140
overexpression and derepressed by miR-140 silencing. Northern blot analysis and 3’UTR
luciferase reporter assays validated CXCL12 as a miR-140 target (Nicolas et al., 2008). A
disintegrin and metalloproteinase with thrombosponin motifs (ADAMTS-5) is a proteolytic
enzyme that cleaves aggrecan and has been associated with the degeneration of osteoarthritic
cartilage (Stanton et al., 2005; Glasson et al., 2005). In a study by Miyaki et al., miR-140-/-
mice
and transgenic (TG) mice overexpressing miR-140 were generated. ADAMTS-5 expression was
increased in the chondrocytes of miR-140-/-
mice and reduced in the chondrocytes of miR-140
TG mice. Furthermore, ds-miR-140 decreased the expression of ADAMTS-5 in miR-140-/-
mice, providing additional evidence that miR-140 targets this gene for degradation. Direct
binding of miR-140 to ADAMTS-5 mRNA was demonstrated by luciferase reporter assay
(Miyaki et al., 2010).
40
Surprisingly, the expression pattern of IGFBP5 correlated directly with miR-140 levels rather
than an inversely, which would be expected if miR-140 facilitated its decay. This data suggests
that IGFBP5 mRNA may not be targeted for degradation by miR-140 during chondrogenic
differentiation. The possibility remains that the translation of this gene is inhibited by miR-140,
however, the small sample quantities and absence of reliably cross-reactive antibodies prohibits
the evaluation of these possibilities at this time. In contrast, ADAMTS-5 and CXCL12 mRNA
levels were high prior to differentiation but low throughout differentiation, suggesting that these
genes were targeted by miR-140. CXCL12 gene expression has been shown to decrease rapidly
upon osteogenic and chondrogenic induction (Zhu et al., 2007; Cristino et al., 2008). Blockade
of CXCL12 signalling prior to BMP-2 stimulated osteogenesis decreased the expression of
osteogenic markers and abrogated the accumulation of osteocalcin, suggesting that CXCL12 is
involved in initiation of BMP-2 induced osteogenesis (Zhu et al., 2007). Regulation of CXCL12
expression appears to be important for chondrogenic induction, but whether its expression
decreases because it would otherwise impede differentiation or whether its expression is required
for initiation of chondrogenesis is unknown.
The roles of ADAMTS-5 suppression in cartilage development are not entirely clear. One
hypothesis is that ADAMTS-5 is suppressed during cartilage differentiation and development to
facilitate the accumulation of aggrecan in the ECM, but that it is increased in established
articular cartilage to regulate baseline turnover of aggrecan (Tortorella et al., 2001). This would
help explain the seemingly high expression of ADAMTS-5 in our samples from articular
chondrocytes (Fig. 5E). However, considerable variability in both CXCL12 and ADAMTS-5
41
expression was evident in those samples. The possibility of clinically undetectable joint disease
remains a potential contributor to the variation, as it cannot be definitively excluded from the
samples. It will be important to study the effect of miR-140 overexpression and knockdown on
the expression of both previously identified and novel targets in eCB-MSCs to provide further
insight into the molecular pathways in these cells.
In conclusion, the results of this study show that miR-140 exhibits a dynamic expression pattern
during chondrogenesis of eCB-MSCs that correlates with the expression of the transcription
factor Sox9. Additionally, CXCL12 and ADAMTS-5 mRNA levels were suppressed during
chondrogenic differentiation while miR-140 expression was increased, suggesting that this
microRNA may target these genes for degradation. Further studies, including overexpression
and knockdown of miR-140, will clarify the role of miR-140 during chondrogenesis of MSCs
and determine the utility of this microRNA as an enhancer or inducer of chondrogenesis.
42
Tables
Table 1. Primer pairs used for qRT-PCR
Primers denoted with an asterisk (*) were designed by Dr Lise C. Berg.
Primers denoted with a dagger (†) were designed by Laurence Tessier.
Gene Forward (5’-3’) Reverse (5’-3’) Primer Source
CollagenIIα1 GACAACCTGGCTCCCAAA ACAGTCTTGCCCCACTTAC NM_001081764*
CollagenIα1 GAAAACATCCCAGCCAAGAA TGATGTTTTGAGAGGCATGG Berg et al., 2009 [7]
CollagenXα1 CCAAGAGGTGCCCCTGGAAT GTTGCCTGTTATACACAATC NM_174634.1*
Aggrecan CTTAGAGGACAGAAAGCGAC ACTTTGGGCGGAAGAAGG Trumble et al., 2001 [25]
Sox9 ATCTGAAGAAGGAGAGCGAG TCAGAAGTCTCCAGAGCTTG Zehentner et al., 1999 [26]
ADAMTS-5 AACTGGGGGTCCTGGGGGTCCTGG CATTTCTTGCCTCACACTGCTCAT Coyne et al., 2009 [27]
IGFBP5 GGAGGAGCCGAGAACACTG GCGAAGCCTCCATGTGTC McGivney et al., 2010 [28]
CXCL12 AGATGTCCTTGCCGGTTCTT CTTCAGTTTCGGGTCAATGC XM_001489644.2†
HDAC4 AGGAACTACCAGGCGTCCAT CTGTTAGTGTTCCCGCAGGT XM_003365703.1†
GAPDH GGGTGGAGCCAAAAGGGTCATCAT AGCTTTCTCCAGGCGGCAGGTCAG Iqbal et al., 2004 [29]
43
Figures
Figure 2: Chondrogenic differentiation of eCB-MSCs. (A) Pellets from eCB-MSC are spherical,
white and glistening after 7, 14 and 21 days in chondrogenic media. (B) Wet mass of pellets
revealed an increase in weight from day 7 to day 21. Data shown as mean ±SEM. (*) p<0.05,
(**) p<0.01. N=5, n=5. (C) Histological appearance of pellets at days 7, 14 and 21. Hematoxylin
and eosin staining shows the development of cells with round morphology inside lacunae (top
row), while Toluidine Blue staining confirms an increase in proteoglycan accumulation in the
extracellular matrix over the differentiation period. Immunostaining for collagens I and II (third
and fourth rows) further confirms chondrogenic differentiation as the staining for collagen I
decreases over time, while collagen II increases. All images are 100x magnification.
44
Figure 3: Gene expression of cartilage markers by eCB-MSC pellets cultured up to 21 days in
chondrogenic media. mRNA levels were assessed by qPCR with GAPDH as a reference gene.
(A, B, D) Collagen II, Aggrecan and Collagen I expression increased from day 0-7 then
decreased from day 7-21. (C) Collagen X expression increased from day 0-14 then decreased at
day 21. Data shown as mean ± SEM. (*) p<0.05, (**) p<0.01, (***) p<0.001, (****) p<0.0001.
N=5 eCB-MSCs from different foals and N=3 chondrocyte samples from different horses.
45
Figure 4: Expression of microRNA-140 (miR-140) in undifferentiated equine CB-MSCs and
articular chondrocytes. MiR-140 expression was significantly higher in chondrocytes (N=3
different horses) compared to eCB-MSCs (N=5 from cord blood of different foals). Data shown
as mean ± SEM. (**) p<0.01.
46
Figure 5: Expression of miR-140, Sox9 and previously identified targets IGFBP5, CXCL12, and
ADAMTS5. (A, B, C) miR-140, Sox9 and IGFBP5 expression increased from day 0-14 then
decreased at day 21. (D, E) CXCL12 and ADAMTS5 expression decreased from day 0-7 and
remained low until day 21. Data shown as mean ± SEM. (*) p<0.05, (**) p<0.01, (***) p<0.001,
(****) p<0.0001. N=5 eCB-MSCs from different foals and N=3 chondrocyte samples from
different horses.
47
CHAPTER 2
Chondrogenic Differentiation of Equine Cord Blood-Derived Mesenchymal Stromal Cells
in Membrane-Based Cultures
48
Introduction
Articular cartilage is a dense connective tissue that covers joint surfaces to protect underlying
bone and allow low-friction articulation. Cartilage damage can be sustained by trauma,
inflammation or disease and there are limited therapeutic options for repair due to the poor
regenerative capacity of the tissue (Mankin, 1982; Williams et al., 2010). The current cell-based
strategies often yield repair tissue consisting of mechanically inferior fibrocartilage, therefore
alternative cell sources are being investigated. Mesenchymal stromal cells (MSCs) proliferate
rapidly and are readily expanded to generate large numbers of cells. Furthermore, they are
multipotent and can be differentiated into multiple different cell lineages, including chondrocytes
(Baksh et al., 2004). In particular, human and equine CB-MSCs are reported to be more
chondrogenic than bone marrow and adipose tissue derived-MSCs (Berg et al., 2009; Zhang et
al., 2011).
In vitro chondrogenic differentiation of MSCs is normally induced by applying three-
dimensional (3-D) culture conditions and including transforming growth factor-β (TGF-β) in the
medium, as described by Johnstone et al. in 1998. However, this system is primarily used to
study molecular pathways involved in chondrogenesis, rather than provide differentiated cells for
biological repair. In fact, only 250 000 - 500 000 cells are seeded to form the cell aggregates, but
increasing pellet size can result in cell necrosis in the center of the aggregate (Ebisawa et al.,
2004). Although immunohistochemistry of the pellets in several reports indicate successful
differentiation through collagen type II staining, it is often heterogeneous and accompanied by
expression of collagen type I, which is characteristic of fibrous tissue, and collagen type X,
which is typical of terminal differentiation of hypertrophic chondrocytes (Steck et al., 2005;
49
Nelea et al., 2005). Interestingly, Lee and colleges have recently developed a protocol in which
2 million bone marrow derived-MSCs (BM-MSCs) are differentiated towards a chondrogenic
fate on collagen IV-coated polytetrafluoroethylene (PTFE) membrane inserts. They reported that
glycosaminoglycan (GAG) and collagen content was similar in pellet and membrane-based
cultures and that hypertrophic markers Runx2 and collagen X were expressed in both culture
types. However, the expression level of collagen I was significantly lower in membrane-
cultured cells compared to pellet (Lee et al., 2011).
The aim of this study was to determine whether the use of a 3-D membrane culture system would
provide a more homogeneous environment for chondrogenic differentiation of equine cord
blood-derived MSCs. We found that it was necessary to implement a 24 hour expansion step
prior to stimulating chondrogenic differentiation in the membrane culture system. Chondrogenic
differentiation of selected eCB-MSCs generated hyaline-like cartilage in both culture systems,
however the tissues were more homogeneous in the membrane system.
50
Materials and Methods
Figure 1: Study design for in vitro chondrogenesis. All eCB-MSC cell lines were screened for
chondrogenic potential prior to the study by differentiating pellets for two weeks then staining
with Toluidine Blue (Appendix 1.). Strongly stained pellets were grouped as high chondrogenic
potential (CP) eCB-MSCs, while weakly stained pellets were grouped as low CP eCB-MSCs.
Three high CP and one low CP eCB-MSCs were selected and differentiated as pellets or on
51
membranes (with or without 24 hour expansion). Chondrogenesis was assessed by histology and
immunostaining.
eCB-MSC Isolation and Culture
The isolation of equine MSCs from umbilical cord blood was performed as previously described
(Koch et al., 2009). Briefly, the nucleated cell fraction was isolated from 5 cord blood samples
using PrepaCyte®-EQ medium (BioE Inc., St Paul, MN) according to the manufacturer’s
instructions. The cells were suspended in isolation medium [low-glucose Dulbecco’s modified
Eagle medium (DMEM; Lonza, Wakersville, MD), 30% FBS (Invitrogen, Burlington, ON,
Canada), dexamethasone (10-7
M; Sigma, Oakville, ON, Canada), penicillin (100 IU/mL;
Invitrogen), streptomycin (0.1 mg/mL; Invitrogen) and L-glutamine (2 mM; Sigma)], seeded in
polystyrene culture flasks and incubated at 38.5°C with 5% CO2 in a humidified incubator.
Selected cryopreserved MSCs were thawed and expanded; experiments were performed in
passages 5-6.
Chondrogenic Differentiation
High density micromass pellet cultures were prepared by centrifuging 2.5x105 cells/pellet at 150
x g in 96-well V-bottom polypropylene plates (Phenix, Candler, NC). For membrane cultures,
PTFE cell culture inserts (0.2 mm pore size; Millipore, Billerica, MA) were coated with
fibronectin (Millipore) overnight then seeded with 2.0x106 cells/membrane, either directly into
chondrogenic media or in expansion media for 24 hours prior to chondrogenic induction. The
selection of fibronectin was based on preliminary studies screening fibronectin (FN) against
laminin and collagen type IV, which suggested that eCB-MSCs adhered more consistently to
52
PTFE membranes coated with FN than the other ECM molecules. The pellets and membranes
were cultured at 38.5°C with 5% O2 for 14 days in chondrogenic differentiation media
containing DMEM-HG, 200mM Glutamax-I, 100 mM Sodium pyruvate, 1x ABAM (Invitrogen),
0.1 mM dexamethasone, 100 μg/ml ascorbic acid-2 phosphate, 40 μg/ml proline (Sigma-
Aldrich), 1x Insulin-Transferrin-Selenium (ITS; BD Biosciences, Bedford, MA) and 10 ng/ml
TGF-β3 (R&D Systems, Minneapolis, MN). Medium was changed every 2-3 days.
Histology and Immunohistochemistry
Pellets and membranes were fixed in 10% formalin and embedded in paraffin. Five micrometer
sections were prepared and stained with Hematoxylin and Eosin or Toluidine Blue. For collagen
type I and type II immunostaining, paraffin-embedded sections were rehydrated and digested
with 20 µg/ml proteinase K and 1600 U/ml hyaluronidase, blocked with 3% bovine serum and
incubated with an antibody reactive to collagen type I (Calbiochem, Gibbstown, NJ) or collagen
type II (Developmental Studies Hybridoma Bank, Iowa City, IA) overnight at 4°C.
Subsequently, samples were incubated with HRP-conjugated anti-mouse secondary antibody
(DAKO, Mississauga, ON, Canada) and immunoreactivity was detected using diaminobenzidine
chromagen (DAKO) with hematoxylin counterstain. QCapture software was used for imaging.
Results
Chondrogenic differentiation of pellets and membranes
Due to known inter-donor variation, all eCB-MSC cell lines were screened for chondrogenic
potential prior to the study by differentiating pellets for two weeks then staining with Toluidine
Blue. Strongly stained pellets were grouped as high chondrogenic potential (CP) eCB-MSCs,
53
while weakly stained pellets were grouped as low CP eCB-MSCs (Appendix I). To examine the
difference between pellet and membrane culture systems, three high CP eCB-MSCs and one low
CP eCB-MSC were selected and differentiated.
Cultures were stained with hematoxylin and eosin to reveal their morphology and with toluidine
blue to determine the presence of proteoglycans. All eCB-MSCs that were seeded directly into
chondrogenic media in the membrane system did not adhere to the membrane and did not
develop a chondrogenic phenotype (Fig. 2), therefore further mention of the membrane system
will refer to the protocol including the 24 hour expansion step. Cells with round morphology
inside lacunae were visible in both culture systems for all cell lines with the exception of the low
CP eCB-MSC pellet. Additionally, cells with a flattened morphology were present in peripheral
areas of high CP eCB-MSC pellets.
High CP eCB-MSCs were strongly stained for toluidine blue as both pellets and membranes
(Fig. 3). However, the low CP eCB-MSC did not stain for toluidine blue in pellet culture, but
was weakly stained in the membrane system. Immunostaining was also performed to evaluate
the protein expression of collagens type I and II (Fig. 3). Collagen type II was highly expressed
in both culture systems for all cell lines with the exception of the low CP eCB-MSC pellet.
Collagen type I was also expressed, but this was primarily in peripheral regions of the pellets
while it was more homogeneously distributed in the membrane culture system.
54
Discussion
In this study, we have successfully induced chondrogenic differentiation of eCB-MSCs in a 3D
membrane culture system as evidenced by changes in cell morphology, strong toluidine blue and
collagen II staining. These characteristics were also observed in the pellet culture system but
were accompanied by peripheral inconsistencies. For instance, the morphology of the cells
within the pellet was consistent with hyaline-like cartilage, but the peripheral areas contained
cells with a flattened morphology, indicating a more fibrous phenotype. Additionally, these
areas were stained for collagen type I, which is a marker of fibrous tissue. Together these results
show that chondrogenic differentiation can be achieved through pellet culture, however, the
resulting tissue is heterogeneous and shows both cartilaginous and fibrous regions. This was
attributed to uneven diffusion of oxygen and nutrients throughout the tissue and the surface
tension caused by the spherical nature of the high density pellets. In contrast, even dispersion of
round cells within lacunae was shown in the membrane system, accompanied by homogeneous
toluidine blue, collagen II and collagen I staining. Therefore, with regard to uniformity of the
differentiated tissue, membrane culture appears to be superior. The increased number of cells in
this system (2 million instead of 250 000) is also advantageous for cartilage tissue engineering
strategies as sufficient numbers of differentiated cells are difficult to obtain from autologous
chondrocytes (Darling & Athanasiou, 2005).
Further evidence in support of the superiority of membrane culture for chondrogenic
differentiation is provided by the difference in chondrogenic induction of the low CP eCB-MSC
in pellet culture compared to membrane culture. While the low CP eCB-MSC pellet was not
55
positively stained for toluidine blue or collagen II, nor did it show any changes toward cartilage-
like morphology, the low eCB-MSC membrane culture stained positively for collagen II and
toluidine blue, albeit weakly. There were some lacunae, although poorly defined, and the overall
thickness of the tissue was lower compared to the high CP eCB-MSCs. However, this suggests
that the membrane system is a more effective method of inducing chondrogenesis since
differentiation was stimulated to some degree in a cell line that was originally thought to have no
chondrogenic potential.
Employing a 24 hour expansion step prior to the application of chondrogenic media appears to
be necessary, since membrane cultures that were immediately induced without the expansion
step did not adhere to the membrane, nor show any evidence of differentiation. Cell-matrix
interactions play an important role in mesenchymal cell condensation, an event required for
cartilage development both in vitro and in vivo. Fibronectin has been implicated in this process
and is thought to facilitate translocation of mesenchymal cells to pre-cartilage condensations
(Frenz et al., 1989). The absence of attachment to the membrane in the direct chondrogenesis
group likely prevented the formation of condensations, which subsequently inhibited
chondrogenic differentiation altogether. However, the molecular basis for the necessity of the 24
hour expansion step to promote adhesion is unclear. One hypothesis is that expansion media
contains serum, while the differentiation media does not, therefore certain factors may be present
in the serum that enhance MSC attachment to the fibronectin-coated substrate at a crucial point
early in chondrogenesis.
56
Further experiments will be conducted to determine additional differences between membrane
and pellet cultures. For instance, transcript levels of chondrogenic markers (Collagen II, Sox9
and Aggrecan), hypertrophic markers (Runx2 and Collagen X) and collagen I should be assessed
to evaluate whether the differentiation culture system has an effect on gene expression. Lee et al.
(2011) reported that both culture systems expressed similar levels of chondrogenic markers and
hypertrophic markers in ovine BM-MSCs, but that membrane cultured cells expressed less
collagen I mRNA. It will be interesting to determine whether the same results will be obtained
for eCB-MSCs or whether this MSC type will have additional beneficial effects on gene
expression during chondrogenic differentiation. In addition, it will be important to ascertain
whether in vitro differentiated cells undergo mineralization in vivo. Bone marrow derived-
MSCs have a tendency to undergo premature hypertrophy and studies have shown that
subcutaneous transplantation of in vitro differentiated pellets into severe combined
immunodeficient (SCID) mice leads to calcification and vascular invasion (Pelttari et al., 2006;
Dickhut et al., 2009). However, direct applications of undifferentiated BM-MSCs to chondral
defects have yielded variable results. For instance, in an equine model, full thickness cartilage
defects were induced in the femoropatellar regions and treated with either fibrin vehicle
containing MSCs or fibrin vehicle alone as a control. Arthroscopic assessment at 30 days
revealed that defects treated with the MSCs were significantly improved compared to the
controls, however these results were not sustained at 8 months (Wilke et al., 2007). In a case
report, two human patients with patella defects were treated with MSCs and after 2 years,
clinical symptoms had improved but the repair tissue consisted of fibrocartilage (Wakitani et al.,
2004). Our hypothesis is that some degree of in vitro induction of MSCs towards a
57
chondrogenic fate is required in order to optimize biological repair, however the optimal duration
and induction protocol has yet to be determined.
Although the overall goal in tissue engineering is usually to perfectly recapitulate the tissue of
interest in vitro, a study by Kandel et al. (2006) suggests that this may not be necessary.
Osteochondral plugs were prepared using calcium polyphosphate substrates seeded with
autologous chondrocytes and implanted into osteochondral defects in sheep. After 9 months in
vivo, proteoglycan content had not changed, collagen had increased slightly and mechanical
properties had improved significantly. Therefore, it is possible that engineered cartilage tissue
with properties inferior to native cartilage could be improved when exposed to an orthotopic in
vivo environment. It will be interesting to determine whether eCB-MSCs differentiated in
membrane or pellet culture systems will mineralize, form fibrocartilage or show improved
biochemical and mechanical properties when they are applied to cartilage defects.
In summary, a protocol for chondrogenic differentiation was developed using cell culture inserts
coated with fibronectin. According to histological evaluation it appears that the membrane
culture system is superior to pellet culture. Further studies are required to determine the effect of
membrane culture on the expression of chondrogenic, osteogenic and fibrous markers. However,
these results suggest that membrane culture is suitable for chondrogenic screening and mini
scale-up of eCB-MSC chondrogenic pre-differentiation.
58
Figures
Figure 2: Histology and immunostaining of chondrogenic differentiation in the membrane
culture system without 24 hour expansion step. All eCB-MSCs shown here were seeded onto
PTFE membranes directly in chondrogenic media. The brown lines are the membranes and two
appear in most images because the membranes were folded in half before embedding in paraffin.
There is little attachment to the membrane and no evidence of chondrogenesis as the cell layers
are thin, they are not stained for toluidine blue or collagen II and they are positively stained for
collagen I. All images are 100x magnification.
59
60
Figure 3: Histological comparison of pellet cultures and membrane cultures with 24 hour
expansion step. eCB-MSCs shown here were either cultured as pellets in V-well polypropylene
plates in chondrogenic media or on PTFE membranes in expansion media for 24 hours then
changed to chondrogenic media. The high chondrogenic potential (CP) pellets (eCB 1012, 1103
and 1108) are strongly stained for Toluidine blue and collagen II, while the low CP pellet (eCB
1101) shows no signs of differentiation. All membrane cultures, including the low CP culture,
were positively stained for Toluidine Blue and collagen II. Collagen type I staining was also
present in these cultures but was more homogeneously distributed compared to the pellets, where
strong peripheral staining is observed. All images are 100x magnification.
61
CHAPTER 3
The Effect of Inflammatory Stimuli on MicroRNA Expression in Equine Chondrocytes
62
Introduction
Osteoarthritis (OA) is a highly prevalent joint disease primarily characterized by the progressive
degradation of articular cartilage. Surveys have reported that approximately 60% of lameness
cases in the sport horse are related to osteoarthritis (Caron & Genovese, 2003). Although the
pathogenesis underlying this disease is unclear, it is generally accepted that the balance between
anabolic and catabolic factors is perturbed in OA, leading not only to articular cartilage damage,
but to synovial tissue inflammation and subchondral bone remodelling. In order to reduce pain
and slow disease progression, non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular
steroids, viscosupplementation and chondroprotectants are commonly prescribed (Goodrich &
Nixon, 2006). However, these drugs cannot halt disease progression nor can they reverse any
damage. A better understanding of the molecular mechanisms involved in the development of
osteoarthritis will be important for the improvement of OA therapy.
Inflammatory cytokines are believed to be critical mediators of OA pathophysiology. In
particular, interleukin-1β (IL-1β) and tumor necrosis factor α (TNFα) are elevated in synovial
fluid, subchondral bone and cartilage of OA patients and associated with cartilage destruction
and the initiation and propagation of inflammatory signals (Kapoor et al., 2011). These
cytokines inhibit anabolic activities in the cartilage by down-regulating the expression of
extracellular matrix (ECM) components collagen type II and aggrecan (Chadjichristos et al.,
2003; Seguin & Bernier, 2003). They also stimulate the release of proteolytic enzymes; matrix
metalloproteinases (MMPs) -1, -3 and -13 (Lefebvre et al., 1990) and ADAMTS-4 (a disintegrin-
like and metalloproteinase with thrombospondin type 1 motifs; Tortorella et al., 2001), which
regulate the degradation of collagens and aggrecan, respectively.
63
Serum amyloid A (SAA) is synthesized by the liver during systemic acute phase response.
However, local expression of SAA mRNA has been reported in other cells in response to
inflammatory stimuli. Both mRNA and protein expression were strongly induced by
lipopolysaccharide (LPS) treatment in chick embryo chondrocytes (Zerega et al., 2004) and SAA
levels were elevated in OA cartilage and synovial fluid (Vallon et al., 2001; Sukenik et al.,
1988). Although the function of SAA is not fully understood, local production suggests a role
for this protein within the site of expression, rather than exclusively during systemic responses.
MicroRNAs (miRNAs) have emerged as important regulators of cartilage development and
homeostasis (Hong & Reddi, 2012). These small non-coding RNA species alter gene expression
by facilitating the decay of specific mRNA targets or by inhibiting translation of target genes.
Expression profiling studies using microarrays and qRT-PCR analysis have identified a number
of microRNA species that are up-regulated and down-regulated in OA cartilage compared to
healthy controls (Illiopoulos et al., 2008; Jones et al., 2009). In particular, several studies have
found the cartilage-specific microRNA miR-140 to be decreased in OA chondrocytes (Tardif et
al., 2009; Miyaki et al., 2009). Asahara and colleagues have shown that the treatment of
chondrocytes with IL-1β reduced miR-140 expression and subsequent studies by the same group
suggested that the regulation of ADAMTS5 by miR-140 contributes to its involvement in OA
pathogenesis (Miyaki et al., 2009; 2010). Another miRNA that has been associated with OA is
miR-146a, which was highly expressed in grade I OA cartilage but decreased with increasing
severity (Yamasaki et al., 2009). Experiments using rat chondrocytes revealed that miR-146a
was induced by IL-1β treatment and identified Smad4 as direct target. Vascular endothelial
64
growth factor (VEGF) was up-regulated by mir-146a expression and this effect was mediated by
Smad4 repression (Li et al., 2012). MicroRNA-9 was increased in human OA cartilage and bone
tissue and its overexpression in chondrocytes suppressed IL-1β-induced TNFα and MMP-13
secretion, suggesting a protective role for this miRNA in OA (Jones et al., 2009). TNFα, IL-1β
and LPS induced miR-155 expression in rheumatoid arthritis synovial fibroblasts (RASFs) and
OASFs, however the expression was higher in RASFs. MiR-155 overexpression in RASFs
repressed mRNA and protein expression of MMP-3 (Stanczyk et al., 2008).
In this study, we examined the effects of proinflammatory cytokines IL-1β and TNFα, and the
acute phase protein SAA on the expression of miR-140, miR-146a, miR-9 and miR-155 in
equine chondrocytes. Of the selected miRNAs, only miR-146a was significantly increased in
response to IL-1β and SAA compared to untreated controls. Although the functional role of
miR-146a in OA has yet to be determined, it appears to be involved in inflammatory pathways in
equine chondrocytes.
65
Materials and Methods
Figure 1: Study design for the isolation and treatment of equine articular chondrocytes.
Following euthanasia, cartilage was harvested and chondrocytes were released by enzymatic
digestion. The cells were treated with recombinant inflammatory proteins or left untreated for 24
or 48 hours at which point RNA was isolated and mRNA levels of cartilage markers,
inflammatory markers and microRNAs were determined.
Chondrocyte isolation, culture and treatment
Cartilage was collected from the articular surface of the third metacarpal bone (MCIII) of 5
horses without clinical evidence of joint or systemic disease, immediately after euthanasia. All
animals were euthanized according to Danish legislative guidelines using captive bolt followed
by exsanguination. Tissue was minced with a scalpel blade and digested with 1.5 mg/ml pronase
66
for 1 hour followed by a second digestion step with 1.5 mg/ml collagenase type II overnight at
37˚C. Digested samples were strained and isolated chondrocytes were seeded in 24-well plates
and maintained in chondrocyte culture medium [high glucose-Dulbecco’s modified eagle
medium (HG-DMEM) with Glutamax, 10% Fetal calf serum, 1% penicillin-streptomycin, 1%
gentamycin, ascorbic acid] at 37˚C with 5% CO2 for 2 days. Chondrocytes were treated with
recombinant equine IL-1β (10ng/mL; R&D Systems, Minneapolis, MN), recombinant equine
TNFα (50ng/mL; R&D Systems, Minneapolis, MN), recombinant human SAA (1μg/mL;
Peprotech, Rocky Hill, NJ) or left untreated for 24 and 48 hours.
RNA isolation, reverse transcription and qPCR
Total RNA, including small RNAs, was isolated using TRI Reagent (Molecular Research Centre,
Cincinnati, OH) according to the manufacturer’s protocol. Briefly, the samples were
homogenized in Tri Reagent and phase separation was achieved by the addition of chloroform.
The RNA in the aqueous phase was precipitated using isopropanol and the pellet was dissolved
in RNAse-free water. RNA concentration and purity were determined using a Nanodrop ND-
1000 spectrophotometer. To determine microRNA expression, 100 ng of RNA was reverse
transcribed using the TaqMan microRNA reverse transcription kit with the appropriate RT stem-
loop primer (Applied Biosystems, Foster City, CA). Quantitative RT-PCR was then performed
using the TaqMan PCR Master Mix and TaqMan microRNA assay (Applied Biosystems, Foster
City, CA). To assess mRNA expression, complementary DNA was synthesized from total RNA
using SuperScript II, oligo(dT)18 and random hexamer primers and qRT-PCR was performed
using Roche LightCycler 480, Fast Start DNA Master SYBR Green I (Roche Diagnostics) and
the equine specific primers found in Table 1. All reactions were run in triplicate. Crossing point
67
(Cp) values for microRNAs were normalized to U6 snRNA, while Cp values for mRNAs were
normalized to GAPDH. Relative gene/miRNA expression was determined using the delta-delta
Ct method.
Protein isolation and quantification
Cells were harvested using Trypsin-EDTA and washed with phosphate buffered saline (PBS).
Once pelleted, cells were lysed using protein lysis buffer [50 mM HEPES (pH 7.6), 100 mM
NaCl, 10 mM EDTA, 1% Triton, 4 mM Na-pyrophosphate, 2 mM Na-orthovanadate, 10 mM
NaF and cOmplete protease inhibitor cocktail (Roche, Indianapolis, IN)] and incubated on ice.
Cell debris was pelleted by 40 000 x g centrifugation at 4°C for 10 minutes. Protein
concentration in the supernatant was quantified using the BioRad DCTM
protein assay according
to the manufacturer’s protocol.
Statistical Analysis
GraphPad Prism 5 Software (San Diego, CA) was used to perform statistical analyses. One way
analysis of variance (ANOVA) with Bonferroni post-test was applied to determine the
differences in gene expression between time points within each treatment group. Data are
expressed as fold differences ± SEM compared with untreated chondrocytes at 0h. Significance
was assigned at p<0.05.
68
Results
Decreased gene expression of cartilage markers
Messenger RNA levels for the ECM components, collagen type II and aggrecan, were decreased
following treatment with IL-1β, TNFα and SAA compared to the untreated controls (Fig. 2).
The expression of collagen type 2 was also reduced at 48h in the untreated controls, highlighting
the importance of avoiding prolonged culture of chondrocytes as this is known to induce
dedifferentiation. CD-RAP mRNA expression decreased in response to IL-1β and SAA and was
increased by TNFα. Similarly, Sox9 was unchanged by IL-1β and SAA but was significantly
increased by TNFα.
Increased gene expression of inflammatory markers
Gene expression of MMPs -1, -3 and -13 was increased by all three treatments, however, the
increase in MMP-1 expression in response to TNFα was not significant. Additionally, mRNA
levels of SAA were increased by all three treatments particularly TNFα which induced SAA
significantly at 48h (Fig. 3).
MicroRNA expression
MiR-140 expression increased at 24h and decreased at 48h in response to all treatments
including controls. A similar pattern was observed for miR-9. MiR-146a expression was
significantly induced by IL-1β and SAA. MiR-155 showed no changes in expression in response
to any of the treatments (Fig. 4).
69
Expression of putative downstream targets
ADAMTS5 showed an increase in expression after 24h which was sustained at 48h. It is not
inversely correlated with miR-140 expression, although neither was altered by inflammatory
stimuli compared to controls. HDAC4 expression was increased in response to all three
treatments, however this induction was only significant for IL-1β and SAA. This gene did not
inversely correlate with miR-140. VEGF expression was significantly increased at 48h in
response to TNFα, although it was expected to be directly correlated to miR-146a as a result of
Smad4 degradation/repression by miR-146a (Li et al., 2012)
Discussion
Osteoarthritis is a degenerative joint disease that affects the cartilage and subchondral bone of
articulating joints. Since proinflammatory cytokines are thought to be involved in OA
development and progression, we treated equine articular chondrocytes with IL-1β or TNFα to
model some of their effects in vitro. Although SAA is normally associated with systemic acute
phase response, this protein has been detected in osteoarthritic cartilage and synovial fluid
(Vallon et al., 2001; Sukenik et al., 1988), suggesting that it may be involved in local
inflammation of OA joints. Therefore SAA was also included as a treatment group. As
expected, the expression of ECM components collagen type II and aggrecan was suppressed by
the cytokines and by SAA. The concentration of CD-RAP is high in OA synovial fluid (Saito et
al., 2002), therefore the expectation was that the inflammatory treatments would increase CD-
RAP mRNA expression, however it was decreased by IL-1β and SAA and slightly increased by
TNFα. The function of CD-RAP in chondrocytes is not clear, but it is thought to inhibit
proliferation (Kondo et al., 2001), therefore the decreased viability of chondrocytes treated with
70
TNFα (Schuerwegh et al., 2003) could be mediated in part by induction of CD-RAP expression.
Sox9 expression levels decline in OA cartilage (Salminen et al., 2001; Brew et al., 2010) and are
suppressed in chondrocytes treated with IL-1β or TNFα (Murakami et al., 2000). Unexpectedly,
Sox9 expression remained relatively unchanged in response to IL-1β and SAA, but was
significantly increased by TNFα.
The expression of inflammatory genes was also determined to confirm the induction of an
inflammatory response by IL-1β, TNFα and SAA. Matrix metalloproteinases -1, -3 and -13 were
induced by all three treatments. SAA expression was induced by inflammatory cytokines as
previously reported in rabbit chondrocytes (Vallon et al., 2001). It was also increased by the
administration of SAA protein, suggesting positive feedback amplification of the inflammatory
signal.
Although the pathogenesis of OA is poorly understood, several studies have suggested that
microRNAs may contribute to the abnormal gene and protein expression characteristic of OA.
MicroRNA expression profiling has revealed that the expression of many miRNAs is altered in
OA cartilage compared to healthy controls (Illiopoulos et al., 2008; Jones et al., 2009). Further
studies have attempted to elucidate the functions of specific altered miRNAs in OA. For
instance, miR-140 has been identified as a cartilage-specific microRNA that is decreased in OA
chondrocytes (Illiopoulos et al., 2008, Miyaki et al., 2009; Tardif et al., 2009), therefore miR-140
was expected to decrease in response to IL-1β, TNFα and SAA treatments. Previous studies
have reported conflicting results, Miyaki et al. (2009) state that miR-140 is downregulated by IL-
71
1β treatment in normal human chondrocytes, while Liang et al. (2012) report that it is increased
by IL-1β stimulation in the human cartilage cell line C28/I2. However, in the present study we
observe an increase in miR-140 expression at 24h which returns to baseline at 48h. This pattern
was observed in all groups including untreated controls, suggesting that miR-140 may not be
involved in inflammatory pathways in equine chondrocytes.
The expression of previously described targets ADAMTS5 (Miyaki et al., 2010) and HDAC4
(Tuddenham et al., 2006) was evaluated to determine whether they were inversely correlated
with miR-140 expression. ADAMTS5 mRNA was increased in all treatment groups including
the controls and did not appear to be regulated by miR-140 under these conditions. This
aggrecanase is important for aggrecan turnover in healthy cartilage, but is also thought to be
involved in OA pathogenesis. Contradictory results have been reported regarding the importance
of ADAMTS5 versus its family member ADAMTS4 (Fosang et al., 2008). Knockout mouse
models indicate that the former is the major aggrecanase in OA (Glasson et al., 2004), however
in vitro studies using human chondrocytes demonstrated that ADAMTS5 expression is
unchanged by IL-1β and TNFα, whereas ADAMTS4 was strongly induced by both cytokines
(Moulharat et al., 2004). In a study using equine cartilage explants, ADAMTS5 expression was
induced by IL-1β but to a lesser extent than ADAMTS4 (Busschers et al., 2010). These
discrepancies could be due to differences in cell versus explant culture, duration of cytokine
treatment or species. Expression of HDAC4 was increased by all three treatments compared to
the controls and was not inversely correlated to miR-140 expression. However, the possibility of
HDAC4 regulation by miR-140 on the translational level still remains and protein levels must be
assessed to explore that possibility. HDAC1 and HDAC2 are elevated in human OA
72
chondrocytes and were reported to repress cartilage specific genes (Hong et al., 2009). Further
studies will be required to determine whether a similar role exists for HDAC4 in response to
inflammatory stimuli.
MiR-9 expression is elevated in human OA cartilage and subchondral bone (Jones et al., 2009),
therefore, its expression was expected to increase in response to the inflammatory treatments in
this study. However, miR-9 showed an expression pattern similar to miR-140 with an increase
occurring at 24h followed by a decrease at 48h. IL-1β, TNFα and LPS induced the expression of
miR-155 in OA synovial fibroblasts (Stanczyk et al., 2008), however the same effect was not
observed in equine chondrocytes; treatment with IL-1β, TNFα and SAA had no effect on the
expression of miR-155. Therefore it appears that these miRNAs are not important regulators of
inflammation in equine chondrocytes.
Asahara and colleagues were the first to associate miR-146a with arthritis. They reported that
miR-146a was highly expressed in the synovial tissues from RA patients compared to OA and
normal samples (Nakasa et al., 2008). Next, they determined its expression pattern in OA
cartilage and demonstrated that miR-146a is intensely expressed in low grade OA cartilage but
decreases with severity and that its expression can be induced by IL-1β stimulation (Yamasaki et
al., 2009). This finding is consistent with the IL-1β-induced upregulation of miR-146a that we
observed in equine chondrocytes. Additionally, we found that miR-146a was significantly
increased by SAA, whereas TNFα had no effect. A study using THP-1 cells has been described
in which LPS, IL-1β and TNFα induced miR-146 through NF-κB (Taganov et al., 2006).
Although IL-1β signals via IL-1 receptor type I (IL-1RI) while SAA appears to signal through
73
Toll-like receptors (TLRs; Sandri et al., 2008), it is possible that these pathways converge at NF-
κB to induce miR-146a. This hypothesis could easily be explored by preventing NF-κB
activation using an inhibitor such as pyrrolidine dithiocarbamate (PDTC), then determining
whether IL-1β and SAA-induced miR-146a expression is abrogated. Pathological
vascularization of cartilage can be observed in OA, and VEGF is thought to be a key regulator of
angiogenesis under inflammatory conditions in articular joints (Murata et al., 2008). In a recent
study, upregulation of VEGF expression by miR-146a through mRNA degradation and
translational repression of Smad4 was demonstrated in rat chondrocytes (Li et al., 2012).
Contrary to the findings of Dai and colleagues, we did not identify a correlation between VEGF
mRNA levels and miR-146a. VEGF expression was relatively unchanged in response to IL-1β
and SAA treatment, but increased by TNFα, suggesting that the role of this miRNA in OA may
not be related to VEGF.
Our findings demonstrate that SAA stimulation of equine articular chondrocytes can suppress the
expression of cartilage genes and induce the expression of catabolic enzymes to similar levels as
IL-1β and TNFα, suggesting a potential role for SAA in OA development. We show that
miRNAs -140, -155 and -9 which were previously identified as being differentially expressed in
response to proinflammatory cytokines, were not significantly altered by IL-1β, TNFα or SAA
treatments compared to the untreated controls. This suggests that these microRNAs are not key
regulators of OA pathogenesis in the horse or that this in vitro model does not appropriately
recapitulate in vivo processes. Additional experiments including determination of their
expression in equine OA tissues will be important before ruling them out as therapeutic targets
for the treatment of OA. MiR-146a expression was significantly induced by IL-1β and SAA,
74
suggesting that this microRNA is involved in equine OA pathogenesis. However, its role does
not appear to be mediated by VEGF as IL-1β and SAA-mediated induction of miR-146a had no
effect on its expression. Investigating other targets of miR-146a in chondrocytes may lead to a
better understanding of OA pathogenesis and consequently improve the therapeutic options for
the treatment of OA.
75
Tables
Table 1. Primer pairs used for qRT-PCR
Gene Forward (5’-3’) Reverse (5’-3’) Primer Source
CollagenIIα1 TCTGCAGAATGGGCAGAGGTATA GATAATGTCATCGCAGAGGACATTC Berg et al., 2009
Aggrecan CTTAGAGGACAGAAAGCGAC ACTTTGGGCGGAAGAAGG Trumble et al., 2001
Sox9 ATCTGAAGAAGGAGAGCGAG TCAGAAGTCTCCAGAGCTTG Zehentner et al., 1999
CD-RAP/MIA ATGCCCAAGCTGGCTGA CTTCGATTTTGCCAGGTTTC Berg et al., 2009
MMP-1 CAG TGC CTT CAG AAA CAC GA GCT TCC CAG TCA CTT TCA GC NM_001081847*
MMP-3 TGT GGA GGT GAT GCA CAA ATC GCA TGC CAG GAA ATG TAG TGA A Fehr et al., 2000
MMP-13 GCT GCC TAT GAG CAT CCT TC ACC TCC AGA CCT GGT TTC CT Nomura et al., 2007
SAA CCT GGG CTG CTA AAG TCA TC AGG CCA TGA GGT CTG AAG TG AY246757.1*
HDAC4 GGACATTTGGGTCGTTGTAG CATCGTGGACTGGGACGTGCACC Eivers et al., 2012
ADAMTS5 AACTGGGGGTCCTGGGGGTCCTGG CATTTCTTGCCTCACACTGCTCAT Coyne et al., 2009
VEGF AGG CCA TGA GGT CTG AAG TG CAT CTC TCC TAT GTG TGG CTT TG Desch et al., 2012
GAPDH GGGTGGAGCCAAAAGGGTCATCAT AGCTTTCTCCAGGCGGCAGGTCAG Iqbal et al., 2004
Primers denoted with * were designed by Dr. Lise C. Berg.
76
Figures
Figure 2: Gene expression of cartilage markers in equine articular chondrocytes treated with IL-
1β, TNFα, SAA or untreated after 0, 24 and 48 hours. Collagen II and aggrecan mRNA levels
decreased in response to all three treatments, though significance was only achieved with ACAN
expression in response to SAA. No significant changes were observed for CD-RAP. Sox9
expression was increased in response to TNFα. Data shown as mean ± SEM. (*) p<0.05, (**)
p<0.01, (****) p<0.0001. N=5 per time point.
77
Figure 3: Gene expression of inflammatory markers in equine articular chondrocytes treated with
IL-1β, TNFα, SAA or untreated after 0, 24 and 48 hours. MMPs -1, -3 and -13 increased
significantly in response to all treatments, with the exception of MMP-1 expression in response
to TNFα. SAA was also increased by all three treatments, however significance was only
reached in TNFα treated samples. Data shown as mean ± SEM. (*) p<0.05, (**) p<0.01, (****)
p<0.0001. N=5 per time point.
78
Figure 4: Expression levels of microRNAs in equine articular chondrocytes treated with IL-1β,
TNFα, SAA or untreated after 0, 24 and 48 hours. MiR-140 expression increased after 24h and
decreased at 48h in all groups, however significance was only achieved in the control group.
Mir-9 showed a similar pattern. No significant differences were observed for miR-155. MiR-
146a expression was significantly induced by IL-1β and SAA. Data shown as mean ± SEM. (*)
p<0.05, (**) p<0.01, (***) p<0.001, (****) p<0.0001. N=5 per time point.
79
Figure 5: Gene expression of miR-140 and miR-146a downstream targets in equine articular
chondrocytes treated with IL-1β, TNFα, SAA or untreated after 0, 24 and 48 hours. ADAMTS5
expression increased after 24 hours in all groups including the controls. HDAC4 was
significantly increased in response to IL-1β and SAA. VEGF was significantly increased by
TNFα. Data shown as mean ± SEM. (*) p<0.05, (**) p<0.01, (***) p<0.001, (****) p<0.0001.
N=5 per time point.
80
GENERAL DISCUSSION AND CONCLUSIONS
Orthopaedic injuries involving the joint cartilage are some of the most common causes of
lameness in racehorses (Bailey et al., 1999). Since the tissues resulting from repair generated by
current treatments often consist of mechanically inferior fibrocartilage, alternative methods are
being explored. The multi-lineage differentiation potential and high proliferative capacity of
mesenchymal stromal cells make them excellent candidates for tissue engineering strategies. In
a study by Wilke et al. (2007), equine cartilage defects that were filled with BM-MSCs were
significantly improved after 30 days compared to controls. However, no difference was
observed between groups after 8 months. This study emphasizes the need for a better
understanding of chondrogenic differentiation. MicroRNAs are potent regulators of gene
expression and have recently been associated with cartilage development and homeostasis (Hong
& Reddi, 2012), therefore the aim of the first study was to determine the expression of miR-140,
a cartilage-specific microRNA, during chondrogenesis of eCB-MSCs. The aim of the second
study was to improve the in vitro differentiation technique in order to generate higher numbers of
differentiated cells, as well as increase the homogeneity of the tissues. The membrane culture
system described in this thesis could be used to pre-differentiate eCB-MSCs prior to use in
cartilage tissue engineering approaches. Osteoarthritis is another challenge in articular cartilage
repair. Little is known about the pathogenesis of this disease, therefore the aim of the third study
was to determine the expression of select microRNAs in an in vitro model of OA. The
expression of microRNAs in equine CB-MSCs and chondrocytes as demonstrated in this thesis
suggests that microRNAs could potentially be used to direct or enhance eCB-MSC chondrogenic
differentiation as well as to develop novel biomarker panels of in vivo joint health.
81
In Chapter 1, I demonstrate both that miR-140 is highly expressed in normal equine articular
cartilage and that eCB-MSCs express significantly higher levels of this microRNA after 14 days
of chondrogenic differentiation. These findings reveal for the first time that miR-140 is
expressed in equine cells, even though miR-140 was not identified during an in silico analysis of
microRNAs in the Equus caballus genome (Zhou et al., 2009). Additionally, this work is
consistent with previous reports that miR-140 is cartilage specific (Tuddenham et al., 2006) and
increases during chondrogenesis of MSCs (Miyaki et al., 2009). MicroRNAs function by
repressing translation or inducing transcript degradation, however this study only examined the
potential of miR-140 to regulate the latter due to absence of reliably cross-reactive antibodies for
protein quantification. The expression of miR-140 target mRNAs encoding ADAMTS-5 and
CXCL12 (Miyaki et al., 2009; Nicolas et al., 2008) was supressed during chondrogenesis,
suggesting potential regulation by miR-140. IGFBP5, another miR-140 target (Tardif et al.,
2009), was also examined, but its expression was directly correlated with miR-140 expression.
Together these results indicate that, while some of our findings are consistent with previous
reports, the regulation of miR-140 target genes could vary between species.
The finding that miR-140 expression correlates with both cartilage differentiation and with the
suppression of CXCL12 and ADAMTS-5 mRNA levels suggests that miR-based manipulation
of gene expression might represent a useful component of therapeutic approaches aimed at
improving cartilage differentiation. It will be important to overexpress miR-140 during
chondrogenic differentiation and determine whether it could improve or even induce
chondrogenesis. Evidence for the potential of microRNAs to alter cell fate has been provided by
recent studies in which specific microRNAs have been used to create induced pluripotent stem
82
cells (Lin et al., 2008) and to transdifferentiate fibroblasts to neurons (Ambasudhan et al., 2011;
Yoo et al., 2011). The induction of in vitro chondrogenesis using microRNA has not yet been
shown, but the tissue specificity of miR-140 makes it an excellent candidate. This approach
could be applied to cell-based cartilage repair strategies such as chondrocyte implantation and
osteochondral grafts. It will be of crucial importance to elucidate miR-140-mediated pathways in
equine cartilage development and homeostasis before applying these small molecules in
veterinary medicine.
Although miR-140 appears to be an important miRNA in chondrogenesis, several other miRNAs
with targets in chondrogenic pathways have been identified. For instance, miR-145 was reported
to directly repress Sox9 during TGF-β3 induced chondrogenic differentiation of murine MSCs
(Yang B et al., 2011) and miR-199a* inhibited BMP2-induced chondrogenesis by targeting
Smad1 (Lin et al., 2009). It would be interesting to determine whether simultaneous
overexpression of miR-140 and knockdown of miR-145 or miR-199a* would have an additive
effect on the induction of a chondrogenic phenotype.
Another parameter that merits investigation is the direct effect of transforming growth factor beta
(TGF-β) on the expression of miR-140. The addition of soluble growth factors of the TGF-β
superfamily to chondrogenic differentiation media is an established method for stimulating in
vitro chondrogenesis (Johnstone et al., 1998). However, a recent study by Davis and colleagues
has revealed that a selective group of microRNAs are directly regulated by signal transducers of
the TGFβ/BMP pathway, the Smads. The majority of miRNAs in this group contain a consensus
sequence (R-SBE) in the stem region of their primary transcripts that is similar to Smad binding
83
element (SBE). They propose a mechanism in which receptor-regulated Smads (R-Smads) bind
directly to R-SBE in pri-miRNAs in response to TGFβ or BMP-4 stimulation to provide a
platform for the recruitment of microRNA processing enzymes Drosha and DGCR8, thus
facilitating pri-miRNA cleavage by Drosha. MiR-140 was identified as one miRNA containing a
putative R-SBE. However, this study was conducted in human pulmonary artery smooth muscle
cells (PASMC) and the TGFβ or BMP-4 stimulation was applied for 24 hours or less (Davis et
al., 2010). Determining whether this mechanism also applies to the expression of miR-140
during chondrogenic differentiation will improve our understanding of the complex network of
molecular interactions that regulate chondrogenesis.
In Chapter 2, chondrogenic differentiation of eCB-MSCs in a membrane-based culture system
was compared to the traditional pellet culture system. While both systems yielded hyaline-like
cartilage tissues, peripheral areas of the pellet cultures appeared fibrous. The tissues generated in
the membrane system were more homogeneous, which suggests that nutrient and oxygen
gradients were more evenly distributed in this system. Although chondrogenic differentiation
using membrane culture has been reported (Lee et al., 2011), this study is the first to show that
membrane culture using fibronectin-coated PTFE inserts can support chondrogenesis of equine
CB-MSCs. A major concern in cartilage tissue engineering is the induction of hypertrophy in
the differentiating chondrocytes. An attempt was made to examine the expression of collagen X
using immunostaining, however the antibody used was a sample developed by a collaborator and
did not appear to stain with any specificity. To determine whether hypertrophy is present or
induced in the membrane system, it will be necessary to examine the expression of hypertrophy-
84
related markers such as MMP-13, collagen X, Runx2 and activity of ALP and to compare with
pellet culture where it is often observed (Pelttari et al., 2006).
Another obstacle to overcome is the variability with which the cells adhere to the membrane.
Fortunately, all membrane cultures remained even, multi-cell layered tissues during the
differentiation period in this study, however, attempts to replicate these results proved to be a
challenge. Uneven distribution of the cells on the membrane, formation of cell ‘clumps’ and
peeling of the cell layers from the membrane were observed during subsequent attempts. One
hypothesis for these inconsistencies is that, although the cells may bind to the fibronectin, the
fibronectin itself was not thoroughly bound to the PTFE membrane. Thus, future work should
take into consideration different types of adhesion molecules and/or different coating procedures.
An attractive alternative to the use of fibronectin is the exploitation of its integrin recognition
sequence, the RGD (arginine-glycine-aspartate) peptide (Pierschbacher & Ruoslahti, 1984). In a
study using sodium alginate scaffolds with chemically immobilized RGD peptides, cell adhesion
of human MSCs and gene expression of sox9 and collagen II following differentiation were
increased in the RGD-immobilized cell constructs compared to unmodified scaffolds (Re’em et
al., 2010). To the author’s knowledge, RGD-coating of PTFE cell culture inserts for
chondrogenic differentiation has not been reported. However, PTFE vascular grafts coated with
RGD-peptides improved endothelial cell attachment using a strategy involving a pre-coating of
poly-L-lysine, incubation with glutardialdehyde and finally RGD-peptide application
(Walluscheck et al., 1996). In theory, a similar approach could be used for cartilage tissue
engineering.
85
Figure 1: Schematic representation of biochemical reactions for RGD-coating on PTFE
(modified from Walluscheck et al., 1996).
Although much is left to be explored with regard to potential hypertrophy and inconsistent
adhesion, it appears that when eCB-MSCs are successfully differentiated in membrane culture,
the resulting cartilage tissue is superior to pellet culture. Additionally, this system is
advantageous as it can generate an increased number of differentiated cells (2 million/membrane
vs. 250 000/pellet) that could be applied to cartilage repair treatments.
In Chapter 3, the expression of 4 different microRNAs previously associated with osteoarthritis
was examined in equine articular chondrocytes treated with inflammatory stimuli. The
application of SAA caused a decrease in the expression of ECM components and a significant
increase in the expression of MMPs to similar levels as IL-1β and TNFα. This suggests that
SAA may have an important role in equine OA. While miR-140, miR-9 and miR-155 were not
differentially expressed in response to the treatments compared to controls, miR-146a expression
was significantly induced by IL-1β and SAA. This finding is consistent with previous reports
associating miR-146a with OA-related inflammation (Nakasa et al., 2008; Yamasaki et al.,
86
2009). During this study, articular chondrocytes were treated with pro-inflammatory cytokines
and SAA in order to simulate an osteoarthritic environment, however, the development and
progression of OA pathogenesis is complex and not fully understood. Assessment of miR-146a
expression in equine OA cartilage, plasma and synovial tissues compared to healthy controls,
will provide a better indication of the utility of this microRNA as a biomarker of OA. Yamasaki
et al. (2009) reported that miR-146a was highly expressed in the cartilage of patients with milder
cases of OA, but that its expression decreased with severity. It will therefore be important to
consider the severity of OA during this type of study.
In a study addressing the function of miR-146a in cartilage homeostasis, human articular
chondrocytes were treated with IL-1α, with or without pre-miR-146a mimics for 48h. They
reported that miR-146a had an antagonistic effect on catabolic signals, as miR-146a transfection
reduced the IL-1α-induced expression of matrix degrading enzymes MMP-13 and ADAMTS5,
and antagonized IL-1α-mediated suppression of collagen II and aggrecan (Li et al., 2011). These
findings support the hypothesis that in early OA, miR-146a is highly induced by inflammatory
cytokines as part of a cellular response to repair or prevent additional tissue damage, and that the
low levels of miR-146a in late-stage OA may contribute to the progression of cartilage
degradation as the catabolic signals are derepressed (Yamasaki et al., 2009).
Although evidence that miR-146a is involved in OA pathogenesis is accumulating, little is
known about its molecular interactions. In fact, the only target reported in chondrocytes is
Smad4. Using miR-146a overexpression and knockdown and 3’UTR luciferase assays, Li and
colleagues (2012) demonstrated that miR-146a directly targets Smad4 for translational repression
87
and mRNA degradation. They propose that miR-146a contributes to OA pathogenesis by
increasing the expression of VEGF and reducing cellular response to TGFβ through the
inhibition of Smad4 (Li et al., 2012). Whether miR-146a acts as an activator during early OA or
serves a protective role as previously suggested (Yamasaki et al., 2009; Li et al., 2011) is
unclear. Elucidation of novel miR-146a targets using in vitro and in vivo models of OA may
lead to a greater understanding of the pathogenesis of this disease and may indicate whether or
not miR-146a represents an appropriate therapeutic target for the treatment of OA.
Clinically, there are several problems associated with direct miRNA administration, such as
delivery to targeted cells, degradation by endogenous RNAses and immunogenic reactions.
However, Ochi and colleagues have reported on intra-articular and intravenous administration of
synthetic miRs in experimental models of arthritis with some success. The injection of double
stranded miR-15a into the joints of arthritic mice induced apoptosis in the synovium by
suppressing Bcl-2 expression and although a therapeutic effect was not demonstrated, there was
little evidence of toxicity (Nagata et al., 2009). More recently, the same group demonstrated that
intravenous administration of miR-146a prevented joint destruction by inhibiting
osteoclastogenesis in arthritic mice (Nakasa et al., 2011). Whether or not double stranded
miRNA can be taken up by chondrocytes in vivo in the joint following cartilage damage has yet
to be determined, but may present a significant challenge due to the avascularity and dense
ECM. Recently, a novel method for cartilage-targeted gene delivery was reported. Using phage
display technology, a chondrocyte affinity peptide (CAP) was identified. This peptide was
conjugated to polyethylenimine (PEI) and the resulting CAP-PEI was complexed to pRL-CMV,
a plasmid that constitutively expresses luciferase. Following CAP-PEI/DNA delivery to rabbit
88
knee joints, tissues were collected and luciferase activity was measured. They found that
transfections using CAP-modified vectors were significantly more efficient and specific than
scrambled peptide-modified vectors (Pi et al., 2011). This innovative technique could potentially
be used to deliver microRNA expression plasmids in cartilage repair therapies.
In conclusion, the hypotheses of this MSc thesis were addressed and supported by the findings
that a) miR-140 is expressed in equine cells, specifically articular chondrocytes and
differentiating eCB-MSCs, b) chondrogenic differentiation using membrane culture appeared
superior to pellet culture based on histological assessment, and c) miR-146a was differentially
expressed in response to IL-1β and SAA. Each chapter of this thesis could be considered as a
stand-alone study, but the common thread is that the purpose of each was to gain a better
understanding of cartilage development and homeostasis in the horse. Although additional work
is required to determine the suitability of miRNA-based therapeutics for equine cartilage repair, a
potential role for microRNAs in eCB-MSC chondrogenesis and OA-related inflammation has
been established.
89
REFERENCES
Abouheif MM, T Nakasa, H Shibuya, T Niimoto, W Kongcharoensombat and M Ochi. (2010). Silencing
microRNA-34a inhibits chondrocyte apoptosis in a rat osteoarthritis model in vitro. Rheumatology
49(11): 2054-60.
Adams CS and IM Shapiro. (2002). The fate of the terminally differentiated chondrocyte: evidence for
microenvironmental regulation of chondrocyte apoptosis. Critical Reviews in Oral Biology & Medicine
13(6): 465-473.
Ahmed N, R Dreier, A Gopferich, J Grifka and S Grassel. (2007). Soluble signalling factors derived from
differentiated cartilage tissue affect chondrogenic differentiation of rat adult marrow stromal cells. Cell
Physiology and Biochemistry 20: 665-678.
Ahmed TAE and MT Hincke. (2010). Strategies for articular cartilage lesion repair and functional
restoration. Tissue Engineering Part B: Reviews 16(3): 305-329.
Akhtar N, Z Rasheed, S Ramamurthy, AN Anbazhagan, FR Voss and TM Haqqi. (2010). MicroRNA-27b
regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. Arthritis
and Rheumatism 62(5): 1361-71.
Amarilio R, SV Viukov, A Sharir, I Eshkar-Oren, RS Johnson and E Zelzer. (2007). HIF1α regulation
of Sox9 is necessary to maintain differentiation of hypoxic prechondrogenic cells during early
skeletogenesis. Development 134: 3917-3928.
Ambasudhan R, M Talantova, R Coleman, X Yuan, S Zhu, SA Lipton and S Ding. (2011). Direct
reprogramming of adult human fibroblasts to functional neurons under defined conditions. Cell Stem
Cell 9(2): 113-118.
Araldi E & E Schipani. (2010). MicroRNA-140 and the silencing of osteoarthritis. Genes & Development
24: 1075-1080.
Bailey CJ, SW Reid, DR Hodgson and RJ Rose. (1999). Impact of injuries and disease on a cohort of
two- and three year-old thoroughbreds in training. Veterinary Record 145(17): 487–493.
Baksh D, Song L and Tuan RS. (2004). Adult mesenchymal stem cells: characterization, differentiation,
and application in cell and gene therapy. Journal of Cellular and Molecular Medicine 8: 301–316.
Bartel DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
Basser PJ, Schneiderman R, Bank R, Wachtel E and Maroudas A. (1998). Mechanical properties of the
collagen network in human articular cartilage as measured by osmotic stress technique. Archives of
Biochemistry and Biophysics 351: 207–19.
Berg LC, TG Koch, T Heerkens, K Besonov, PD Thomsen and DH Betts. (2009). Chondrogenic potential
of mesenchymal stromal cells derived from equine bone marrow and umbilical cord blood. Veterinary
and Comparative Orthopaedics and Traumatology 22: 363-370.
90
Brew CJ, PD Clegg, RP Boot-Handford, JG Andrew and T Hardingham. (2010). Gene expression in
human chondrocytes in late osteoarthritis is changed in both fibrillated and intact cartilage without
evidence of generalised chondrocyte hypertrophy. Annals of Rheumatic Diseases 69: 234-240.
Brittberg M, A Lindahl, A Nilsson, C Ohlsson, O Isaksson and L Peterson. (1994). Treatment of deep
cartilage defects in the knee with autologous chondrocyte transplantation. New England Journal of
Medicine 331: 879–895.
Busschers E, JP Holt and DW Richardson. (2010). Effects of glucocorticoids and interleukin-1b on
expression and activity of aggrecanases in equine chondrocytes. American Journal of Veterinary Research
71(2): 176-185.
Cai X and BR Cullen. (2007). The imprinted H19 noncoding RNA is a primary microRNA precursor.
RNA 13: 313-316.
Carlevaro MF, S Cermelli, R Cancedda and F Descalzi Cancedda. (2000). Vascular endothelial growth
factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during
endochondral bone formation. Journal of Cell Science 113(1): 59–69.
Caron JP and RL Genovese. (2003). Principles and practices of joint disease treatment. In: M.W. Ross
and S.J. Dyson (Ed.) Diagnostics and Management of Lameness in the Horse. p. 746-763. Elsevier
Science, Philadelphia.
Castro-Malaspina H, RE Gay, G Resnick, N Kapoor, P Meyers, D Chiarieri, S McKenzie, HE Broxmeyer
and MA Moore. (1980). Characterization of human bone marrow fibroblast colony-forming cells (CFU-F)
and their progeny. Blood 56 (2): 289-301.
Chadjichristos C, Ghayor C, Kypriotou M, Martin G, Renard E, Ala-Kokko L, Suske G, de Crombrugghe
B, Pujol JP and Galéra P. (2003). Sp1 and Sp3 transcription factors mediate interleukin-1beta down-
regulation of human type II collagen gene expression in articular chondrocytes. The Journal of Biological
Chemistry 278: 39762-39772.
Chen WH, MT Lai, ATH Wu, CC Wu, JG Gelovani, CT Lin, SC Hung, WT Chiu and WP Deng. (2009).
In vitro stage-specific chondrogenesis of mesenchymal stem cells committed to chondrocytes. Arthritis
and Rheumatism 60: 450–459.
Chen CZ, L Li, HF Lodish and DP Bartel. (2004). MicroRNAs modulate hematopoietic lineage
differentiation. Science 303: 83–86.
Coyne MJ, H Cousin, JP Loftus, PJ Johnson, JK Belknap, CM Gradil, SJ Black and D Alfandari. (2009).
Cloning and expression of ADAM-related metalloproteases in equine laminitis. Veterinary Immunology
and Immunopathology 129(3–4): 231–241.
Cristino S, A Piacentini, C Manferdini, K Codeluppi, F Grassi, A Facchini and Gina Lisignoli. (2008).
Expression of CXC chemokines and their receptors is modulated during chondrogenic differentiation of
human mesenchymal stem cells grown in three-dimensional scaffold: evidence in native cartilage. Tissue
Engineering Part A 14(1): 97-105.
Darling EM and KA Athanasiou. (2005). Rapid phenotypic changes in passaged articular chondrocyte
subpopulations. Journal of Orthopaedic Research 23: 425-432.
91
Davis BN, AC Hilyard, PH Nguyen, G Lagna and A Hata. (2010). Smad proteins bind a conserved RNA
sequence to promote microrna maturation by Drosha. Molecular Cell 39(3): 373–384.
De Bari C, TB Kurth and Andrea Augello. (2010). Mesenchymal stem cells from development to
postnatal joint homeostasis, aging, and disease. Birth Defects Research (C) 90:257–271.
Desch A, Strozyk EA, Bauer AT, Huck V, Niemeyer V, Wieland T and Schneider SW. (2012). Highly
invasive melanoma cells activate the vascular endothelium via an MMP-2/Integrin αvβ5-induced
secretion of VEGF-A. The American Journal of Pathology 181(2): 693-705.
Dickhut A, Pelttari K, Janicki P, Wagner W, Eckstein V, Egermann M and Richter W. (2009).
Calcification or dedifferentiation: requirement to lock mesenchymal stem cells in a desired differentiation
stage. Journal of Cell Physiology 219(1): 219-26.
Du T and PD Zamore. (2005). MicroPrimer: the biogenesis and function of miRNA. Development 132:
4645–4652.
Dudek KA, JE Lafont, A Martinez-Sanchez and CL Murphy. (2010). Type II collagen expression is
regulated by tissue-specific mir-675 in human articular chondrocytes. The Journal of Biological
Chemistry 285: 24381-24387.
Dunn W, G DuRaine and AH Reddi. (2009). Profiling microRNA expression in bovine articular cartilage
and implications for mechanotransduction. Arthritis & Rheumatism 60: 2333–2339.
Ebert JR, WB Robertson, J Woodhouse, M Fallon, MH Zheng, T Ackland and DJ Wood. (2011). Clinical
and magnetic resonance imaging–based outcomes to 5 years after matrix-induced autologous chondrocyte
implantation to address articular cartilage defects in the knee. American Journal Sports Medicine 39(4):
753-763.
Ebisawa K, Hata K, Okada K, Kimata K, Ueda M, Torii S, Watanabe H. (2004). Ultrasound enhances
transforming growth factor beta-mediated chondrocyte differentiation of human mesenchymal stem cells.
Tissue Engineering 10 : 921-929.
Eivers SS, BA McGivney, J Gu, DE MacHugh, LM Katz and EW Hill. (2012). PGC-1α encoded by the
PPARGC1A gene regulates oxidative energy metabolism in equine skeletal muscle during exercise.
Animal Genetics 43(2): 153–162.
Elia L, M Quintavalle, J Zhang, R Contu, L Cossu, MVG Latronico, KL Peterson, C Indolfi, D Catalucci,
J Chen, SA Courtneidge and G Condorelli. (2009). The knockout of miR-143 and -145 alters smooth
muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death and
Differentiation 16: 1590–1598.
Fehr JE, GW Trotter, JT Oxford and DA Hart. (2000). Comparison of Northern blot hybridization and a
reverse transcriptase-polymerase chain reaction technique for measurement of mRNA expression of
metalloproteinases and matrix components in articular cartilage and synovial membrane from horses with
osteoarthritis. American Journal of Veterinary Research 61(8): 900-905.
Fortier LA and RKW Smith. (2008). Regenerative medicine for tendinous and ligamentous injuries of
sport horses. Veterinary Clinics of North America: Equine Practice 24(1): 191-201.
92
Fosang AJ, FM Rogerson, CJ East and H Stanton. (2008). ADAMTS-5: the story so far. European Cells
and Materials 15: 11-26.
Frenz DA, Akiyama SK, Paulsen DF and Newman SA. (1989). Latex beads as probes of cell surface-
extracellular matrix interactions during chondrogenesis: evidence for a role for amino-terminal heparin-
binding domain of fibronectin. Developmental Biology 136(1): 87-96.
Gadjanski I, K Spiller and G Vunjak-Novakovic. (2012). Time-dependent processes in stem cell-based
tissue engineering of articular cartilage. Stem Cell Reviews and Reports 8 (3): 863-881.
Glasson SS, R Askew, B Sheppard, B Carito, T Blanchet, HL Ma, CR Flannery, D Peluso, K Kanki, Z
Yang, MK Majumdar and EA Morris. (2005). Deletion of active ADAMTS5 prevents cartilage
degradation in a murine model of osteoarthritis. Nature 434: 644-648.
Goodrich LR and AJ Nixon. (2006). Medical treatment of osteoarthritis in the horse – A review. The
Veterinary Journal 171: 51–69.
Grad S, Eglin D, Alini M and Stoddart MJ. (2011). Physical stimulation of chondrogenic cells in vitro:
a review. Clinical Orthopaedics and Related Research 469(10): 2764-72.
Guest DJ, Smith MR, Allen WR. (2008). Monitoring the fate of autologous and allogeneic mesenchymal
progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study. Equine
Veterinary Journal 40(2): 178–181.
Guan Y-J, X Yang, L Wei and Q Chen. (2011). MiR-365: a mechanosensitive microRNA stimulates
chondrocyte differentiation through targeting histone deacetylase 4. The FASEB Journal 25: 4457-4466.
Guo X, TF Day, X Jiang, L Garrett-Beal, L Topol and Y Yang. (2004). Wnt/-catenin signaling is
sufficient and necessary for synovial joint formation. Genes & Development 18:2404-2417.
Hangody L, G Vásárhelyi, LR Hangody, Z Sükösd, G Tibay, L Bartha and G Bodó. (2008). Autologous
osteochondral grafting—Technique and long-term results. Injury 39(1): 32-39.
Hardingham TE and AJ Fosang. (1992). Proteoglycans: many forms and many functions. FASEB Journal
6: 861–70.
Hong E and AH Reddi. (2012). MicroRNAs in chondrogenesis, articular cartilage and osteoarthritis:
implications for tissue engineering. Tissue Engineering Part B: Reviews. -Not available-, ahead of print.
Hong S, A Derfoul, L Pereira-Mouries and DJ Hall. (2009). A novel domain in histone deacetylase 1 and
2 mediates repression of cartilage-specific genes in human chondrocytes. The FASEB Journal 23(10):
3539-3552.
Huang W, UI Chung, HM Kronenberg, and B de Crombrugghe. (2001). The chondrogenic transcription
factor Sox9 is a target of signaling by the parathyroid hormone-related peptide in the growth plate of
endochondral bones. Proceedings of the National Academy of Sciences 98: 160-165.
Iliopoulos D, KN Malizos, P Oikonomou and A Tsezou. (2008). Integrative microrna and proteomic
approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory
networks. PLoS ONE 3(11): e3740.
93
Iqbal J, JL Bird, AP Hollander and MT Bayliss. (2004). Effect of matrix depleting agents on the
expression of chondrocyte metabolism by equine chondrocytes. Research in Veterinary Science 77(3):
249–256.
Johnstone B, TM Hering, AI Caplan, VM Goldberg and JU Yoo. (1998). In vitro chondrogenesis of bone
marrow-derived mesenchymal progenitor cells. Experimental Cell Research 238(1): 265-272.
Jones SW, G Watkinsy, N Le Goody, S Roberts, CL Murphy, SMV Brockbank, MRC Needham, SJ Read
and P Newham. (2009). The identification of differentially expressed microRNA in osteoarthritic tissue
that modulate the production of TNF-a and MMP13. Osteoarthritis and Cartilage 17: 464-472.
Kandel RA, M Grynpas, R Pilliar, J Lee, J Wang, S Waldman, P Zalzal, M Hurtig and CIHR-
Bioengineering of Skeletal Tissues Team. (2006). Repair of osteochondral defects with biphasic
cartilage-calcium polyphosphate constructs in a Sheep model. Biomaterials 27: 4120–4131.
Kanichai M, Ferguson D, Prendergast P and Campbell VA. (2008). Hypoxia promotes chondrogenesis in
rat mesenchymal stem cells: A role for AKT and hypoxia-inducible factor (HIF)-1α. Journal of Cellular
Physiology 216: 708–715.
Kapoor M, J Martel-Pelletier, D Lajeunesse, J-P Pelletier and H Fahmi. (2011). Role of proinflammatory
cytokines in the pathophysiology of osteoarthritis. Nature Reviews Rheumatology 7: 33-42.
Kataoka N, M Fujita and M Ohno. (2009). Functional association of the microprocessor complex with the
spliceosome. Molecular and Cellular Biology 29(12): 3243-3254.
Kellner K, Liebsch G, Klimant I, Wolfbeis OS, Blunk T, Schulz MB and Göpferich A. (2002).
Determination of oxygen gradients in engineered tissue using a fluorescent sensor. Biotechnology and
Bioengineering 80:73–83.
Kern S, H Eichler, J Stoeve, H Klüter and K Bieback. (2006). Comparative analysis of mesenchymal stem
cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24(5): 1294–1301.
Khan IM, SN Redman, R Williams, GP Dowthwaite, SF Oldfield, CW Archer. (2007). The development
of synovial joints. Current Topics in Developmental Biology 79: 1-36.
Khan WS, Adesida AB, Tew SR, Lowe ET and Hardingham TE. (2010), Bone marrow-derived
mesenchymal stem cells express the pericyte marker 3G5 in culture and show enhanced chondrogenesis
in hypoxic conditions. Journal of Orthopaedic Research 28: 834–840.
Kim D, J Song and E-J Jin. (2010). MicroRNA-221 regulates chondrogenic differentiation through
promoting proteosomal degradation of slug by targeting mdm2. The Journal of Biological Chemistry
285(35): 26900–26907.
Kim YJ, HJ Kim and GI Im. (2008). PTHrP promotes chondrogenesis and suppresses hypertrophy from
both bone marrow-derived and adipose tissue-derived MSCs. Biochemical and Biophysical Research
Communications 373(1): 104-8.
Kim HJ, JD Delaney and T Kirsch. (2010). The role of pyrophosphate/phosphate homeostasis in terminal
differentiation and apoptosis of growth plate chondrocytes. Bone 47(3): 657-665.
94
Knutsen G, L Engebretsen, TC Ludvigsen, JO Drogset, T Grøntvedt, E Solheim, T Strand, S Roberts, V
Isaksen and O Johansen. (2004). Autologous chondrocyte implantation compared with microfracture in
the knee a randomized trial. The Journal of Bone & Joint Surgery 86(3): 455-464.
Kobayashi T, J Lu, BS Cobb , SJ Rodda, AP McMahon, E Schipani, M Merkenschlager and HM
Kronenberg. (2008). Dicer-dependent pathways regulate chondrocyte proliferation and differentiation.
Proceedings of the National Academy of Sciences. 105: 1949–1954.
Koch TG, T Heerkens, PD Thomsen and DH Betts. (2007). Isolation of mesenchymal stem cells from
equine umbilical cord blood. BMC Biotechnology 7(26).
Koch TG, PD Thomsen and DH Betts. (2009). Improved isolation protocol for equine cord blood-derived
mesenchymal stromal cells. Cytotherapy 11(4): 443-447.
Kogler G, S Sensken and P Wernet. (2006). Comparative generation and characterization of pluripotent
unrestricted somatic stem cells with mesenchymal stem cells from human cord blood. Experimental
Hematology 34(11): 1589–1595.
Kondo S, Cha SH, Xie WF and Sandell LJ. (2001). Cytokine regulation of cartilage-derived retinoic acid-
sensitive protein (CD-RAP) in primary articular chondrocytes: suppression by IL-1, bfGF, TGFbeta and
stimulation by IGF-1. Journal of Orthopaedic Research 19(4):712-719.
Koyama E, Shibukawa Y, Nagayama M, Sugito H, Young B, Yuasa T, Okabe T, Ochiai T, Kamiya
N, Rountree RB, Kingsley DM, Iwamoto M, Enomoto-Iwamoto M and Pacifici M. (2008). A distinct
cohort of progenitor cells participates in synovial joint and articular cartilage formation during mouse
limb skeletogenesis. Developmental Biology 316: 62–73.
Kortesidis A, A Zannettino, S Isenmann, S Shi, T Lapidot and S Gronthos. (2005). Stromal-derived
factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells.
Blood 105: 3793-3801.
Krichevsky AM, KC Sonntag, O Isacson and KS Kosik. (2006). Specific microRNAs modulate
embryonic stem cell–derived neurogenesis. Stem Cells 24: 857–864.
Lacourt M, C Gao, A Li, C Girard, G Beauchamp, JE Henderson, S Laverty. (2012). Relationship
between cartilage and subchondral bone lesions in repetitive impact trauma-induced equine osteoarthritis.
Osteoarthritis and Cartilage 20(6): 572-583.
Lagos-Quintana M, R Rauhut, W Lendeckel and T Tuschl. (2001). Identification of novel genes coding
for small expressed RNAs. Science 294: 853–858.
Lee RC, RL Feinbaum and Victor Ambros. (1993). The C. elegans heterochronic gene lin-4
encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843–854.
Lee CR, AJ Grodzinsky, H-P Hsu, SD Martin and M Spector. (2000). Effects of harvest and selected
cartilage repair procedures on the physical and biochemical properties of articular cartilage in the canine
knee. Journal of Orthopaedic Research 18: 790–799.
Lee OK, TK Kuo, W-M Chen, K-D Lee, S-L Hsieh and T-H Chen. (2004). Isolation of multipotent
mesenchymal stem cells from umbilical cord blood. Blood 103(5): 1669-1675.
95
Lee WD, Hurtig MB, Kandel RA, Stanford WL. Membrane culture of bone marrow stromal cells yields
better tissue than pellet culture for engineering cartilage-bone substitute biphasic constructs in a two-step
process. Tissue Engineering Part C: Methods. 17: 939-948, 2011.
Lefebvre V, Peeters-Joris C and Vaes G. (1990). Modulation by interleukin 1 and tumor necrosis factor a
of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated
and dedifferentiated articular chondrocytes. Biochimica Biophysica Acta 1052: 366-378.
Lefebvre V and P Smits. (2005). Transcriptional control of chondrocyte fate and differentiation. Birth
Defects Research Part C: Embryo Today 75(3): 200-212.
Lewis BP, CB Burge and DP Bartel. (2005). Conserved seed pairing, often flanked by adenosines,
indicates that thousands of human genes are microRNA targets. Cell 120(1): 15-20.
Li J, J Huang, L Dai, D Yu, Q Chen, X Zhang and K Dai. (2012). MiR-146a, an IL-1b responsive
miRNA, induces vascular endothelial growth factor and chondrocyte apoptosis by targeting Smad4.
Arthritis Research & Therapy 14: R75.
Li X, G Gibson, J-S Kim, J Kroin, S Xu, AJ van Wijnen, H-J Im. (2011). MicroRNA-146a is linked to
pain-related pathophysiology of osteoarthritis. Gene 480(1–2): 34-41.
Liang Z, H Zhuang, G Wang, Z Li, H Zhang, T Yu and B Zhang. (2012). MiRNA-140 is a negative
feedback regulator of MMP-13 in IL-1β-stimulated human articular chondrocyte C28/I2 cells.
Inflammation Research 61(5): 503-509.
Lin S-L, DC Chang, S Chang-Lin, C-H Lin, DTS Wu, DT Chen and S-Y Ying. (2008). Mir-302
reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 14: 2115-2124.
Lin EA, L Kong, X-H Bai, Y Luan and C Liu. (2009). miR-199a*, a bone morphogenic protein 2-
responsive microRNA, regulates chondrogenesis via direct targeting to Smad1. The Journal of Biological
Chemistry 284: 11326-11335.
Mankin, HJ. (1982). The response of articular cartilage to mechanical injury. Journal of Bone and Joint
Surgery 64: 460.
Markway BD, G-K Tan, G Brooke, JE Hudson, JJ Cooper-White and MR Doran. (2010). Enhanced
chondrogenic differentiation of human bone marrow-derived mesenchymal stem cells in low oxygen
environment micropellet cultures. Cell Transplantation 19: 29-42.
Martinez-Sanchez A, KA Dudek and CL Murphy. (2012). Regulation of human chondrocyte function
through direct inhibition of cartilage master regulator Sox9 by MicroRNA-145. The Journal of Biological
Chemistry 287: 916-924.
McGivney BA, PA McGettigan, JA Browne, ACO Evans, RG Fonseca, BJ Loftus, A Lohan, DE
MacHugh, BA Murphy, LM Katz and EW Hill. (2010). Characterization of the equine skeletal muscle
transcriptome identifies novel functional responses to exercise training. BMC Genomics 11: 398.
Miyaki S, T Nakasa, S Otsuki, SP Grogan, R Higashiyama, A Inoue, Y Kato, T Sato, MK Lotz and H
Asahara. (2009). MicroRNA-140 is expressed in differentiated human articular chondrocytes and
modulates interleukin-1 responses. Arthritis and Rheumatism 60(9): 2723-2730.
96
Miyaki S, T Sato, A Inoue, S Otsuki, Y Ito, S Yokoyama, Y Kato, F Takemoto, T Nakasa, S Yamashita,
S Takada, MK Lotz, H Ueno-Kudo and H Asahara. (2010). MicroRNA-140 plays dual roles in both
cartilage development and homeostasis. Genes and Development 24: 1173-1185.
Moulharat N, Lesur C, Thomas M, Rolland-Valognes G, Pastoureau P, Anract P, De Ceuninck F and
Sabatini M. (2004). Effects of transforming growth factor-beta on aggrecanase production and
proteoglycan degradation by human chondrocytes in vitro. Osteoarthritis and Cartilage 12: 296-305.
Murakami S, V Lefebvre and B de Crombrugghe. (2000). Potent inhibition of the master chondrogenic
factor Sox9 gene by interleukin-1 and tumor necrosis factor-α. The Journal of Biological Chemistry 275:
3687-3692.
Murata M, K Yudoh and K Masuko. (2008). The potential role of vascular endothelial growth factor
(VEGF) in cartilage: How the angiogenic factor could be involved in the pathogenesis of osteoarthritis?
Osteoarthritis and Cartilage 16(3): 279-286.
Nagata Y, T Nakasa, Y Mochizuki, M Ishikawa, S Miyaki, H Shibuya, K Yamasaki, N Adachi, H
Asahara and M Ochi. (2009). Induction of apoptosis in the synovium of mice with autoantibody-mediated
arthritis by the intraarticular injection of double-stranded MicroRNA-15a. Arthritis & Rheumatism 60(9):
2677–2683.
Nakamura Y, JB Inloes, T Katagiri and T Kobayashi. (2011). Chondrocyte-specific microRNA-140
regulates endochondral bone development and targets dnpep to modulate bone morphogenetic protein
signaling. Molecular and Cellular Biology 31(14): 3019-3028.
Nakasa T, S Miyaki, A Okubo, M Hashimoto, K Nishida, M Ochi and H Asahara. (2008). Expression of
microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis & Rheumatism 58(5): 1284–1292.
Nakasa T, H Shibuya, Y Nagata, T Niimoto and M Ochi. (2011). The inhibitory effect of microRNA-
146a expression on bone destruction in collagen-induced arthritis. Arthritis & Rheumatism 63(6): 1582–
1590.
Nehrer S and Minas T. (2000). Treatment of articular cartilage defects. Investigative Radiology 35(10):
639-46.
Nelea V, Luo L, Demers CN, Antoniou J, Petit A, Lerouge S, R Wertheimer M and Mwale F. (2005).
Selective inhibition of type X collagen expression in human mesenchymal stem cell differentiation on
polymer substrates surface-modified by glow discharge plasma. Journal of Biomedical Materials
Research 75A: 216–223.
Ng LJ, S Wheatley, GE Muscat, J Conway-Campbell, J Bowles, E Wright, DM Bell, PP Tam, KS Cheah
and P Koopman. 1997. SOX9 binds DNA, activates transcription, and coexpresses with type II collagen
during chondrogenesis in the mouse. Developmental.Biology 183: 108-121.
Nicolas FE, H Pais, F Schwach, M Lindow, S Kauppinen, V Moulton and T Dalmay. (2008).
Experimental identification of microRNA-140 targets by silencing and overexpressing miR-140. RNA
14: 2513-2520.
Nicoloso MS, R Spizzo, M Shimizu, S Rossi and GA Calin. (2009). MicroRNAs — the micro steering
wheel of tumour metastases. Nature Reviews Cancer 9: 293-302.
97
Nomura M, Hosaka Y, Kasashima Y, Ueda H, Takehana K, Kuwano A and Arai K. (2007). Active
expression of matrix metalloproteinase-13 mRNA in the granulation tissue of equine superficial digital
flexor tendinitis. The Journal of Veterinary Medical Science 69(6): 637-9.
Ohgawara T, S Kubota, H Kawaki, S Kondo, T Eguchi, N Kurio, E Aoyama, A Sasaki and M Takigawa.
(2009). Regulation of chondrocytic phenotype by micro RNA 18a: involvement of Ccn2/Ctgf as a major
target gene. FEBS Letters 583: 1006–1010.
Pacini S, Spinabella S, Trombi L, Fazzi R, Galimberti S, Dini F, Carlucci F and Petrini M. (2007).
Suspension of bone marrow-derived undifferentiated mesenchymal stromal cells for repair of superficial
digital flexor tendon in race horses. Tissue Engineering 13(12): 2949–2955.
Paik S, HS Jung, S Lee, DS Yoon, MS Park and JW Lee. (2012). miR-449a Regulates the
Chondrogenesis of Human Mesenchymal Stem Cells Through Direct Targeting of Lymphoid Enhancer-
Binding Factor-1. Stem Cells and Development 21(18): 3298-308.
Pais H, FE Nicolas, SM Soond, TE Swingler, IM Clark, A Chantry, V Moulton and T Dalmay. (2010).
Analyzing mRNA expression identifies Smad3 as a microRNA-140 target regulated only at protein level.
RNA 16: 489-494.
Palmer GD, A Steinert, A Pascher, E Gouze, J-N Gouze, O Betz, B Johnstone, CH Evans and
SC Ghivizzani. (2005). Gene-induced chondrogenesis of primary mesenchymal stem cells in vitro.
Molecular Therapy 12: 219–228.
Pelttari K, A Winter, E Steck, KGoetzke, T Hennig, BG Ochs, T Aigner and W Richter. (2006).
Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells
correlates with calcification and vascular invasion after ectopic transplantation in SCID mice. Arthritis
and Rheumatism 54(10):3254-66.
Pi Y, X Zhang, J Shi, J Zhu, W Chen, C Zhang, W Gao, C Zhou, Y Ao. (2011). Targeted delivery of non-
viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display.
Biomaterials 32(26): 6324-6332.
Pierschbacher MD and E Ruoslahti. (1984). Variants of the cell recognition site of fibronectin that retain
attachment-promoting activity. Proceedings of the National Academy of Sciences 81(19): 5985-5988.
Re’em T, O Tsur-Gang, S Cohen. (2010). The effect of immobilized RGD peptide in macroporous
alginate scaffolds on TGFβ1-induced chondrogenesis of human mesenchymal stem cells. Biomaterials
31(26): 6746-6755.
Rountree RB, Schoor M, Chen H, Marks ME, Harley V, Mishina Y, Kingsley DM. (2004). BMP receptor
signaling is required for postnatal maintenance of articular cartilage. PLoS Biology 2:e355.
Rubinstein P, RE Rosenfeld, JW Adamson and CE Stevens. (1993). Stored placental blood for unrelated
bone marrow reconstitution. Blood 81: 1679 –1690.
Saito S, S Kondo, S Mishima, N Ishiguro, Y Hasegawa, LJ Sandell and H Iwata. (2002). Analysis of
cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid from patients with
osteoarthritis and rheumatoid arthritis. Journal of Bone and Joint Surgery 84-B:1066-1069.
98
Salminen H, Vuorio E, Saamanen AM. (2001). Expression of Sox9 and type IIA procollagen during
attempted repair of articular cartilage damage in a transgenic mouse model of osteoarthritis. Arthritis and
Rheumatism 44: 947–55.
Sandri S, D Rodriguez, E Gomes, H Pequeno Monteiro, M Russo and A Campa. (2008) Is serum
amyloid A an endogenous TLR4 agonist? Journal of Leukocyte Biology 83(5): 1174-1180.
Saris DBF, J Vanlauwe, J Victor, M Haspl, M Bohnsack, Y Fortems, Vandekerckhove B, Almqvist
KF, Claes T, Handelberg F, Lagae K, van der Bauwhede J,Vandenneucker H, Yang KG, Jelic M,
Verdonk R, Veulemans N, Bellemans J and Luyten FP. Characterized chondrocyte implantation results in
better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled
trial versus microfracture. American Journal of Sports Medicine 36(2): 235-46.
Schuerwegh AJ, EJ Dombrecht, WJ Stevens, JF Van Offel, CH Bridts and LS De Clerck. (2003).
Influence of pro-inflammatory (IL-1α, IL-6, TNF-α, IFN-γ) and anti-inflammatory (IL-4) cytokines on
chondrocyte function. Osteoarthritis and Cartilage 11(9): 681–687.
Seguin CA and Bernier SM. (2003). TNFalpha suppresses link protein and type II collagen expression in
chondrocytes: Role of MEK1/2 and NF-kappaB signaling pathways. Journal of Cellular Physiology 197:
356-369.
Sekiya I, BL Larson, JT Vuoristo, RL Reger and DJ Prockop. (2005). Comparison of effect of BMP-2, -
4, and -6 on in vitro cartilage formation of human adult stem cells from bone marrow stroma. Cell and
Tissue Research 320:269-276.
Silver IA. Measurement of pH and ionic composition of pericellular sites. (1975). Philosophical
Transactions of the Royal Society B: Biological Sciences 271:261–72.
Smith RK, Korda M and Blunn GW. (2003). Isolation and implantation of autologous equine
mesenchymal stem cells from bone marrow into the superficial digital flexor tendon as a potential novel
treatment. Equine Veterinary Journal 35(1): 99–102.
Solchaga LA, K Penick, VM Goldberg, AI Caplan and JF Welter. (2010). Fibroblast growth factor-2
enhances proliferation and delays loss of chondrogenic potential in human adult bone-marrow-derived
mesenchymal stem cells. Tissue Engineering Part A 16(3): 1009–1019.
Son B-R, LA Marquez-Curtis, M Kucia, M Wysoczynski, AR Turner, J Ratajczak, MZ Ratajczak and A
Janowska-Wieczorek. (2006). Migration of bone marrow and cord blood mesenchymalstem cells in vitro
is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves
matrix metalloproteinases. Stem Cells 24: 1254–1264.
Stanczyk J, DML Pedrioli, F Brentano, O Sanchez-Pernaute,C Kolling, RE Gay, M Detmar, S Gay and D
Kyburz. (2008). Altered expression of microRNA in synovial fibroblasts and synovial tissue in
rheumatoid arthritis. Arthritis and Rheumatism 58: 1001–1009.
Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ,
Campbell IK, Fourie AM and Fosang AJ (2005) ADAMTS5 is the major aggrecanase in mouse cartilage
in vivo and in vitro. Nature 434: 648-652.
99
Steck E, Bertram H, Abel R, Chen B, Winter A and Richter W. (2005). Induction of intervertebral disc-
like cells from adult mesenchymal stem cells. Stem Cells. 23(3):403−411.
Steinert AF, GD Palmer, C Pilapil, U Nöth, CH Evans and SC Ghivizzani. (2009). Enhanced in
vitro chondrogenesis of primary mesenchymal stem cells by combined gene transfer. Tissue Engineering
Part A 15(5): 1127-1139.
Steinwachs MR, T Guggi and PC Kreuz. (2008). Marrow stimulation techniques. Injury 39(1): 26-31.
Stenderup K, J Justuesen, C Clausen and M Kassem. (2003). Aging is associated with decreased maximal
life span and accelerated senescence of bone marrow stromal cells. Bone 33: 919 –926.
Sukenik S, Henkin J, Zimlichman S, Skibin A, Neuman L, Pras M, Horowitz J and Shainkin-Kestenbaum
R. (1988). Serum and synovial fluid levels of serum amyloid A protein and C-reactive protein in
inflammatory and noninflammatory arthritis. Journal of Rheumatology 15(6):942-5.
Swingler TE, G Wheeler, V Carmont, HR Elliott, MJ Barter, M Abu-Elmagd, ST Donell, RP Boot-
Handford, MK Hajihosseini, A Münsterberg, T Dalmay, DA Young and IM Clark. (2012). The
expression and function of microRNAs in chondrogenesis and osteoarthritis. Arthritis and Rheumatism
64(6): 1909-19.
Taganov KD, MP Boldin, K Chang and D Baltimore. (2006). NF-κB-dependent induction of microRNA
miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the
National Academy of Sciences 103(33): 12481-12486.
Tardif G, D Hum, J-P Pelletier, N Duval and J Martel-Pelletier. (2009). Regulation of the IGFBP-5 and
MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC
Musculoskeletal Disorders 10: 148.
Tortorella MD, Malfait AM, Deccico C and Arner E. (2001). The role of ADAM-TS4 (aggrecanase-1)
and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis and Cartilage 9(6):
539-52.
Trumble TN, GW Trotter, JR Thom Oxford, W McIlwraith, S Cammarata, JL Goodnight, RC
Billinghurst and DD Frisbie. (2001). Synovial fluid gelatinase concentrations and matrix
metalloproteinase and cytokine expression in naturally occurring joint disease in horses. American
Journal of Veterinary Research 62(9): 1467-1477.
Tuddenham L, G Wheeler, S Ntounia-Fousara, J Waters, MK Hajihosseini, I Clark and T Dalmay. (2006).
The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Letters 580:
4214-4217.
Vallon R, F Freuler, N Desta-Tsedu, A Robeva, J Dawson, P Wenner, P Engelhardt, L Boes, J Schnyder,
C Tschopp, R Urfer and G Baumann. (2001). Serum Amyloid A (apoSAA) expression is up-regulated in
rheumatoid arthritis and induces transcription of matrix metalloproteinases. Journal of Immunology 166:
2801-2807.
Vinatier C, D Mrugala, C Jorgensen, J Guicheux and D Noël. (2009). Cartilage engineering: a crucial
combination of cells, biomaterials and biofactors, Trends in Biotechnology 27(5): 307-314.
100
von der Mark K and H von der Mark. (1977). Immunological and biochemical studies of collagen type
transition during in vitro chondrogenesis of chick limb mesodermal cells. Journal of Cell Biology 73:
736-747.
Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y and Horibe S. (2004). Autologous bone
marrow stromal cell transplantation for repair of fullthickness articular cartilage defects in human
patellae: two case reports. Cell Transplantation 13(5):595−600.
Walluscheck KP, G Steinhoff, S Kelm and A Haverich. (1996). Improved endothelial cell attachment on
ePTFE vascular grafts pretreated with synthetic RGD-containing peptides. European Journal of Vascular
and Endovascular Surgery 12(3): 321–330.
Wang Y, Ding C, Wluka AE, Davis S, Ebeling PR, Jones G and Cicuttini FM. (2006). Factors affecting
progression of knee cartilage defects in normal subjects over 2 years. Rheumatology 45(1): 79-84.
Wienholds E, WP Kloosterman, E Miska, E Alvarez-Saavedra, E Berezikov, E de Bruijn, HR Horvitz, S
Kauppinen and RHA Plasterk. (2005). MicroRNA expression in zebrafish embryonic development.
Science 309: 310-311.
Wightman B, I Ha and G Ruvkun. (1993). Posttranscriptional regulation of the heterochronic gene lin-14
by lin-4 mediates temporal pattern formation in C. elegans. Cell 75: 855–862.
Wilke MM, DV Nydam and AJ Nixon. (2007). Enhanced early chondrogenesis in articular defects
following arthroscopic mesenchymal stem cell implantation in an equine model. Journal of Orthopaedic
Research 25: 913-925.
Williams GM, EF Chan, MM Temple-Wong, WC Bae, K Masuda, WD Bugbee and RL Sah. (2010).
Shape, loading, and motion in the bioengineering design, fabrication, and testing of personalized synovial
joints. Journal of Biomechanics 43(1): 156-165.
Winter J, S Jung , S Keller, RI Gregory and S Diederichs. (2009). Many roads to maturity: microRNA
biogenesis pathways and their regulation. Nature Cell Biology 11(3):228-34.
Wohn DY. (2012). Korea okays stem cell therapies despite limited peer-reviewed data. Nature Medicine
18: 329.
Xin M, EM Small, LB Sutherland, X Qi, J McAnally, CF Plato, JA Richardson , R Bassel Duby and EN
Olson. (2009). MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of
smooth muscle cells to injury. Genes & Development 23:2166-2178.
Xu N, T Papagiannakopoulos, G Pan, JA Thomson and KS Kosik. (2009) MicroRNA-145 regulates oct4,
sox2, and klf4 and represses pluripotency in human embryonic stem cells. Cell 137(4):647-58.
Yamasaki K, T Nakasa, S Miyaki, M Ishikawa, M Deie, N Adachi, Y Yasunaga, H Asahara and M Ochi.
(2009). Expression of MicroRNA-146a in osteoarthritis cartilage. Arthritis & Rheumatism 60: 1035–
1041.
Yang B, H Guo, Y Zhang, L Chen, D Ying and S Dong. (2011). MicroRNA-145 regulates chondrogenic
differentiation of mesenchymal stem cells by targeting Sox9. PLoS ONE 6(7): e21679.
101
Yang J, S Qin, C Yi, G Ma, H Zhu, W Zhou, Y Xiong, X Zhu, Y Wang, L He and X Guo. (2011). MiR-
140 is co-expressed with Wwp2-C transcript and activated by Sox9 to target Sp1 in maintaining the
chondrocyte proliferation. FEBS Letters 585 (19): 2992-2997.
Yoo AS, AX Sun, L Li, A Shcheglovitov, T Portmann, Y Li, C Lee-Messer, RE Dolmetsch, RW Tsien
and GR Crabtree. (2011). MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 476:
228-231.
Zehentner BK, C Dony and H Burtscher. (1999). The transcription factor Sox9 is involved in BMP-2
signaling. Journal of Bone and Mineral Research 14(10): 1734–1741.
Zerega B, A Paganoa, A Pianezzi, V Ulivi, L Camardella, R Cancedda and F Descalzi Cancedda. (2004).
Expression of Serum Amyloid A in chondrocytes and myoblasts differentiation and inflammation:
possible role in cholesterol homeostasis. Matrix Biology 23: 35–46.
Zhang X, M Hirai, S Cantero, R Ciubotariu, L Dobrila, A Hirsh, K Igura, H Satoh, I Yokomi, T
Nishimura, S Yamaguchi, K Yoshimura, P Rubinstein and TA Takahashi. (2011). Isolation and
characterization of mesenchymal stem cells from human umbilical cord blood: Reevaluation of critical
factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as
compared to mesenchymal stem cells from bone marrow and adipose tissue. Journal of Cellular
Biochemistry 112: 1206–1218.
Zhong N, J Sun, Z Min, W Zhao, R Zhang, W Wang, J Tian, L Tian, J Ma, D Li, Y Han and S Lu. (2012).
MicroRNA-337 is associated with chondrogenesis through regulating TGFBR2 expression. Osteoarthritis
and Cartilage 20(6): 593-602.
Zhou M, Wang Q, Sun J, Li X, Xu L, Yang H, Shi H, Ning S, Chen L, Li Y, He T and Zheng Y. (2009).
In silico detection and characteristics of novel microRNA genes in the Equus caballus genome using an
integrated ab initio and comparative genomic approach. Genomics 94(2):125-31.
Zhu W, O Boachie-Adjei, BA Rawlins, B Frenkel, AL Boskey, LB Ivashkiv and CP Blobel. (2007). A
novel regulatory role for stromal-derived factor-1 signaling in bone morphogenic protein-2 osteogenic
differentiation of mesenchymal C2C12 cells. The Journal of Biological Chemistry 282:18676-18685.
Zuk PA, M Zhu, P Ashjian, DA De Ugarte, JI Huang, H Mizuno, ZC Alfonso, JK Fraser, P Benhaim
and MH Hedrick. (2002). Human adipose tissue is a source of multipotent stem cells. Molecular Biology
of the Cell 13(12): 4279-4295.
102
APPENDIX 1. Screening of eCB-MSCs
All eCB-MSC cell lines were screened for chondrogenic potential by differentiating pellets for
two weeks then staining with Toluidine Blue. Strongly stained pellets with hyaline-like
morphology (lacunae formation) were grouped as high chondrogenic potential (CP) eCB-MSCs,
while weakly stained pellets were grouped as low CP eCB-MSCs.
103
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedures for culturing eCB-
MSCs, including thawing, expansion, passaging and cryopreservation.
2.0 Related Documents
Document Document No.
Equine cord blood collection and processing SOP.TK.1.0
Cell count using Trypan Blue SOP.TK.2.1
3.0 Definitions
FBS: Fetal Bovine Serum
PBS: Phosphate Buffered Salt solution
HBSS: Hank’s Balanced Salt Solution
EDTA: Ethylenediaminetetraacetic acid
DMEM: Dulbecco’s modified eagle medium
DMSO: Dimethyl sulfoxide
RT: Room temperature
4.0 General Equipment & Materials
Pipette aid & sterile serological pipettes (5, 10 and 25 ml; Corning, cat. nos. 4487, 4488 and 4489, respectively)
RAININ micropipettes & autoclaved sterile tips
Sterile centrifuge tubes (15 ml and 50 ml; Corning, cat. no. 430290)
Sterile bottles with 0.22um filter top.
Rack for centrifuge tubes
Waste Disposal Cup
Ethanol 70% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
Trypan Blue 0.4%
Hemocytometer
Inverted phase contrast microscope
5.0 Procedure
5.1 Reagent Preparation
Title: Cell culture of equine cord-blood derived mesenchymal stromal cells
Prepared by: Approved by: Document no.: SOP.TK.2.0
Carmon Co & Midori Buechli Thomas Koch Review Date: 2012.12.3
104
5.1.1 Expansion Media - 500 ml
Thaw 150 ml FBS (Note: significant batch variability between lots), 5 ml Pen/Strep (10,000IU/mL) and 5 ml L-glutamine (100mM).
Remove 150ml from the 500ml DMEM Lonza bottle to 50ml tubes, date, initial and store in 4°C [7 tubes can be pooled (350 ml) and filter sterilized to make a new bottle].
Add 150 ml of FBS, 5 ml Pen/Strep and 5 ml L-glutamine.
Label bottle with contents, date and initials, store at 4°C.
5.1.2 DPBS 1x
Dilute DPBS 10X stock using MilliQ water (found in the sterilization suite. Record volume taken in log book).
Filter sterilize, aliquot in 50ml tubes, date and initial, store at 4°C.
5.1.3 Trypsin EDTA – 1000 ml
Set up 700mL of Milli-Q water in a 1L-graduated cylinder on a stir plate with a magnetic stir bar.
Add 100mL of HBSS, 1.2 grams of NaHCO3, 0.46 grams of EDTA, 2.5 grams of trypsin, and 200μL of phenol red solution.
Add NaOH until a pH of 8.0 is reached, as EDTA dissolves best at this pH. As the EDTA dissolves, the pH will decrease, so the pH of the solution should be monitored and adjusted during preparation. ! CRITICAL be patient with EDTA dissolving, you may damage the EDTA by rushing the process.
Once all reagents have completely dissolved, add Milli-Q water until the volume of solution of 1L. Adjust the pH of the solution to 7.2-7.4.
Filter sterilize the solution and aliquot into 50mL centrifuge tubes. Label, date, initial, store at -20˚C.
5.1.4 Cryopreservation media
Determine the volume of freezing media required.
Add 20% DMSO to the required volume of expansion media (note- add the DMSO to the media, NOT vice versa).
Cool the solution in the fridge before use. **Before any cell culturing, prepare a culture hood by raising the sash, and spraying ethanol
over the entire surface. Spray down all items that are entering the hood. Allow minimum 5
minutes of air exchange in the hood before cell work.
5.2 Thawing eCB-MSCs
Select a cryovial, note the OVC ID#, e.g. 1289, and the location under Tank/Canister, e.g. TK1/5 in your lab book and mark as removed in the liquid nitrogen log book with date and initials
Spray the cryovial, loosen the lid inside the hood, tighten
Thaw in the 37° C water bath until a sliver of ice remains
In the hood, transfer contents to a labelled 15 ml tube
105
Add 5ml expansion media dropwise and stir with pipette tip. Before the entire 5ml is added, mix by aspirating up and down
Rinse cryovial with 1-2ml of the suspension and add to the 15 ml tube
Centrifugre 150 x g, 5min, RT (blue buttons change settings)
Carefully remove the supernatant without disturbing the pellet at the bottom
Resuspend the pellet with 5 ml expansion media by aspirating up and down
Perform a cell count using trypan blue (see SOP.TK.2.1) and note cell viability and live cells/ml
Seed cells at 5000 live cells/cm2. Label all flasks with culture name, passage number (Pfrozen+1), date and initials
Rock flasks (do not swirl), loosen the caps and incubate at 37.5° C, 5%CO2
5.3 Changing media (every 2-3 days)
Using the microscope, determine the confluency of the culture (what percentage of the surface of the flask is covered). Generally, for <60%, change media, but different cultures grow at different rates so a judgement call will have to be made based on the specific MSC line
In the hood, aliquot the required volume of expansion media into 50ml tube/s and warm in the water bath
Aspirate old media from flask and expel into the waste beaker
Add required volume fresh media (4ml for 25cm2, 12ml for 75cm2, 28ml for 175cm2)
Pipette down the side of the flask to avoid disturbing the cells adhered to the bottom
Rock flasks and incubate at 37.5° C, 5% CO2
5.4 Passaging eCB-MSCs
Warm required volumes of expansion media, trypsin EDTA and 1x DPBS in the water bath
Remove media from flask and rinse the culture surface with DPBS (5ml for T75)
Add trypsin to cover the culture surface (4ml for T75, 1.5ml for T25, 7ml for T175). Rock flask and incubate at 37.5°C for 5 mins
Use the microscope to make sure the cells are round and detached
Place flask in upright position and add an equal volume of media to inactivate the trypsin
Pipette up and down to get single cell suspension and transfer to a labeled 15ml tube
Rinse culture surface with another volume of media and add this to the tube
Centrifuge 150 x g, 5min, RT
Discard the supernatant and resuspend the pellet with 5 ml expansion media
Perform a cell count using trypan blue (see SOP.TK.2.1) and note cell viability and live cells/ml
Seed new flasks (with passage = P+1) or cryopreserve cells
5.5 Cryopreservation
106
After passaging, obtain 2x desired final concentration, e.g. desired 1.0x106/ml, concentrate to 2.0x106/ml
Centrifuge 150 x g, 5min, RT
Resuspend with required volume of expansion media to obtain 2x final concentration, then refrigerate
Prepare the required volume of cryopreservation media, cool before use
Label cryovials (found under the incubator) by hand or using the labelmaker. Include culture name, passage number, total live cells, date frozen and initials
Add cryopreservation media 1:1 with cell suspension – dropwise (avoid osmotic shock to cells), mix
Aspirate solution into pipette and expel 1ml to each cryovial
Put cryovials into the “Mr Freezie” (note Isopropyl alcohol (IPA) use max=5) and place in the -80ºC overnight
Enter sample information into the liquid nitrogen log book, e.g.
Project ID OVC ID# Tank/Canister #Samples Contents Date frozen
Midori 1370 TK1/3 2x4vials 1eCB1006p4-33 2e6/vial
Sept22.10
Label canes with the OVC ID#. Retrieve the cryovials from the -80 and place in canes, then place in the liquid nitrogen tank. (Wear insulated gloves and face protection when using liquid nitrogen)
107
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure outlines the procedure to count cells using trypan
blue. Trypan blue is a dye that can penetrate into cells that have damaged cell
membranes, i.e. dead cells.
2.0 General Equipment & Materials
RAININ micropipettes & autoclaved sterile tips
1.5ml tube containing cell suspension
Trypan Blue 0.1%
Hemocytometer
EtOH 70% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
Inverted phase contrast microscope
3.0 Procedure
In the hood, transfer a small volume of the cell suspension (tip of the pipette) to a 1.5ml tube
On the bench top, add 20ul of cell suspension to 20ul of trypan blue
Pipette up and down to mix
Add 10ul to each chamber of the hemocytometer
Count 8 chambers using the 10x objective
Using the cell counter, count total cells on the left and dead cells on the right (Live cells are round and clear, dead cells are blue)
Calculate cell viability, live cells/mL, volume of cell suspension required and volume of media required according to the following:
Cell viability: (Total-dead)/total x100 = ______%
Total live cell count: [(Total-dead)/nb chambers] x dilution factor x 10 000 =_____cells/ml
Seeding requirement: 5000 cells/cm2 x size of flask cm2 = ________ cells
Cell suspension vol requirement: Seeding requirement/total live cell count =_____ml susp.
Media culture volume: Media vol flask – cell susp. Vol = _______ ml of media
Add the calculated volumes of expansion media and cell suspension to the flask
Clean the hemocytometer with 70% EtOH.
Title: Cell counting using Trypan Blue
Prepared by: Approved by: Document no.: SOP.TK.2.1
Midori Buechli Thomas Koch Review Date: 2012.12.3
108
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for inducing MSCs
towards a chondrogenic cell fate using standard pellet culture or membrane-based
culture.
2.0 Related Documents
Document Document No.
Cell Culture of eCB-MSCs SOP.TK.2.0
Cell count using Trypan Blue SOP.TK.2.1
3.0 Definitions
MSC: Mesechymal stromal cells
PBS: Phosphate Buffered Salt solution
RT: Room temperature
ITS: Insulin Transferrin Selenium
DMEM: Dulbecco’s modified eagle medium
ABAM: Antibacterial-antimycotic
TGFβ: Transforming Growth Factor Beta
PTFE: Polytetrafluoroethylene
4.0 General Equipment & Materials
Pipette aid & sterile serological pipettes (5, 10 and 25 ml; Corning, cat. nos. 4487, 4488 and 4489, respectively)
RAININ micropipettes & autoclaved sterile tips
Sterile centrifuge tubes (15 ml and 50 ml; Corning, cat. no. 430290)
Sterile bottles with 0.22um filter top.
Rack for centrifuge tubes
Waste Disposal Cup
Ethanol 70% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
Centrifuge
Trypan Blue 0.4%
Hemocytometer
Title: Chondrogenic induction of MSCs – membrane and pellet protocols
Prepared by: Approved by: Document no.: SOP.TK.3.0
Midori Buechli & Carmon Co Thomas Koch Review Date: 2012.12.3
109
Polypropylene V-bottom plates (Phenix, cat. no. MPG-651201)
PTFE cell culture inserts 0.4um (Millipore cat. no. PICM01250)
5.0 Procedure
5.1 Reagent Preparation
5.1.1 Chondrogenic Media
Thaw ITS, Proline and ABAM in the water bath
Prepare Chondrogenic media according to the table below. NOTE: Add the ascorbic acid and TGFβ immediately before use.
Filter sterilize using bottle with 0.2 um filter top
Location Reagent Volume for 250ml media
Fridge High Glucose DMEM 240 ml
-20 freezer ITS 1X 2.5 ml
Cupboard Glutamax 200mM 2.5 ml
Fridge in 15ml tubes Sodium pyruvate 100mM 2.5 ml
Fridge in solid/freezer aliquots
Dexamethosone
(100nM in media)
150 µl
-20 freezer Proline 10 mg
-20 freezer ABAM 2.5 ml
Cupboard Ascorbic acid **Add FRESH 1 mg per 10 ml media used
-80 freezer TGFβ3 **Add FRESH 5 µl per 10 ml media used
5.1.2 Coating membranes
Place membranes in a 24 well plate with sterile tweezers
Add 150ul of fibronectin to 1350ul of DMEM. Vortex.
Pipette 100ul of this solution evenly onto the cell culture membranes
Dry overnight in the culture hood with the lid tilted for airflow and the lights off
Before use, UV irradiate for 30 minutes.
NOTE: Coated (DRY) membranes can be stored in a sealed autoclave paper bag. Date and initial.
5.2 Membrane Culture
Expand cells according to SOP.TK.2.0 when a sufficient cell number is reached for the number of membranes to be seeded.
Trypsinize the cells and perform a cell count. Concentrate the cells to 5 x 106 cells/mL in expansion media.
Seed 400uL in each cell culture insert to obtain 2 x 106 cells/membrane.
110
Add 600uL expansion media around the insert.
Incubate at 37.5° C, 5%CO2.
After 24 hours, carefully aspirate the spent expansion media using a 1000uL pipette.
Add 1.5mL chondrogenic media, with ascorbic acid and TGFβ3 added fresh, to each well. NOTE: Aim the pipette tip at the top edge of the cell culture insert so that media runs down the inside and outside wall.
Change chondrogenic media every 2-3 days thereafter for 14-28 days.
5.3 Pellet Culture using 96-well plates
Expand cells according to SOP.TK.2.0 when a sufficient cell number is reached for the number of pellets to be seeded.
Trypsinize the cells and perform a cell count.
Add the required cell suspension volume to seed 2.50 x 105 cells per pellet in the polypropylene plates.
Centrifuge 200 x g, 5 min, RT.
Resuspend the pellet in 200uL chondrogenic media.
Centrifuge 200 x g, 10 min, RT.
Incubate at 37.5° C, 5% CO2 or 5% O2.
Observe small white spherical pellets in the bottom of the plate.
Change chondrogenic media every 2-3 days for 14-28 days. NOTE: Can use a multichannel pipette to add and remove media, but be sure to check the wells after aspirating to make sure that the pellet is still there.
111
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for processing,
embedding and sectioning tissues for histology and immunostaining.
2.0 Related Documents
Document Document No.
3.0 Definitions
IHC: immunohistochemistry
PBS: Phosphate Buffered Salt solution
RT: Room temperature
4.0 General Equipment & Materials
15ml conical tubes
Ethanol 70% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
10% Formalin
Histoprep 2-propanol
Plastic petri dish
Tissue processor
Tissue cassettes
Lens paper
Tissue embedder and embedding trays
Microtome
Water bath
Snowcoat X-tra Slides White for IHC (Surgipath, cat.no. 3800200)
5.0 Procedure
5.1 Tissue Fixation
For termination of membrane cultures: Remove spent media and turn the insert upside down in a petri dish. Hold the insert with tweezers and cut the membrane out using a scalpel. It is best to slice from one side, then the other and meet at the center.
Title: Tissue preparation for Histology and Immunohistochemistry
Prepared by: Approved by: Document no.: SOP.TK.4.0
Midori Buechli & Carmon Co Thomas Koch Review Date: 2012.12.3
112
Deposit samples (membranes, pellets or other tissues) into labelled 15mL tubes containing enough PBS to cover the sample
In the fume hood, change the PBS to 10% Formalin Leave the samples to fix overnight at 4°C. In the fume hood, change the formalin to 70% EtOH. The samples can then
be processed immediately or stored at 4°C for ~1 week.
5.2 Tissue Processing
Retrieve the samples from the 4°C. In the fume hood in the Histology room, put down paper towels, prepare one beaker with 70% 2-propanol (enough to cover your cassettes) and one small beaker with a few mL of Eosin working solution. Cut squares of lens paper if there aren’t enough there. Label the cassettes in pencil.
Place membrane/pellet on lens paper o Cover with a few drops of eosin stain o Fold the lens paper around the tissue so it will be easy to unfold later
Place the sample in the labelled cassette and place in the 70% alcohol beaker
Place cassettes only (no alcohol) in the processor o Close the latch o Program the processor to delayed start and choose a low fill level o The next morning, retrieve samples at the time indicate
5.3 Embedding
Turn on the embedder
Remove the cassettes from the processor and transfer them to the heating compartment of the embedder. (Hold the paper plate under the basket during transfer to prevent wax from dripping on the floor)
Let the embedder heat up for 30 minutes
Flush the processor according to the instructions.
Take a cassette out of the heating compartment and place on the heated surface
Open the cassette and unwrap the lens paper
Place a metal embedding tray of appropriate size under the wax dispenser and fill the ‘well’ with wax.
Place the sample in the centre of the tray. For the membranes, cut/fold in half on the cutting board using a scalpel blade then place upright in the wax. Make sure there are no bubbles around the tissue.
Press the labelled part of the cassette down into the wax and pour more wax on top to fill.
Cover the cold surface with wax to prevent cracking. Place the trays on this surface to harden the wax.
When the top of the wax in shiny, the wax block can be removed from the tray.
If the wax is cracked or has bubbles etc, place back in heating compartment for half an hour and re-embed
5.4 Sectioning
113
Fill the water bath with water and warm for 15 minutes.
Trim the wax down to the level of the tissue o Press the trim button o Position the wax block near the blade but not touching o Trim until you reach the tissue o Put the cassette back on ice
Section at 5µ using the microtome o Press the section button o Slice at least 3 sections o Carefully place sections on water bath
Pick up section with slide (labelled) o Gently separate desired sections using the tweezers o Pick up the section by approaching the section at a perpendicular
angle to the slide o When the section curls, lift up the slide and the section will be picked
up with it o For slides destined for IHC, be sure to have at least 2 sections on
each slide (a negative control (-1°Ab) is required for IHC)
Dry on rack
Place on slide warmer or the slide incubator overnight
114
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for staining tissues for
Hematoxylin and Eosin and Toluidine Blue.
2.0 Related Documents
Document Document No.
Tissue preparation for Histology and IHC SOP.TK.4.0
3.0 Definitions
IHC: immunohistochemistry
H&E: Hematoxylin and Eosin
NaCl: Sodium Chloride
HCl: Hydrochloric acid
IPA: Isopropyl alcohol
4.0 General Equipment & Materials
Slides with tissue sections
Stains (H&E reagents prepared by Helen)
Xylene
Isopropyl alcohol
Coverslips
5.0 Procedure
5.1 Reagent preparation
5.1.1 Toluidine Blue Stock solution
Add 1g Toluidine Blue powder to 100mL 70%EtOH
Mix to dissolve
5.1.2 1% Sodium Chloride (fresh)
Prepare 1% NaCl in distilled water. E.g. 2g NaCl in 200mL water.
Mix to dissolve
pH to 2.0 with HCl 1N
Title: Histology – Toluidine Blue and Hematoxylin and Eosin staining
Prepared by: Approved by: Document no.: SOP.TK.4.1
Midori Buechli & Carmon Co Thomas Koch Review Date: 2012.12.3
115
5.1.3 Toluidine Blue Working Solution 10%
Add 25mL of Toluidine Blue Stock to 225mL of fresh 1% NaCl
Mix well.
This solution must be made fresh before use.
5.2 Toluidine Blue Staining
Turn the fan on before staining
Deparaffinize in xylene, 3 changes, 2 minutes each
100% IPA, 3 changes, 2 minutes each
70% IPA, 2 minutes
Hydrate in Deionized water, 2 minutes
Stain sections in toluidine blue working solution for 3 minutes.
Wash in distilled water, 3 changes.
Dehydrate: 4 dips 95% IPA, 10 dips 100% IPA (2 changes), Xylene 3 changes, 2 minutes each.
Mount out of the last xylene.
5.3 Hematoxylin and Eosin Staining
Turn the fan on before staining
Deparaffinize in xylene, 3 changes, 2 minutes each
100% IPA, 3 changes, 2 minutes each
70% IPA, 2 minutes
Hydrate in Deionized water, 2 minutes
Stain in Harris hematoxylin solution for 8 minutes
Wash in running tap water for 5 minutes
Differentiate in 1% acid alcohol for 30 seconds
Wash running tap water for 1 minute
Bluing in 0.2% ammonia water for 30 seconds to 1 minute
Wash in running tap water for 5 minutes
Rinse in 95% alcohol, 10 dips
Counterstain in eosin solution for 1 minute
Dehydrate through 3 changes 100% IPA, 2 minutes each and 3 changes Xylene, 2 minutes each
Mount out of the last xylene.
5.4 Mounting
Place a stack of several paper towels in the fume hood
Bring the last xylene container with the boat of slides into the fume hood
Pick up the slide with the tweezers and dry the back with a kimwipe o Be careful not to disturb the stained tissue
Place the cover slip on the paper towel and add one drop of mounting glue in the centre
Place the slide (with the tissue facing downwards) onto the coverslip o The mounting glue will spread out over the slide o Remove any air bubbles by pressing on the coverslip
Allow the slides to air dry in the fume hood.
116
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for staining cartilage
and cartilage-like tissues for collagens type I and II.
2.0 Related Documents
Document Document No.
Tissue preparation for Histology and IHC SOP.TK.4.0
3.0 Definitions
IHC: immunohistochemistry
RT: Room temperature
Ab: Antibody
NaCl: Sodium Chloride
PBS: Phosphate buffered saline
FBS: Fetal bovine serum
IPA: Isopropyl alcohol
DAB: Diaminobenzidine chromagen
HRP: Horse radish peroxidase
4.0 General Equipment & Materials
Slides with tissue sections
Proteinase K
Hyaluronidase
Anti-collagen type I, mAb (VWR int’l, cat.no. CA60801-158)
Anti-collagen type II (Iowa Hybridoma Bank, cat.no. II-II6B3)
DAKO pen, Envision+ HRP mouse, DAB Chromagen (DAKO Cytomation, cat.nos. S2002, K4000, K3467)
FBS
Xylene
Isopropyl alcohol
Coverslips
5.0 Procedure
5.1 Reagent preparation
Title: Immunostaining of cartilage/cartilage-like tissues
Prepared by: Approved by: Document no.: SOP.TK.4.2
Midori Buechli Thomas Koch Review Date: 2012.12.3
117
5.1.1 Sodium acetate buffer, pH 5.5, + 150mM NaCl
Acetic Acid 0.2M o Add 2.89mL glacial acetic acid to 250mL water o Mix well and store at RT
Sodium acetate 0.2M o Add 6.8g of sodium acetate to 250ml water o Mix well and store at RT
Sodium acetate buffer, pH 5.5, + 150mM NaCl o Mix 8.8ml 0.2M Acetic acid with 41.2ml 0.2M Sodium acetate o Add 0.88g NaCl o pH to 5.5 using the acetic acid and sodium acetate solutions o Bring the final volume to 100mL with distilled water o Mix well and store at RT
5.1.2 Hyaluronidase 1600U/mL
Look for the number of units on the bottle (U/mg)
Calculate the number of mgs required to obtain 1600U/mL
Weigh and dissolve in the sodium acetate buffer, pH5.5, 150mM NaCl
Aliquot and store at -20°C
5.1.3 Proteinase K
Prepare a 5mg/mL stock solution using dH2O. Aliquot and store at -20°C.
Prepare a 20μg/mL working solution by diluting the stock solution in PBS. E.g. 20uL of stock solution plus 5mL PBS.
Aliquot and store at -20°C or use immediately.
5.2 Deparaffinization and hydration
Turn the fan on
Deparaffinize in xylene, 3 changes, 2 minutes each
100% IPA, 3 changes, 2 minutes each
70% IPA, 2 minutes
Hydrate in Deionized water, 2 minutes
Remove the slides from the staining boat and place in humidified chamber (tupperware with moistened paper towel lining the bottom and grate on top)
** For all subsequent steps DO NOT to let the sections dry**
5.3 Antigen Retrieval
Use the DAKO pen to separate the (+) section from the (-) section.
Add 100-200uL (enough to cover) of proteinase K 20μg/mL working solution to each section using a dropper
At all times, do not pipette directly onto the tissue section as it could wash the tissue off the slide
Incubate at RT for 10 minutes with the lid on loosely
o Tip off the proteinase K solution and wash the slides 3x with PBS, 2 minutes each
118
o Add 100-200uL (enough to cover) of hyaluronidase 1600U/mL solution to each section using a dropper
o Incubate at 37°C for 20 minutes with the lid on loosely o Tip off the hyaluronidase solution and wash the slides 3x with PBS, 2
minutes each
5.4 Blocking
Prepare a 3% blocking solution o E.g. 5 slides x 2 section/slide = 10sections
x 200uL blocking/section = 2000uL blocking required
o 2000uL x 30% = 60uL FBS o Add 1940uL PBS
Apply the blocking solution to the sections
Incubate for 30 minutes at RT.
Wash the slides 3x with PBS, 2 minutes each
5.5 Primary Antibody incubation
Prepare Antibody dilutions. The following table provides an example.
Antibody Dilution Nb Samples Vol. (x 200uL) Antibody Vol.
Collagen I 1:250 7 1400 5.6uL
Collagen II 1:50 6 1200 24uL
Optimization of dilution will be required for new antibodies
Apply 200uL of primary antibody dilution to the (+) section and 200uL of PBS to the (-) control.
Incubate at 4°C overnight.
5.6 Secondary Antibody incubation
Take the slides out of the fridge and allow to reach RT (10 minutes)
Wash the slides 3x with PBS, 2 minutes each
Add 2-3 drops of secondary antibody (DAKO Envision+ HRP) to cover the (+) and (-)
Incubate at RT for 1 hour.
Wash the slides 3x with PBS, 2 minutes each
5.7 DAB colour development
Prepare the required amount of DAB chromagen o 100uL of solution per section (+) and (-) o Add 1 drop of DAB chromagen into 1ml of substrate o Can only prepare 1ml increments
o Left over solution can be store at 4°C for ~1 week
Add 2-3 drops of DAB solution to cover the (+) and (-)
Incubate for the predetermined amount of time
119
o The incubation time with DAB needs to be optimized for each antibody at the specific primary Ab dilution
o For Collagen I: 12 seconds o For Collagen II: 20 seconds
Tap off the solution and quickly place in a container of water to stop the reaction.
Rinse in running water.
Counterstain with hematoxylin o 1 dip in Harris hematoxylin o Dip in water to remove the excess stain o Dip in ammonia water until blue
Dehydrate through 3 changes 100% IPA, 2 minutes each and 3 changes Xylene, 2 minutes each
Mount out of the last xylene.
5.6 Mounting
Place a stack of several paper towels in the fume hood
Bring the last xylene container with the boat of slides into the fume hood
Pick up the slide with the tweezers and dry the back with a kimwipe o Be careful not to disturb the stained tissue
Place the cover slip on the paper towel and add one drop of mounting glue in the centre
Place the slide (with the tissue facing downwards) onto the coverslip o The mounting glue will spread out over the slide o Remove any air bubbles by pressing on the coverslip
Allow the slides to air dry in the fume hood.
120
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for isolating RNA from
monolayer cultures and chondrogenic differentiated tissues using the mirVana miRNA
isolation kit.
2.0 Related Documents
Document Document No.
3.0 Definitions
RNA: Ribonucleic acid
PBS: Phosphate Buffered Salt solution
EDTA: Ethylenediaminetetraacetic acid
DMEM: Dulbecco’s modified eagle medium
RT: Room temperature
4.0 General Equipment & Materials
Pipette aid & sterile serological pipettes (5, 10 and 25 ml; Corning, cat. nos. 4487, 4488 and 4489, respectively)
RAININ micropipettes & RNAse free tips
RNAse free 1.5mL microfuge tubes
Ethanol 70% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
mirVana miRNA isolation kit
Acid-Phenol: Chloroform
RNAse ZAP
Centrifuge
Heating block
Fume hood
Nanodrop
5.0 Procedure
**Perform all RNA isolations in the RNA room to avoid contamination.
5.1 Reagent Preparation
Title: RNA isolation using mirVana miRNA isolation kit
Prepared by: Approved by: Document no.: SOP.TK.5.0
Midori Buechli Thomas Koch Review Date: 2012.12.3
121
5.1.1 Wash solutions
Add 21ml ACS grade 100% ethanol to miRNA Wash Soln 1. Mix well (Check box).
Add 40 ml ACS grade 100% ethanol to Wash Soln 2/3. Mix well (Check box).
Note: Cap tightly, ignore precipitate that may form in Wash Soln 2/3.
5.2 Preparation and notes for RNA isolation
Turn the heater on and set the temperature to 55°C
Clean lab bench and pipettors with RNAse zap, alcohol and bleach
Change gloves frequently
Use RNase-free tips.
Wash equipment for homogenization with detergent and rinse thoroughly
5.3 Sample Disruption
Monolayer cultures: pellet 1.0x106 cells in a 1.5 ml microfuge tube and wash by resuspending in 1 ml 1xPBS. Centrifuge 150 x g, 5 min, RT. Place cells on ice.
Remove PBS and add 500ul lysis/binding solution.
Vortex.
Chondrogenic pellets: pool 4-5 pellets in a 1.5 ml microfuge tube and add 500ul lysis/binding solution.
Add 10ul Proteinase K to each sample, vortex, incubate 10 minutes at 55°C.
Use the handheld homogenizer to homogenize the pellets. Change tips after each sample.
5.4 Organic Extraction
Add 50ul miRNA Homogenate Additive and mix well by vortexing.
Leave on ice 10 min.
In the fume hood, add 500ul Acid-Phenol:Chloroform. (Note: be sure to withdraw from bottom phase of bottle)
Vortex 30-60 sec.
Centrifuge 5 min, 10 000 x g, RT. If the interphase is cloud-like, repeat centrifugation.
Remove the aqueous phase and transfer to a fresh tube. Note the volume removed.
5.5 Total RNA Isolation
Add 1.25 volumes of RT 100% ethanol to the aqueous phase recovered
Place Filter Cartridge into Collection Tubes and apply up to 700ul at a time
Centrifuge 15 s, 10 000 x g, RT. Discard flow through and repeat until all the solution is through.
Add 700ul miRNA Wash Soln 1 and centrifuge 5-10 sec. Discard flow through.
Add 500ul Wash Soln 2/3 and centrifuge 5-10 sec. Discard flow through. Repeat.
122
Spin assembly for 1 min, 10 000 x g, RT
Transfer Filter Cartridge to fresh Collection tube.
Add 100 ul of 95°C Elution Solution to centre of filter and close cap. (Note: Add 50ul of elution solution for pooled pellet samples)
Spin 20-30 sec at max speed to recover RNA.
5.6 RNA integrity
Open the Nanodrop software and select Nucleic Acid.
Clean the pedestals using water and kimwipes.
Load a clean water sample to initialize.
Change the nucleic acid type to RNA.
Load 1uL elution solution and hit Blank. Clean pedestals.
Flick sample to mix. Load 1uL sample and hit Measure. Note the concentration and the OD 260/280. This value should be 1.8-2.0.
Wipe the pedestals with a kimwipe after each measurement.
If you are running many samples, blank again every 3-5 samples.
123
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for isolating RNA from
monolayer cultures using TRI Reagent.
2.0 Related Documents
Document Document No.
3.0 Definitions
RNA: Ribonucleic acid
PBS: Phosphate Buffered Salt solution
RT: Room temperature
4.0 General Equipment & Materials
Pipette aid & sterile serological pipettes (5 ml; Corning 4487)
RAININ micropipettes & RNAse free tips
RNAse free 1.5mL microfuge tubes
Ethanol 75% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
TRI Reagent
Chloroform
Isopropanol
RNAse free water
RNAse Zap
Centrifuge
Fume hood
Heating block
Nanodrop
5.0 Procedure
**Perform all RNA isolations in the RNA room to avoid contamination.
5.1 Preparation and notes for RNA isolation
Turn the heating block on and set the temperature to 55°C
Title: RNA isolation using TRI Reagent
Prepared by: Approved by: Document no.: SOP.TK.5.1
Midori Buechli Thomas Koch Review Date: 2012.12.3
124
Turn on the centrifuge and set the temperature to 4°C
Clean lab bench and pipettors with RNAse zap, bleach and alcohol
Change gloves frequently
Use RNase-free tips.
5.2 Homogenization
Monolayer cultures in multiwell plates: Remove media and rinse culture surfaces with PBS.
Add 100uL TRI Reagent per cm2 (e.g. 200uL/well in a 24-well plate) and pipette up and down to disrupt the cells.
Transfer the solution to RNAse free 1.5mL microfuge tube.
Incubate at room temperature for 5 minutes.
5.3 RNA extraction
Perform all subsequent steps in the fume hood
Add 40uL chloroform per 100uL TRI Reagent, mix vigorously for 15s.
Incubate RT for 10 min.
Centrifuge 12 000 x g, 15 min, 4°C. If the interphase is cloud-like, repeat centrifugation.
5.4 RNA precipitation
Transfer the aqueous phase to a clean tube.
Add isopropanol at the same volume as Tri Reagent used. Vortex.
Incubate RT for 10 min.
Centrifuge 12 000 x g, 8 min, 4°C.
Carefully discard supernatant without touching the bottom of the tube. A gel-like pellet may or may not be visible.
Add 75% ethanol at 2x the volume of Tri Reagent used. Vortex.
Centrifuge 7 500 x g, 5 min, 4°C.
5.5 RNA solubilisation
Carefully remove the supernatant without disturbing the pellet (Note: if no pellet is visible, do not panic. Just leave a few uL at the bottom of the tube)
Air dry 3-5 minutes. Make sure they DO NOT completely dry.
Dissolve with RNAse free water 50-100uL.
Incubate at 55°C in the heating block for 10 minutes.
5.6 RNA integrity
Open the Nanodrop software and select Nucleic Acid.
Clean the pedestals using water and kimwipes.
Load a clean water sample to initialize.
Change the nucleic acid type to RNA.
Load 1uL nuclease free water and hit Blank. Clean pedestals.
Flick sample to mix. Load 1uL sample and hit Measure. Note the concentration and the OD 260/280. This value should be 1.8-2.0.
If you are running many samples, blank again every 3-5 samples.
125
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for creating double
stranded complementary DNA from single stranded RNA
2.0 Related Documents
Document Document No.
RNA isolation using the mirVana miRNA isolation kit
SOP.TK.5.0
RNA isolation using TRI Reagent SOP.TK.5.1
3.0 Definitions
RNA: Ribonucleic acid
RT: Reverse transcriptase
cDNA: complementary DNA
PCR: Polymerase chain reaction
MM: Master Mix
4.0 General Equipment & Materials
RAININ micropipettes & RNAse free tips
RNAse free 1.5mL and 0.2mL microfuge tubes
Ethanol 75% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
RNAse free water
Invitrogen Reverse transcription kit
Thermocycler
Ice
5.0 Procedure
5.1 Preparation and Calculations
Determine the amount of RNA to reverse transcribe based on the sample with the lowest RNA concentration. Use 0.2-2ug per reaction depending on the amount of RNA in the samples.
Example: Lowest RNA conc. in set of samples = 36ng/uL
Max volume for RNA= 9.9 ul
Title: Reverse transcription using standard oligodT protocol
Prepared by: Approved by: Document no.: SOP.TK.6.0
Midori Buechli Thomas Koch Review Date: 2012.12.3
126
Conc. x vol. = 36ng/uL x 9.9 uL = 356.4 ng ~ 350ng
Therefore, 350ng must be used for all samples.
Determine the volume of RNA and water required for each sample in order to have 350ng RNA/sample in 9.9uL.
Example: 350ng ÷ 124ng/uL = 2.82 uL RNA sample
Vol water to add = 9.9 – 2.82 = 7.08 uL water
Clean lab bench and pipettors with RNAse zap, bleach and alcohol
Change gloves frequently
Use RNase-free tips and tubes
Make sure you have enough reagents for the number of samples you want to run
5.2 Reverse transcription
Retrieve reverse transcription kit from the -20°C and thaw on ice. This will include 5x buffer, 0.1M DTT, 10mM dNTPs, RNAsin (or RNAse out), Superscript II and oligodT.
Dilute the RNA samples according to the calculations in section 5.1.
Add 1.6uL oligodT to each sample.
Turn the thermocycler ON, find program (RT-Laura on #1) or create new program with the following settings
72°C for 2 minutes
42°C for 2 minutes
42°C for 60 minutes
70°C for 30 minutes
4°C forever
Verify parameters, Run, Pause (this allows the machine to warm up while you prepare your MM).
Prepare the MM for number of samples + 1 or + 5-10%. Vortex
Reagent (1x) (5x)
5x Buffer 4 20
DTT 2 10
dNTPs 1 5
RNAsin 0.5 2.5
Superscript II 1 5
Unselect pause and wait until the chamber reaches 72°C.
Add the samples to the thermocycler for the 72°C, 2 min.
At 42°C, place the MM in the chamber to warm. Add 8.5uL MM to each sample. Proceed until the end of the program.
When finished, hit stop and turn the machine off. Store cDNA samples at -
20°C.
127
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for creating
complementary DNA for specific microRNAs
2.0 Related Documents
Document Document No.
RNA isolation using the mirVana miRNA isolation kit
SOP.TK.5.0
RNA isolation using TRI Reagent SOP.TK.5.1
3.0 Definitions
RNA: Ribonucleic acid
RT: Reverse transcriptase
cDNA: complementary DNA
PCR: Polymerase chain reaction
MM: Master Mix
miRNA: microRNA
4.0 General Equipment & Materials
RAININ micropipettes & RNAse free tips
RNAse free 1.5mL and 0.2mL microfuge tubes
Ethanol 75% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
RNAse free water
TaqMan Reverse Transcription kit
TaqMan microRNA primers
RNA samples
Thermocycler
Ice
5.0 Procedure
5.1 Preparation and Calculations
Title: Reverse transcription for microRNAs using TaqMan microRNA assay kit
Prepared by: Approved by: Document no.: SOP.TK.6.1
Midori Buechli Thomas Koch Review Date: 2012.12.3
128
Determine the volume of RNA and water required for each sample in order to have 100ng RNA/sample in 5 uL. BUT for each sample you need to make cDNA for each microRNA you are studying, so be sure to prepare enough RNA dilution.
Example: 100ng ÷ 165ng/uL = 0.61 uL RNA sample
Vol water to add = 5 – 0.61 = 4.39 uL water
BUT let’s say your microRNAs of interest are miR-140, miR-9 and miR-
146, PLUS your housekeeper U6 snRNA.
Then you will need to multiply those volumes by the number of
microRNAs of interest +1.
Example: RNA volume = 0.61 x (4+1) = 3.05 uL RNA
Volume of water = 4.39 x (4+1) = 21.95 uL dH2O
Clean lab bench and pipettors with RNAse zap, bleach and alcohol
Change gloves frequently
Use RNase-free tips and tubes
Make sure you have enough reagents for the number of samples you want to run
5.2 Reverse transcription
Retrieve reverse transcription kit and TaqMan primers from the -20°C and thaw on ice. This will include buffer, dNTPs, RNAse inhibitor and multiscribe.
Dilute the RNA samples according to the calculations in section 5.1.
Turn the thermocycler ON, find program (microRNA on #2) or create new program with the following settings
16°C for 30 minutes
42°C for 30 minutes
85°C for 5 minutes
4°C forever
Prepare the MM for number of samples + 1 or + 5-10%. Vortex
Reagent (1x) (15x)
Buffer 1.50 22.5
Multiscribe 1.00 15.0
dNTPs 0.15 2.25
RNAse inhibitor 0.19 2.85
dH2O 4.16 62.4
Add 7uL MM, 3uL primers, 5uL RNA dilution in 0.2 mL PCR tubes. Vortex.
Spin down.
Add the samples to the thermocycler and run the program.
When finished, hit stop and turn the machine off. Store cDNA samples at -
20°C.
129
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for running quantitative
real-time polymerase chain reaction for messenger RNAs using a SYBR green-based
protocol and LightCycler machinery.
2.0 Related Documents
Document Document No.
RNA isolation using the mirVana miRNA isolation kit
SOP.TK.5.0
RNA isolation using TRI Reagent SOP.TK.5.1
Reverse Transcription using standard oligodT protocol
SOP.TK.6.0
3.0 Definitions
mRNA: messenger ribonucleic acid
RT: Real-time
cDNA: complementary DNA
qPCR: Quantitative polymerase chain reaction
MM: Master Mix
4.0 General Equipment & Materials
RAININ micropipettes & RNAse free tips
Nuclease free 1.5mL microfuge tubes
Ethanol 75% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
Nuclease free water
LightCycler FastStart DNA Master SYBR Green I (Roche, cat. no. 12239264001)
LightCycler 480 Multiwell Plate 384 (Roche, cat.no. 05102430001)
cDNA from samples and calibrator
LightCycler 480
Forward and reverse primers
Multistepper
Title: Quantitative Polymerase Chain Reaction for messenger RNAs using SYBR green
Prepared by: Approved by: Document no.: SOP.TK.7.0
Midori Buechli Thomas Koch Review Date: 2012.12.3
130
Ice
Centrifuge with adaptors for plates
5.0 Procedure
5.1 Preparation
Be sure that your primer sequences align to your gene of interest and in the right species (use http://blast.ncbi.nlm.nih.gov/Blast.cgi)
Prepare primer stocks at 100μM, then dilute some to 10μM as working stock
Make sure you have enough reagents for the number of samples you want to run
Plan how to pipette out your samples before starting. It’s easy to get confused when pipetting a 384-well plate or even a 96-well plate. E.g. mark out the triplicates on the plate itself, mark the triplicates in the tip boxes, draw a diagram or list which samples below in which wells.
5.2 Preparation of PCR mix
Retrieve the SYBR Green Master, cDNA and primers (forward and reverse)
from the -20°C and thaw on ice.
Prepare the MM for number of samples + 5-10% (do not forget to calculate enough MM for the blank control and the calibrator). Vortex.
Reagent (1x) (140x)
SYBR Green Master 5.0 700
Water 1.0 140
Primer F 10uM 1.0 140
Primer R 10uM 1.0 140
In a shallow styrofoam box lid filled with ice (prevents evaporation during prolonged pipetting), use the Multistepper (if available) to add 8uL of MM to each well.
Add 2uL of cDNA to each well. NOTE: Do not forget to run triplicates. NOTE: Do not forget to run a blank with water instead of cDNA and the calibrator.
Centrifuge the plate at 3000rpm for 2 minutes, RT.
5.3 LightCycler 480 instrument protocol
Turn on the instrument and open the LightCycler 480 Software. Wait for the machine to warm up and for the light on the machine to turn green.
Make sure the appropriate adaptor is in the machine (384 vs. 96-well)
Put the plate in
Set up a program using the following parameters:
131
NOTE: Do NOT forget to change the plate type to white or clear (whichever you happen to have), detection type to SYBR Green I, the plate to 384 and the reaction volume to 10uL.
Start Run.
When the run is finished, take the plate out and turn the machine off. The plate can be saved at -20°C if you want to have any of the products sequenced.
132
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for running quantitative
real-time polymerase chain reaction for microRNAs using TaqMan microRNA assays
and LightCycler machinery.
2.0 Related Documents
Document Document No.
RNA isolation using the mirVana miRNA isolation kit
SOP.TK.5.0
RNA isolation using TRI Reagent SOP.TK.5.1
Reverse Transcription using TaqMan microRNA assays
SOP.TK.6.1
3.0 Definitions
miRNA: micro ribonucleic acid
RT: Real-time
cDNA: complementary DNA
qPCR: Quantitative polymerase chain reaction
MM: Master Mix
4.0 General Equipment & Materials
RAININ micropipettes & RNAse free tips
Nuclease free 1.5mL microfuge tubes
Ethanol 75% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
Nuclease free water
LightCycler 480 Multiwell Plate 384 (Roche, cat.no. 05102430001)
microRNA-specific cDNA from samples and calibrator
LightCycler 480
TaqMan probes (Life Tech, cat.no.4427975)
TaqMan Universal PCR Master Mix, NoAmpErase UNG (Life Tech, cat.no.4324018)
Multistepper
Title: Quantitative Polymerase Chain Reaction for microRNAs using TaqMan microRNA assays
Prepared by: Approved by: Document no.: SOP.TK.7.1
Midori Buechli Thomas Koch Review Date: 2012.12.3
133
Ice
Centrifuge with adaptors for plates
5.0 Procedure
5.1 Preparation
Be sure that the sequences of the TaqMan probes align with your miRNA of interest in the species you’re studying
Make sure that your control miRNA is expressed in all your samples at a similar level for all treatment groups
Make sure you have enough reagents for the number of samples you want to run
Plan how to pipette out your samples before starting. It’s easy to get confused when pipetting a 384-well plate or even a 96-well plate. E.g. mark out the triplicates on the plate itself, mark the triplicates in the tip boxes, draw a diagram or list which samples belong in which wells.
5.2 Preparation of PCR mix
Retrieve the TaqMan probes and cDNA samples from the -20°C and thaw on ice.
Retrieve the Universal PCR MM from the fridge and keep on ice.
Prepare the MM for number of samples + 5-10% (do not forget to calculate enough MM for the blank control and the calibrator). Vortex.
Reagent (1x) (150x)
Universal PCR MM 10 1500
Water 7.67 1150.5
Primer 1.0 150
In a shallow styrofoam box lid filled with ice (prevents evaporation during prolonged pipetting), use the Multistepper (if available) to add 18.67 uL of MM to each well.
Add 1.5 uL of cDNA to each well. NOTE: Do not forget to run triplicates. NOTE: Do not forget to run a blank with water instead of cDNA and the calibrator.
Centrifuge the plate at 3000rpm for 2 minutes, RT.
5.3 LightCycler 480 instrument protocol
Turn on the instrument and open the LightCycler 480 Software. Wait for the machine to warm up and for the light on the machine to turn green.
Make sure the appropriate adaptor is in the machine (384 vs. 96-well)
Put the plate in
Set up a program using the following parameters:
134
Program Temperature
(°C)
Acquisition mode
Time Ramp Rate
(°C/s)
Pre-incubation 95 none 10min 4.8
Amplification
95 none 15sec 4.8
60 Single 60sec 2.5
72 None 1sec 4.8
Cooling 40 None 30sec 2.0
NOTE: Do NOT forget to change the plate type to white or clear (whichever you happen to have), detection type to Monocolour Hydrolysis Probe, the plate to 384 and the reaction volume to 20uL.
Start Run.
When the run is finished, take the plate out and turn the machine off. The plate can be saved at -20°C if you want to have any of the products sequenced.
135
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for isolating chondrocytes from fresh articular cartilage.
2.0 Related Documents
Document Document No.
Cell count using Trypan Blue SOP.TK.2.1
3.0 Definitions
PBS: Phosphate Buffered Salt solution
MCIII: Third Metacarpal
DMEM: Dulbecco’s modified eagle medium
FCS: Fetal calf serum
4.0 General Equipment & Materials
Plastic bags and tape
Hair trimmer
Disposable scalpels
Sterile centrifuge tubes (15 ml and 50 ml; Corning, cat. no. 430290)
Cell strainers 70μm (BD Falcon, cat. No. 352350)
Pipette aid & sterile serological pipettes (5, 10 and 25 ml; Corning, cat. nos. 4487, 4488 and 4489, respectively)
RAININ micropipettes & autoclaved sterile tips
Rack for centrifuge tubes
Waste Disposal Cup
Ethanol 70% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
Centrifuge
Trypan Blue 0.4%
Hemocytometer
5.0 Procedure
5.1 Reagent Preparation
5.1.1 Digestion Solution 1
Title: Chondrocyte isolation from articular cartilage
Prepared by: Approved by: Document no.: SOP.TK.8.0
Midori Buechli Thomas Koch Review Date: 2012.12.3
136
Prepare approximately 10mL per 300mg cartilage
1.5mg/ml pronase, 1% pen-strep and 1% gentamycin in LG-DMEM
Filter sterilize 0.2 μm.
5.1.2 Digestion Solution 2
Prepare approximately 10mL per 300mg cartilage
1.5mg/ml collagenase type II, 1% pen-strep and 1% gentamycin in LG-DMEM
Filter sterilize 0.2 μm.
5.1.3 Chondrocyte Media
Prepare chondrocyte media according to the following table:
Reagent Final Concentration Volume for 500ml
HG-DMEM with GlutaMAX n/a 442.5 mL
FCS 10% 50 mL
Pen-strep 1% 5 mL
Gentamycin 1% 2.5 mL
Ascorbic acid (1mg/mL) 0.25mg/mL 125 uL
**If using HG-DMEM without GlutaMAX, be sure to add glutamine or glutamax.
5.2 Sample Collection
Equine joints are collected 0-16 hours after euthanasia, then the cartilage can be collected immediately or can be refrigerated overnight
Cover both ends (the hoof and the cut end) with plastic bags and tape in place.
Shave off the hair using trimmers, then clean the surface with 70% EtOH
Designate three scalpels; one for removing the skin (dirtiest), one for dissecting the joint (less dirty) and one for removing the cartilage samples (cleanest).
Using scalpel 1, cut all the way around the leg at either end (a few cm from the taped part), then make one cut down the length of the leg to connect the two previous cuts. Cut in between the skin and the tissue to remove the rectangle of skin.
Find two ligaments at the back of the fetlock joint and cut them with scalpel 2. Cut the ligaments on either side of the joint until the joint opens up. Cut to completely separate the two pieces.
With scalpel 3, slice the cartilage and deposit into weighed 50ml conical tubes containing sterile PBS. NOTE: Any pieces of cartilage that are not directly put into the tube should be considered as contaminated and should be discarded, i.e. if they touch your glove or the table.
5.3 Cartilage Digestion
In the lab, weigh the tubes again and determine the mass of cartilage harvested.
In the culture hood, finely mince (<1mm) the cartilage shavings in a petri dish in a bit of PBS to prevent drying.
137
Add ~ 300mg cartilage to a 50mL tube and add 10mL of Digestion Solution 1.
Seal the lid tightly and lie the tube down on its side in the 37°C incubator/shaker (if this machine is not available, place in the regular incubator and vortex several times throughout the incubation). Incubate for 1 hour.
Remove as much of Digestion Solution 1 as possible without removing too much sample.
Add 10mL Digestion Solution 2 and incubate in the same manner as 1, but for 18 hours.
5.4 Seeding the chondrocytes
Mix the solution by pipetting up and down.
Strain the cells using a 70μm filter and pool into a 50mL tube (if you had several tubes in digestion for the same sample)
Centrifuge 900 rpm, 5 min, RT.
Discard supernatant and resuspend the pellets with 1x PBS.
Centrifuge 900 rpm, 5 min, RT.
Discard supernatant and resuspend the pellets with chondrocyte media.
Perform a cell count (SOP.TK.2.1) and note live, dead, total cell counts and cell viability.
Seed cells at 200 000 cells/cm2. E.g. 400 000 cells/well in a 24-well plate.
NOTE: if you want to study chondrocyte-specific properties, do not passage the cells, they tend to dedifferentiate. Let them settle from the stress of the isolation for a couple days, then run experiments day 3 post-isolation.
138
KOCH Lab Standard Operating Procedure
1.0 Purpose
This standard operating procedure (SOP) outlines the procedure for extracting protein
from cells without degradation by proteases.
2.0 Related Documents
Document Document No.
3.0 Definitions
HEPES:
EDTA: Ethylenediaminetetraacetic acid
NaCl: Sodium Chloride
NaF: Sodium Fluoride
PBS: Phosphate buffered saline
4.0 General Equipment & Materials
Sterile centrifuge tubes (15 ml and 50 ml; Corning, cat. no. 430290)
Pipette aid & sterile serological pipettes (5, 10 and 25 ml; Corning, cat. nos. 4487, 4488 and 4489, respectively)
RAININ micropipettes & autoclaved sterile tips
Ethanol 70% (vol/vol) ! CAUTION Ethanol is highly flammable. It may also cause eye and respiratory tract irritation.
Sterile 1.5mL microfuge tubes
Centrifuge that can reach 4°C
Protein lysis buffer
Protease inhibitors
Ice
BioRad DC protein assay
5.0 Procedure
5.1 Reagent Preparation 5.1.1 Protein Lysis Buffer
50mM HEPES pH 7.6
Title: Protein extraction from cells
Prepared by: Approved by: Document no.: SOP.TK.9.0
Midori Buechli Thomas Koch Review Date: 2012.12.3
139
100mM NaCl
10mM EDTA
1% Triton X
4mM Na-Pyrophosphate
Stored at 4°C.
5.1.2 Protease inhibitors stock solutions
2mM Na-Orthovanadate
10mM NaF
cOmplete protease inhibitor cocktail 1:25 (Roche)
Each of these is stored at -20°C
5.1.3 Protein Lysis Buffer with protease inhibitors
Prepare this solution immediately before use (cannot be stored) o Approximately 200uL required per sample
Reagent Number of uL per mL Volume for 2.5ml
Na-orthovanadate 20 50
NaF 20 50
cOmplete protease inh. 40 100
Protein Lysis Buffer 920 2300
Keep on ice
5.2 Cell Lysis and protein collection
Harvest the cells using Trypsin/EDTA protocol (See SOP.TK.2.0)
Distribute cells into 1.5mL microfuge tubes
Centrifuge 8000 x g, 2 minutes, RT.
Remove supernatant and add 200uL 1xPBS. Spin.
Remove 150uL of the supernatant and resuspend the pellet with the remaining 50uL of PBS supernatant.
Add 200uL of the protein lysis buffer + protease inhibitors and pipette up and down
Leave on Ice for 10 minutes
Centrifuge 40 000 x g, 10 minutes, at 4 °C. o Cell debris is at the bottom and the protein is in the supernatant
Transfer and aliquot the supernatant to fresh tubes and store at -20 or -80°C.
5.3. Protein Quantification using BioRad DC protein assay
Prepare working reagent, require 25uL/sample o E.g. 20uL Reagent S + 1mL Reagent A]
Prepare protein standard using BSA in lysis buffer (0.25, 0.5, 0.75, 1.0, 1.25, 1.5 mg/ml)
Pipette 5uL of standards and samples in triplicate into a 96-well plate
140
Add 25uL working reagent to each well
Add 200uL Reagent B to each well and mix gently to avoid bubbles
Incubate RT for 15 minutes
Read the absorbance at 750nm.
Determine the concentration of protein in the samples by extrapolating against the standard curve.